UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Form 10-K/A
Amendment No. 1
|
|
|
(Mark One)
|
|
|
|
þ
|
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the fiscal year ended:
March 31, 2007
|
OR
|
o
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the transition period
from to .
|
Commission File Number:
001-33216
OCULUS INNOVATIVE SCIENCES,
INC.
(Exact name of Registrant as
specified in its charter)
|
|
|
Delaware
|
|
68-0423298
|
(State or other jurisdiction
of
incorporation or organization)
|
|
(I.R.S. Employer
Identification Number)
|
|
|
|
1129 N. McDowell
Blvd.
Petaluma, California
(address of principal
executive offices)
|
|
94954
(zip
code)
|
(707) 782-0792
(Registrants telephone
number, including area code)
None
(Securities registered pursuant
to Section 12(b) of the Act)
Common Stock
(Securities registered pursuant
to Section 12(g) of the Act and Title of Class)
Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities
Act. Yes o No þ
Indicate by check mark if the registrant is not required to file
reports pursuant to Section 15(d) of the Act.
Yes o No þ
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been
subject to such filing requirements for the past
90 days. Yes þ No o
Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of
Regulation S-K
is not contained herein, and will not be contained, to the best
of registrants knowledge, in definitive proxy or
information statements incorporated by reference in
Part III of this
Form 10-K
or any amendment to this
Form 10-K. þ
Indicate by check mark whether registrant is a large accelerated
filer, an accelerated filer, or a non-accelerated filer. See
definition of accelerated filer and large accelerated
filer in
Rule 12b-2
of the Exchange Act. (check one):
Large accelerated
filer o Accelerated
filer o Non-accelerated
filer þ
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the
Act). Yes o No þ
The registrants common stock first traded on the Nasdaq
Global Market on January 25, 2007. Accordingly, the
registrants common stock was not trading publicly on
September 30, 2006. As of May 31, 2007, the aggregate
market value of voting and non-voting common stock held by
non-affiliates of the registrant was approximately
$74.2 million, based on the closing price of the common
stock as reported on the Nasdaq Global Market for that date.
There were 11,881,911 shares of the registrants
Common Stock issued and outstanding on July 24, 2007.
DOCUMENTS
INCORPORATED BY REFERENCE
None.
EXPLANATORY
NOTE
Oculus Innovative Sciences, Inc. is filing this Amendment
No. 1, or the Amended Report, to our Annual Report on
Form 10-K
for the fiscal year ended March 31, 2007, filed with the
Securities and Exchange Commission, or the SEC, on June 20,
2007, or the Original Report, in order to add certain
information required by the following items of
Form 10-K:
|
|
|
Item
|
|
Description
|
|
ITEM 1.
|
|
Executive Officers
|
ITEM 10.
|
|
Directors, Executive Officers and
Corporate Governance
|
ITEM 11.
|
|
Executive Compensation
|
ITEM 12.
|
|
Security Ownership of Certain
Beneficial Owners and Management and Related Stockholder Matters
|
ITEM 13.
|
|
Certain Relationships and Related
Transactions, and Director Independence
|
ITEM 14.
|
|
Principal Accountant Fees and
Services
|
ITEM 15.
|
|
Exhibits, Financial Statement
Schedules
|
This Amendment No. 1 on
Form 10-K/A
(this Amendment) amends our annual report on
Form 10-K
for the fiscal year ended March 31, 2007 as filed with the
Securities and Exchange Commission on June 20, 2007 (our
Original Report), and is being filed solely to amend
Item 15 of Part IV, Item 1 of Part I in order to
add the section Executive Officers, and
Items 10, 11, 12, 13 and 14 of Part III of our
Original Report by deleting the text of such Items 10, 11,
12, 13 and 14 in their entirety and replacing them with the
information provided below under the respective headings.
This Amendment contains the complete text of the Original Report
except as noted in the immediately preceding sentence, with the
additional information appearing in Item 1 of Part I
and Items 10, 11, 12, 13 and 14 of Part III and
Item 15 of Part IV.
The Amended Report does not affect any other items in our
Original Report. As a result of this amendment, we are also
filing as exhibits to this Amended Report the certifications
pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
Except as otherwise expressly stated for the items amended in
this Amended Report, this Amended Report continues to speak as
of the date of the Original Report and we have not updated the
disclosure contained herein to reflect events that have occurred
since the filing of the Original Report. Accordingly, this
Amended Report should be read in conjunction with our Original
Report and our other filings made with the SEC subsequent to the
filing of the Original Report.
All references to the Company, we,
us, or our mean Oculus Innovative
Sciences, Inc.
ii
PART I
This Report contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
When used in this Report, the words expects,
anticipates, intends,
estimates, plans, projects,
continue, ongoing,
potential, expect, predict,
believe, intend, may,
will, should, could,
would and similar expressions are intended to
identify forward-looking statements. These are statements that
relate to future periods and include statements about, but not
limited to: the progress and timing of our development programs
and regulatory approvals for our products; the benefits and
effectiveness of our products; the development of protocols for
clinical studies; enrollment in clinical studies; the progress
and timing of clinical trials and physician studies; our
expectations related to the use of our cash reserves; our
ability to manufacture sufficient amounts of our product
candidates for clinical trials and products for
commercialization activities; the outcome of discussions with
the FDA and other regulatory agencies; the content and timing of
submissions to, and decisions made by, the FDA and other
regulatory agencies, including demonstrating to the satisfaction
of the FDA the safety and efficacy of our products; the ability
of our products to meet existing or future regulatory standards;
the rate and causes of infection; the accuracy of our estimates
of the size and characteristics of the markets which may be
addressed by our products; our expectations and capabilities
relating to the sales and marketing of our current products and
our product candidates; our ability to penetrate markets through
our sales force, distribution network, and strategic
business partners and generate attractive margins; the expansion
of our sales force and distribution network; the establishment
of strategic partnerships for the development or sale of
products; the ability to attain specified revenue goals within a
specified time frame, if at all, or to reduce costs; the timing
of commercializing our products; our ability to protect our
intellectual property and operate our business without
infringing on the intellectual property of others; our ability
to continue to expand our intellectual property portfolio; our
expectations about the outcome of litigation and controversies
with third parties; our ability to attract and retain qualified
directors, officers and employees; our relationship with Quimica
Pasteur; our ability to compete with other companies that are
developing or selling products that are competitive with our
products; the ability of our products to become the standard of
care for controlling infection in chronic and acute wounds; our
ability to expand to and commercialize products in markets
outside the wound care market; our estimates regarding future
operating performance, earnings and capital requirements; our
expectations with respect to our microbiology contract testing
laboratory; our expectations relating to the concentration of
our revenue from international sales; and the impact of the
Sarbanes-Oxley Act of 2002 and any future changes in accounting
regulations or practices in general with respect to public
companies.
Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ
materially from those projected. These risks and uncertainties
include, but are not limited to, those risks discussed below, as
well as our ability to develop and commercialize new products;
the risk of unanticipated delays in research and development
efforts; the risk that we may not obtain reimbursement for our
existing test and any future products we may develop; the risks
and uncertainties associated with the regulation of our products
by the U.S. Food and Drug Administration; the ability to
compete against third parties; our ability to obtain capital
when needed; our history of operating losses and the risks set
forth under Risks Related to our Business. These
forward-looking statements speak only as of the date hereof. The
Company expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in the
Companys expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement
is based.
Corporate
Information
We were incorporated in California in 1999 as Micromed
Laboratories, Inc. In August 2001, we changed our name to Oculus
Innovative Sciences, Inc. In December 2006, we reincorporated in
Delaware. Our principal executive offices are located at
1129 N. McDowell Blvd., Petaluma, California, 94954,
and our telephone number is
(707) 782-0792.
We have two principal subsidiaries: Oculus Technologies of
Mexico, S.A. de C.V., organized in Mexico, and Oculus Innovative
Sciences Netherlands, B.V., organized in The Netherlands. We
also have a subsidiary, Oculus Innovative Sciences Japan, KK.,
organized under Japanese law. Our website is
www.oculusis.com.
1
Overview
We have developed, and we manufacture and market, a family of
products intended to prevent and treat infections in chronic and
acute wounds. Infection is a serious potential complication in
both chronic and acute wounds, and controlling infection is a
critical step in wound healing. Our platform technology, called
Microcyn, is a proprietary oxychlorine small molecule
formulation that is designed to treat a wide range of organisms
that cause disease, or pathogens, including viruses, fungi,
spores and antibiotic resistant strains of bacteria, such as
Methicillin-resistant Staphylococcus aureus, or MRSA, and
Vancomycin-resistant Enterococcus, or VRE, in wounds. We
do not have the necessary regulatory approvals to market
Microcyn in the United States as a drug, nor do we have the
necessary regulatory clearance or approval to market Microcyn in
the U.S. as a medical device for an antimicrobial or wound
healing indication. However, our device product is cleared for
sale in the United States as a medical device for wound
cleaning, or debridement, lubricating, moistening and dressing;
is a device under CE Mark in Europe; and is approved as a drug
in India and Mexico.
Clinical testing we conducted in connection with our submissions
to the FDA, as well as physician clinical studies, suggest that
our Microcyn-based product may help reduce a wide range of
pathogens from acute and chronic wounds. These physician
clinical studies suggest that our Microcyn-based product is easy
to use and complementary to most existing treatment methods in
wound care. Physician clinical studies in the United States
suggest that our 510(k) product may shorten hospital stays,
lower aggregate patient care costs and, in certain cases, reduce
the need for system-wide, or systemic, antibiotics.
In 2005, chronic and acute wound care represented an aggregate
of $9.6 billion in global product sales, of which
$3.3 billion was spent for the treatment of skin ulcers,
$1.6 billion to treat burns and $4.7 billion for the
treatment of surgical and trauma wounds, according to Kalorama
Information, a life sciences market research firm. We believe
our addressable market for the treatment of skin ulcers is
approximately $1.3 billion, $300 million for the
treatment of burns and $700 million for the treatment of
surgical and trauma wounds. Common methods of controlling
infection, including topical antiseptics and antibiotics, have
proven to be only moderately effective in combating infection in
the wound bed. However, topical antiseptics tend to inhibit the
healing process due to their toxicity and may require
specialized preparation or handling. Antibiotics can lead to the
emergence of resistant bacteria, such as MRSA and VRE. Systemic
antibiotics may not be effective in controlling infection in
patients with disorders affecting circulation, such as diabetes,
which are commonly associated with chronic wounds. As a result,
no single treatment is used across all types of wounds and
stages of healing.
We believe Microcyn provides significant advantages over current
methods of care in the treatment of a wide range of chronic and
acute wounds throughout all stages of treatment. These stages
include cleaning, or debridement, prevention and treatment of
infections and wound healing. We believe that Microcyn may be
the first topical product that is effective against a broad
range of bacteria and other infectious microbes including
antibiotic resistant strains such as MRSA and VRE, without
causing irritation of or damage to healthy tissue. Unlike most
antibiotics, we believe Microcyn does not target specific
strains of bacteria, a practice which has been shown to promote
the development of resistant bacteria. In addition, our products
are shelf stable, require no special preparation, and are easy
to use.
Our goal is to become a worldwide leader in anti-infectives in
treating wounds. We currently have, and intend to seek
additional regulatory clearances and approvals to market our
Microcyn-based products worldwide. In July 2004, we began
selling Microcyn in Mexico after receiving approval from the
Mexican Ministry of Health, or MOH, for the use of Microcyn as
an antiseptic, disinfectant and sterilant. Since then,
physicians in the United States, Europe, India and Mexico have
conducted 21 physician clinical studies assessing
Microcyns use in the treatment of infections in a variety
of wound types, including hard-to-treat wounds such as diabetic
ulcers and burns. These studies were not intended to be
rigorously designed or controlled clinical trials and, as such,
did not have all of the controls required for clinical trials
used to support an NDA submission to the FDA in that they did
not include blinding, randomization, predefined clinical end
points, use of placebo and active control groups or
U.S. good clinical practices requirements. We used the data
generated from some of these studies to support our application
for the CE Mark, or European Union certification, for wound
cleaning and reduction of infection. We received the CE Mark in
November 2004 and additional international approvals in Canada,
Mexico and India. Microcyn has also received three FDA 510(k)
2
clearances for use as a medical device in wound cleaning, or
debridement, lubricating, moistening and dressing, including
traumatic wounds and acute and chronic dermal lesions.
In the second quarter of 2007, we initiated a Phase II
randomized clinical trial, which is designed to evaluate the
effectiveness of Microcyn in mildly infected diabetic foot
ulcers with endpoints of resolution of all symptoms of
inflammation, or clinical cure, and improvement in signs
and symptoms of infection supported by microbiological response
as described in FDA guidelines. We are using more than 10
clinical sites with a target of enrolling 60 patients in
three arms using Microcyn alone, Microcyn plus an oral
antibiotic and saline plus an oral antibiotic. We expect to
announce the results of our Phase II trial in autumn of
2007. A well known contract research organization is
coordinating, monitoring and documenting results of this trial.
Following the completion of this trial, and a review meeting
with the FDA, we intend to initiate two Phase III trials.
We anticipate that patient enrollment for Phase III trials
will start in early 2008, and the trials will last about 12 to
18 months. These Phase II and Phase III clinical
trials are intended to provide the clinical basis for submission
to the FDA of a new drug application, or NDA, for the treatment
of infected diabetic foot ulcers. In the event that we obtain
drug approval from the FDA, we may seek clearance for treatment
of other types of wounds. We are currently pursuing strategic
partnerships to assess potential applications for Microcyn in
several other markets, including respiratory, ophthalmology,
dermatology, dental and veterinary markets, and FDA or other
governmental approvals may be required for any potential new
products or new indications. We have reduced expenses in our
international operations in order to focus our resources on our
U.S. clinical trials.
We currently make Microcyn available under our 510(k) clearances
in the United States primarily through our website, one national
distributor and several regional distributors. We plan for a
more aggressive commercialization and product launch in the
event we obtain drug approval from the FDA. Most of our current
marketing efforts in the United States are designed to build
brand awareness. In Europe, we sell Microcyn through exclusive
distribution agreements with distributors, all of which, we
believe, are experienced suppliers to hospitals, supported by a
distributor coordinator. We are seeking a significant
distribution partner to sell the product in Europe into the
wound care market. Also, we have a distribution agreement with a
private company in Europe, that distributes Microcyn in Europe
to salons for cleaning hands and feet during treatment. In
Mexico, we sell Microcyn through a network of distributors and
through a contract sales force, including salespeople, nurses
and clinical support staff. In India we sell through Alkem, the
6th largest pharmaceutical company in India. This year is
the first full year of the product launch of Microcyn in India.
In China, we recently signed a distribution agreement with China
Bao Tai, which intends to distribute Microcyn to hospitals,
doctors and clinics through Sinopharm, the largest
pharmaceutical company in China, and to retail pharmacies
through Lianhua Supermarkets after required regulatory approval
in China is obtained.
Our goal is to achieve the following milestones through calendar
2009:
2007
|
|
|
|
|
Initiate and complete Phase II trial for use of Microcyn in
the treatment of infections in mildly infected diabetic foot
ulcers
|
|
|
|
Complete a meeting with FDA regarding our Phase II results
and Phase III protocols
|
|
|
|
Initiate site selection and investigation review board, or IRB,
approvals for Phase III clinical trial for Microcyn in the
treatment of infections in mildly infected diabetic foot ulcers
|
|
|
|
Execute distribution/partnership agreements for Microcyn outside
of the United States
|
|
|
|
Initiate partner discussions on Microcyn involving non-wound
care applications
|
|
|
|
File additional patents on new formulations and drug delivery
systems
|
2008
|
|
|
|
|
Initiate Phase III trials for evaluating Dermacyns
effectiveness for treatment of infection in infected diabetic
foot ulcers
|
3
|
|
|
|
|
Execute additional partnerships for commercialization of
Microcyn in non-wound care applications
|
|
|
|
File and obtain additional patents on new formulations and drug
delivery systems
|
2009
|
|
|
|
|
Data expected from Phase III clinical trials for Microcyn
in the treatment of infections in foot ulcers
|
|
|
|
File an NDA with the FDA for treatment of infected foot ulcers
|
We cannot guarantee that we will obtain on a timely basis, if at
all, the necessary FDA approval to market Microcyn in the United
States for the treatment of infection in diabetic foot ulcers. A
number of factors can delay or prevent completion of human
clinical trials, particularly patient recruitment. Moreover,
many drug candidates fail to successfully complete clinical
trials. After an NDA is filed with the FDA, the FDA commences an
in-depth review of the NDA that takes ten months to a year to
complete but may take longer. In addition, we cannot guarantee
that we will obtain on a timely basis, or at all, the necessary
510(k) clearances for the next generation Microcyn product
formulation. The milestones described above assume that we have
sufficient funds to complete, and that we do complete, our
clinical trials for the treatment of infection in mildly
infected diabetic foot ulcers, that we have sufficient funds to
conduct Phase III trials, that the results from these
clinical trials support an NDA filing and that our products will
be commercially viable. We cannot guarantee that we will find
appropriate distribution or strategic partners, generate revenue
sufficient to fund our cash flow needs or that we will meet any
of the milestones described above in a timely manner or at all.
We also operate a microbiology contract testing laboratory
division that provides consulting and laboratory services to
medical companies that design and manufacture biomedical devices
and drugs, as well as testing on our products and potential
products. Our testing laboratory complies with U.S. good
manufacturing practices and quality systems regulation. We are
in the process of transitioning our business away from providing
laboratory services to others, as we continue to focus our
efforts on completion of our clinical trials.
Industry
Background
Wound
Care Industry Overview
According to Medtech Insight, a Division of Windhover
Information, there were over 90 million incidents of wounds
in the United States during 2004. Of these, over six million
were chronic wounds, including arterial, diabetic, pressure and
venous ulcers. The remaining 84 million were acute wounds,
which follow the normal process of healing and commonly include
burns, traumatic wounds, and approximately 67 million
surgical incisions.
Key trends in wound care include:
|
|
|
|
|
large and increasing elderly, diabetic and obese populations,
each of which is vulnerable to developing a variety of
difficult-to-heal ulcers;
|
|
|
|
increased emphasis on controlling the cost of patient care in
hospitals, wound care centers and in private practice;
|
|
|
|
technological innovation, which has expanded treatment options
from traditional ointments and gauze to include advanced
treatments, such as vacuum devices, silver dressings, ultrasound
and skin grafts;
|
|
|
|
increased focus on improving the patient experience, including
reduction of pain and accelerated healing time; and
|
|
|
|
adjunctive nature of the market where multiple treatment methods
are employed, either simultaneously or sequentially, depending
on the type and stage of the wound.
|
Wound care is complex, and controlling infection is a critical
step in wound healing. Difficult-to-heal wounds can result from
traumatic injury, diabetes, peripheral vascular disease,
complications following surgery, rheumatoid arthritis,
congestive heart failure, arterial or venous ulcers and many
other conditions which compromise
4
circulation. Without proper medical intervention and control of
infection, these types of wounds typically remain open and
chronically infected.
Chronic Wounds
Chronic wounds are wounds that do not heal within a normally
expected time frame under standard care. The most frequently
occurring chronic wounds are venous, arterial, pressure and
diabetic foot ulcers. According to Medtech Insight, in 2004, the
incidence of chronic wounds in the United States was
approximately 6.1 million, comprised of 2.0 million
pressure ulcers, 1.7 million arterial ulcers,
1.6 million venous ulcers and 800,000 diabetic foot ulcers.
In addition to being expensive to treat, chronic wounds are
debilitating, painful and can result in amputations and other
serious consequences. Clinical studies suggest that, depending
on the severity of the wound, up to 43% of patients with
diabetic foot ulcers undergo an amputation. Furthermore, the
five year survival rate for patients undergoing amputations as a
result of diabetic foot ulcers is 27%.
The increasing prevalence of chronic wounds is driven by the
large and growing elderly, diabetic and obese populations.
Aging. People aged 65 and over are more
susceptible to wounds that become chronic than the overall
population. In 2006, there were more than 37 million people
in the United States over 65, representing more than 12% of the
population. By 2030, this group is expected to comprise more
than 19% of the total population of the United States, according
to U.S. Census Bureau projections. Additionally, according
to Medtech Insight, 70% of pressure ulcers occur in people
age 70 years or older, and 25% of patients in nursing
homes suffer from pressure ulcers.
Diabetes. Diabetics are particularly
vulnerable to chronic wounds as a result of the debilitating
effect of diabetes on the circulatory system. According to the
Centers for Disease Control and Prevention, or CDC, one out of
three children born in 2000 in the United States will develop
diabetes. In 2004 there were approximately 14.7 million
diabetic Americans, representing 5% of the total population, up
from 2.7% in 1990. Furthermore, according to the CDC, the
incidence of diabetes is significantly higher in people over 65:
in 2004, 16% of people over 65 were diabetic compared to 7.5% of
the total population.
Obesity. Obesity is a leading cause of Type
II, or adult onset, diabetes, making the obese
population more likely to eventually sustain chronic wounds.
Obesity in the United States is a growing problem. According to
the National Institute of Diabetes and Digestive and Kidney
Diseases, more than 30% of the United States adult population
was obese in 2000, up from 13% in 1960.
Acute
Wounds
Acute wounds are typically caused by traumatic injury or
surgical incision and are broadly categorized as those that can
be expected to heal within a definable timeframe. However, the
healing process may be affected by complicating factors such as
infection, leading to chronic wounds.
All acute wounds have the potential for infection and may
require prophylactic treatment to prevent infection. According
to Medtech Insight, in 2004, about 16.2 million traumatic
wounds were treated, including 8.7 million open wounds.
Also according to Medtech Insight, in 2004, approximately
67 million surgical wounds were reported in the United
States, including 36 million completed under anesthesia.
Despite modern infection control procedures, and technologies at
hospitals and surgery centers, every time the skin is opened
there is a risk of infection. We believe that there is a higher
likelihood of infection in surgeries involving anesthesia
because of the length of time the wound is open. In a clinical
study on surgical infections, it was shown that infection rates
vary with the time required to complete the surgery. For
example, infection rates varied from about 3.6% for surgeries
taking less than 30 minutes to about 16.4% for those longer than
5 hours.
Critical
Steps for Wound Treatment
Infection
Control
According to the Committee to Reduce Infection Deaths, or RID,
one out of every 20 patients contracts an infection while
in the hospital. Certain infections are increasingly dangerous
because they cannot be effectively
5
controlled by commonly used antibiotics. In addition, RID
estimates that each year in the United States, approximately two
million patients contract infections while in hospitals and, of
those, an estimated 100,000 die as a result. According to data
from RID in 2005, post-surgical wound infections more than
double a patients hospital costs, and patients with Staph
infections more than triple the average hospital costs. Surgical
site infections account for approximately 500,000 hospital
acquired infections in the United States each year, according to
the CDC.
Staphylococcus aureus, or Staph, is one of the most
common hospital acquired infections. One of the deadliest forms
of Staph infection is MRSA. According to data from the CDC, in
2003, 57% of the Staph infections reported were MRSA, up
from 22% in 1995 and 2% in 1974. Patients who do survive MRSA
often spend months in the hospital and endure repeated surgeries
to remove infected tissue.
When infection is present in a wound, standard treatments can
include cleansing, debridement and systemic antibiotics. Many
cleansing agents can harm tissue, causing irritation and
sensitization and impeding the wound healing process. Some forms
of debridement may increase scar tissue and complicate skin
grafting. Systemic antibiotics may be ineffective if the
patients metabolic state is compromised. Additionally, the
effectiveness of oral or systemic antibiotics in diabetic foot
ulcer patients may be diminished due to the patients poor
circulation, limiting delivery of the antibiotics to the wound
site.
Because there is a risk of infection with many surgical
procedures, clinicians perform several procedures before and
after surgery designed to prevent infection. Pre-operative
procedures generally involve preparing the surgical site with an
anti-bacterial agent, such as Betadine. Post-operative
procedures can include an anti-infective irrigation, a
therapeutic body cavity cleansing and the use of systemic
antibiotics.
Wound
Healing and Closure
Wound healing is a cascade process comprised of inflammation,
proliferation and maturation. The first stage of the wound
healing process is the inflammatory phase, which is associated
with swelling, redness and heat, and involves the migration of
healthy cells to the wound bed. Removing dead tissue or debris
from the wound prepares the wound bed for regeneration of new
tissue. The second phase is the proliferative phase, which
involves collagen and blood vessel formation and tissue growth.
The final phase, maturation, occurs as the wound begins to take
on its permanent form as collagen is reconstituted, forming new
skin. None of these phases, however, will progress normally in
the presence of infection.
Advanced
Technologies
Techniques and devices have been developed to treat complex and
hard-to-treat wounds, ranging from specialized devices to
antimicrobial dressings. Negative pressure wound therapy, high
pressure oxygen chambers and localized devices, sophisticated
water-based tissue removal devices, oxygenated mist devices and
tissue engineered skin substitutes are some of the most advanced
devices available to the wound care specialist. Although
relatively effective, many of these treatments have limitations
or drawbacks in that they cannot be used on certain types of
wounds or are expensive and complex to use. Despite these
advanced technologies, treatment of challenging wounds continues
to be multi-pronged, with a number of associated therapies
employed in an attempt to achieve wound closure.
Market
Opportunity Key Limitations of Existing
Treatments
Commonly used topical antiseptics and antibiotics have
limitations and side effects that may constrain their usage. For
example:
|
|
|
|
|
many antiseptics, including Betadine, hydrogen peroxide and
Dakins solution, are toxic, can destroy human cells and
tissue, may cause allergic reactions and can impede the wound
healing process;
|
|
|
|
silver-based products are expensive and require precise dosage
and close monitoring by trained medical staff to minimize the
potential for tissue toxicity allergic reactions and bacterial
resistance; and
|
6
|
|
|
|
|
the increase in antibiotic resistant bacterial strains, such as
MRSA and VRE, have compromised the effectiveness of some widely
used topical antibiotics including Neosporin and Bacitracin.
|
|
|
|
Oral and systemic antibiotics often are not effective in
treating topical infections and can cause serious side effects.
|
Our
Solution
We believe Microcyn has potential advantages over current
methods of care in the treatment of chronic and acute wounds,
including the following:
|
|
|
|
|
Wound Care Solution. Our 510(k) product is
cleared as a medical device for sale in the United States in
wound cleaning, or debridement, lubricating, moistening and
dressing. Although we do not have the necessary regulatory
approvals to market Microcyn in the United States as a drug,
laboratory testing and physician clinical studies further
suggest that our 510(k) Microcyn product may be effective
against a wide range of bacteria that causes infection in a
variety of acute and chronic wounds. In addition, because of its
mechanism of action, we believe Microcyn does not target
specific strains of bacteria, the practice of which has been
shown to promote the development of resistant bacteria. In
physician clinical studies, our 510(k) Microcyn product has been
used in conjunction with other wound care therapeutic products.
Data from these studies suggest that patients generally
experienced less pain, improved mobility and physical activity
levels and better quality of life.
|
|
|
|
Non-irritating. Our 510(k) product label
states that our 510(k) product, which is based on our Microcyn
technology, is non-irritating and non-sensitizing to the skin
and eyes. Throughout all our clinical trials and physician
clinical studies to date and since our first commercial sale of
Microcyn in Mexico in 2004, we have received no reports of
serious adverse events related to the use of Microcyn products.
|
|
|
|
Ease of Use. Our 510(k) product label states
that our 510(k) product requires no special handling
precautions. Our products require no preparation before use or
at time of disposal, and caregivers can use our products without
significant training. In addition, Microcyn can be stored at
room temperature. Unlike other super-oxidized water solutions,
which are typically stable for not more than 48 hours, our
laboratory tests show that Microcyn has a shelf life ranging
from one to two years depending on the size and type of
packaging. Our products are also designed to be complementary to
most advanced technologies to treat serious wounds, such as
negative pressure wound therapy, jet lavage and
tissue-engineered skin substitutes.
|
|
|
|
Cost-Effectiveness. The treatment of many
wounds requires extended hospitalization and care, including the
use of expensive systemic antibiotics. Infection prolongs the
healing time and necessitates increased use of systemic
antibiotics. We believe that Microcyn has the potential to help
treat infection, accelerate healing time and, in certain cases,
may help reduce the need for systemic antibiotics, reduce the
need for amputation and lead to earlier hospital discharge,
thereby lowering overall patient cost.
|
Our
Strategy
Our goal is to become a worldwide leader in anti-infectives in
treating wounds. We also intend to leverage our expertise in
wound care into additional market opportunities. The key
elements of our strategy include the following:
Obtain
drug regulatory approvals in the United States
We intend to seek additional regulatory clearances and
approvals, which we believe will allow us to accelerate adoption
of our products by wound care specialists worldwide. We have
initiated a Phase II trial which is designed to evaluate
the effectiveness of Microcyn in mildly infected diabetic foot
ulcers with endpoints of clinical cure and improvement in signs
and symptoms of infection supported by microbiological response.
We expect to use more than 10 clinical sites with a target of
enrolling 60 patients, using Microcyn alone, Microcyn plus
an oral antibiotic, and saline plus an oral antibiotic. We
expect to announce the results of our Phase II trial in
autumn of 2007. A well known contract research organization is
coordinating, monitoring and documenting results of this trial.
Following
7
the completion of this trial and a review meeting with the FDA,
we intend to initiate two Phase III trials, enrolling
patients with infected diabetic foot ulcers. We anticipate that
Phase III trials will start in early 2008 and will last
about 12 to 18 months. Results from these Phase II and
Phase III clinical trials are intended to provide the
clinical basis for submission to the FDA of an NDA for the
treatment of infected diabetic foot ulcers.
Drive
adoption of Microcyn as the standard of care in the wound care
market to help prevent and treat infection
We believe our products are well positioned to become the
standard of care in helping to treat infections. We seek to
drive adoption of Microcyn as the standard of care in the wound
care market by establishing strong scientific, evidence-based
rationale for its use. We intend to continue to maintain a
marketing presence in key medical communities throughout the
world through targeted direct marketing, publication in
scientific journals, and sponsorships of physician presentations
at medical conferences and seminars.
Develop
strategic collaborations and distribution in the acute and
chronic wound care market
Outside the United States and Mexico, we intend to pursue
strategic relationships with respect to both sales, marketing
and distribution. To accelerate adoption of our products, we may
enter into strategic relationships with healthcare companies
that have product lines, a sales force and distribution channels
that are complementary to ours. We believe collaborations allow
us to leverage our resources and technology. We intend to pursue
access to these markets through strategic partnerships. We have
engaged an investment banker to assist us in identifying
appropriate partners for development and commercialization of
our products. These relationships may take the form of
co-development, co-promotion, co-marketing or distribution
agreements. For instance, in India we sell through Alkem
Laboratories, the
6th largest
pharmaceutical company in India. This year is the first full
year of the product launch of Microcyn in India. In China, we
recently signed a distribution agreement with China Bao Tai,
which intends to distribute Microcyn to hospitals, doctors and
clinics through Sinopharm, the largest pharmaceutical company in
China, and to independent and retail pharmacies through Lianhua
Supermarkets, after required regulatory approval in China is
obtained.
We currently make Microcyn available under our 510(k) clearances
in the United States primarily through our website, one national
distributor and several regional distributors. We plan for a
more aggressive commercialization and product launch in the
event we obtain drug approval from the FDA. After filing the NDA
with the FDA, we may hire a direct sales force or form a
strategic collaboration with a company that already has an
existing sales force to address the US market.
Develop
strategic partnerships in numerous indications outside the wound
care market
We believe our products have potential applications in several
other large markets, including respiratory, ophthalmology,
dermatology, dental and veterinary markets. We intend to pursue
access to these markets through strategic partnerships.
Microcyn
Platform Technology
Mechanism
of Action
We believe Microcyns ability to treat and prevent
infection is based on its uniquely engineered chemistry. As a
result of our proprietary manufacturing process, Microcyn is a
proprietary oxychlorine small molecule formulation that, among
other things, interacts with and inactivates surface proteins on
cell walls and membranes of microorganisms and viruses. The
function of these proteins are varied and play significant roles
in cell communication, nutrient and waste transport and other
required functions for cell viability. Once Microcyn surrounds
single cell microorganisms, it damages these proteins, causing
the cell membrane to rupture, leading to cell death, which we
believe is caused by increased membrane permeability and induced
osmotic pressure imbalance. We continue to study the exact
mechanisms by which protein and structural components of the
bacterial cell walls and membranes, and the protein shell that
surrounds a virus, are affected by Microcyn. This destruction of
the cell appears to occur through a fundamentally different
process than that which occurs as a result of contact with a
bleach-based solution because experiments have demonstrated that
Microcyn kills bleach-resistant bacteria. However, we believe
the
8
solution remains non-irritating to human tissues because human
cells have unique protective mechanisms, are interlocked, and
prevent Microcyn from targeting and surrounding single cells
topically on the body. Our laboratory tests suggest that our
solution does not penetrate and kill multi-cellular organisms
and does not damage or affect human DNA.
In laboratory tests, Microcyn has been shown to destroy certain
biofilms. A biofilm is a complex cluster of microorganisms or
bacteria marked by the formation of a protective shell, allowing
the bacteria to collect and proliferate. It is estimated that
over 65% of microbial infections in the body involve bacteria
growing as a biofilm. Bacteria living in a biofilm typically
have significantly different properties from free-floating
bacteria of the same species. One result of this film
environment is increased resistance to antibiotics and to the
bodys immune system. In chronic wounds, biofilms interfere
with the normal healing process and halt or slow wound closure.
In our laboratory studies, Microcyn was shown to destroy two
common biofilms after five minutes of exposure.
In a recently published case study, Microcyn was shown to
significantly increases the dilation of capillaries in wounds as
indicated by higher levels of oxygen at a wound site after the
application of our product.
It is widely accepted that reducing inflammation surrounding an
injury or wound is beneficial to wound healing. Our independent
laboratory research suggests that Microcyn may inhibit certain
inflammatory responses from allergy-producing, or mast cells.
These reactions are critical components of the bodys
natural inflammatory response to injury or wounds. Our
laboratory research suggests that Microcyns interference
with these cells is selective to only the inflammatory response
and does not interfere with other functions of these cells.
Additionally, physician clinical studies suggest that Microcyn
only inhibits this inflammatory activity in tissue that is
directly exposed to the solution.
Microcyn has demonstrated antimicrobial activity against
numerous bacterial, viral and fungal pathogens, including
antibiotic-resistant strains, as evidenced by passing results in
numerous standardized laboratory microbiology tests conducted on
our 510(k) product by a variety of certified independent testing
laboratories. Some of the pathogens against which Microcyn has
demonstrated antimicrobial activity are listed below:
|
|
|
|
|
|
|
Pathogen
|
|
|
|
|
|
|
Antibiotic-Resistant
Bacteria
|
|
|
|
|
|
|
Vancomycin Resistant
Enterococcus faecalis (VRE)
|
|
|
|
|
|
|
Methicillin resistant
Staphylococcus aureus (MRSA)
|
|
|
|
|
|
|
Other Bacteria
|
|
|
|
|
|
|
Acinetobacter
baumanii
|
|
|
|
|
|
|
Aspergillus niger
|
|
|
|
|
|
|
Clostridium difficile
|
|
|
|
|
|
|
Escherichia coli
|
|
|
|
|
|
|
Escherichia coli
O157:H7
|
|
|
|
|
|
|
Mycobacterium bovis
|
|
|
|
|
|
|
Pseudomonas
aeruginosa
|
|
|
|
|
|
|
Salmonella typhi
|
|
|
|
|
|
|
Viruses
|
|
|
|
|
|
|
Human Coronavirus
|
|
|
|
|
|
|
Human Immunodeficiency Virus Type
1 HIV
|
|
|
|
|
|
|
Influenza A
|
|
|
|
|
|
|
Rhinovirus Type 37
|
|
|
|
|
|
|
Fungi
|
|
|
|
|
|
|
Candida albicans
|
|
|
|
|
|
|
Trichophyton
mentagrophytes
|
|
|
|
|
|
|
In addition to the above mentioned independent laboratory
microbiology tests, a study was completed and published in the
Journal of Hospital Infection in 2005, which was co-authored by
our Director of Medical Affairs,
9
Andres Gutiérrez, M.D., Ph.D., that showed that
Microcyn exerts a wide range of antimicrobial activity
(Landa-Solis, González-Espinosa D, Guzman B, Snyder M,
Reyes-Terán G, Torres K and Gutiérrez AA. Microcyn: a
novel super-oxidized water with neutral pH and disinfectant
activity. J Hosp Infect (UK) 61:
291-299).
Current
Regulatory Approvals and Clearances
All our current products are based on our Microcyn platform
technology. We are able to modify the chemistry of Microcyn by
changing the oxidation-reduction potential, pH-level and
concentrations of specific ions or chemicals, which allows us to
manufacture a variety of solutions, each specifically designed
for maximum efficacy and safety by indication. The indications
for our products vary from country to country due to different
regulatory requirements and standards from jurisdiction to
jurisdiction. The indications below are summaries of the
indications approved by the regulatory authority or authorities
in the listed jurisdiction. The similarly named products have
similar formulations; however, they may not have identical
specifications due to varying requirements in different
jurisdictions regulatory agencies. The following is a list
of the regulatory approvals and clearances that Microcyn-based
products have received for our most significant or potentially
significant markets:
|
|
|
|
|
|
|
|
|
|
|
Approval or
|
|
Year of Approval
|
|
|
|
Region
|
|
Clearance Type
|
|
or Clearance
|
|
|
Summary Indication
|
|
United States
|
|
510(k)
|
|
|
2005
|
|
|
Moistening and lubricating
absorbent wound dressings for traumatic wounds.
|
|
|
510(k)
|
|
|
2005
|
|
|
Moistening and debriding acute and
chronic dermal lesions.
|
|
|
510(k)
|
|
|
2006
|
|
|
Moistening absorbent wound
dressings and cleaning minor cuts.
|
European Union
|
|
CE Mark
|
|
|
2004
|
|
|
Debriding, irrigating and
moistening acute and chronic wounds in comprehensive wound
treatment by reducing microbial load and creating moist
environment.
|
Mexico
|
|
Product Registration
|
|
|
2004
|
|
|
Antiseptic treatment of wounds and
infected areas.
|
|
|
Product Registration
|
|
|
2003
|
|
|
Antiseptic disinfection solution
for high level disinfection of medical instruments, and/or
equipment and clean-rooms, areas of medical instruments,
equipment and clean room areas.
|
Canada
|
|
Class II Medical Device
|
|
|
2004
|
|
|
Moistening, irrigating, cleansing
and debriding acute and chronic dermal lesions, diabetic ulcers
and post-surgical wounds.
|
India(1)
|
|
Drug License
|
|
|
2006
|
|
|
Cleaning and debriding in wound
management.
|
|
|
|
(1) |
|
Drug license held by Indian distributor as required by Indian
law. |
Clinical
Trials
We have initiated a trial, which is designed to evaluate the
effectiveness of Microcyn in mildly infected diabetic foot
ulcers with endpoints of clinical cure and improvement in signs
and symptoms of infection supported by microbiological response.
We expect to use more than 10 clinical sites with a target of
enrolling 60 patients, using Microcyn alone, Microcyn plus
an oral antibiotic, and saline plus an oral antibiotic. We
expect to announce the results of our Phase II trial in
autumn of 2007. A well known contract research organization is
coordinating,
10
monitoring and documenting results of our Phase II trial.
Following the completion of this study and a review meeting with
the FDA, we intend to initiate two Phase III trials. We
anticipate that Phase III trials will start in early 2008
and will last about 12 to 18 months. These Phase III
clinical trials are intended to provide the clinical basis for
submission to the FDA of an NDA for the treatment of infected
diabetic foot ulcers.
Physician
Clinical Studies
In addition to the trials mentioned above, several physicians
and scientists have conducted twenty-one clinical evaluations of
Microcyn generating data suggesting that our 510(k) Microcyn
product is non-irritating to healthy tissue, reduces microbial
load, shortens treatment time and may have the potential to
reduce costs to healthcare providers and patients. We have
sponsored the majority of physicians performing these studies by
supplying Microcyn, unrestricted research grants, paying
expenses or providing honoraria. In some cases, the physicians
who performed these studies also hold equity in our company. The
studies were performed in the United States, Europe, India and
Mexico, and used various endpoints, methods and controls (for
example, saline, antiseptics and antibiotics). These studies
were not intended to be rigorously designed or controlled
clinical trials and, as such, did not have all of the controls
required for clinical trials used to support an NDA submission
to the FDA in that they did not include blinding, randomization,
predefined clinical endpoints, use of placebo and active control
groups or U.S. good clinical practice requirements.
In many cases the physicians who led these studies have
published articles on their studies and results. The following
table lists a selection of articles and publications from
physicians who have completed studies on the use of Microcyn for
wound care and wound irrigation.
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of
|
|
|
|
Physician
|
|
Country
|
|
Patients
|
|
|
Publication
|
|
David E. Allie, M.D.(1)
|
|
U.S.
|
|
|
40
|
|
|
Allie D. Super-Oxidized Dermacyn
in Lower-Extremity Wounds. Wounds, 2006, Jan (Suppl), 3-6
|
Tom Wolvos, M.D.(2)
|
|
U.S.
|
|
|
26
|
|
|
Wolvos TA. Advanced Wound Care
with Stable, Super-Oxidized Water. A look at how combination
therapy can optimize wound healing. Wounds, 2006, Jan
(Suppl), 11-13
|
Cheryl Bongiovanni, Ph.D.(3)
|
|
U.S.
|
|
|
8
|
|
|
Bongiovanni CM. Superoxidized
Water Improves Wound Care Outcomes in Diabetic Patients.
Diabetic Microvascular Complications Today, 2006,
May-Jun: 11-14
|
|
|
|
|
|
3
|
|
|
Biogiovanni CM. Nonsurgical
Management of Chronic Wounds in Patients with Diabetes.
Journal of Vascular Ultrasound, 2006, 30: 215-218,
|
Luca Dalla Paola, M.D.(4)
|
|
Italy
|
|
|
218
|
|
|
Dalla Paola L, Brocco E, Senesi,
A, Merico M, De Vido D, Assaloni R, DaRos R. Super-Oxidized
Solution (SOS) Therapy for Infected Diabetic Foot Ulcers.
Wounds, 2006, vol. 18: 262-270
|
|
|
|
|
|
|
|
|
Dalla Paola, L. Treating diabetic
foot ulcers with super-oxidized water. Wounds, 2006, Jan
(Suppl), 14-16
|
Alberto Piagessi, M.D.(5)
|
|
Italy
|
|
|
33
|
|
|
Clinical Outcomes of Wide
Postsurgical Lesions in the Infected Diabetic Foot Managed With
2 Different Local Treatment Tegimes Compared Using a
Quasi-Experimental Study Design: A Preliminary Communication.
Int. J.Lower Extremity Wounds, 2007 6: 22-27.
|
11
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of
|
|
|
|
Physician
|
|
Country
|
|
Patients
|
|
|
Publication
|
|
Ariel Miranda, M.D.(5)
|
|
Mexico
|
|
|
64
|
|
|
Miranda-Altamirano A. Reducing
Bacterial Infectious Complications from Burn Wounds. A look at
the use of Oculus Microcyn60 to treat wounds in Mexico.
Wounds, 2006, 18 (Suppl), 17-19
|
Lenka Veverkova, M.D.(3)
|
|
Czech Republic
|
|
|
27
|
|
|
Veverkova L, Jedlicka V,
Vesely M, Tejkalova R, Zabranska S, Capov I, Votava M.
Methicilin-resistent Staphylococcus
aureus problem in health care. J Wound
Healing 2005, 2:201-202.
|
Elia Ricci M.D.(6)
|
|
Italy
|
|
|
40
|
|
|
Ricci E, Astolfi S, Cassino R.
Clinical results about an antimicrobial solution (Dermacyn Wound
Care) in the treatment of infected chronic wounds.
17th Conference. EWMA Meeting 2005. Glasgow, UK. May 2-4,
2007. In preparation for publication.
|
Steenvoorde, P.M.D, Van
Doorn, L.P., M.A.,
Jacobi, C.E, PhD &
Oskam, J., M.D., PhD.(3)
|
|
Netherlands
|
|
|
10
|
|
|
An unexpected effect of Dermacyn
on infected leg ulcers, J Wound Care 2007, 16: 60-61.
|
Notes
|
|
|
(1) |
|
indicates that the physician is an investor and was a member of
our Medical and Business Advisory Board which the Company
dissolved in April 2007, a paid consultant and received research
grants, expense payments, honorarium and Microcyn to complete
the study |
|
(2) |
|
indicates that the physician was a paid consultant, received
expenses in connection with corporate development and licensing
evaluations and is a warrant holder |
|
(3) |
|
indicates that the doctor received Microcyn to complete the study |
|
(4) |
|
indicates that the physician is a paid consultant, was a member
of our Medical and Business Advisory Board, which the Company
dissolved in April 2007, and received expense payments and
Microcyn to complete the study |
|
(5) |
|
indicates that the physician received payments, expense payments
and Microcyn to complete the study |
|
(6) |
|
indicates that the physician received reimbursement of travel
expenses and received Microcyn to complete the study |
There are also several ongoing and planned physician clinical
studies in the United States, Europe and India to assess
Microcyns effectiveness in preventing and treating
infections in wounds and are summarized in the table below. For
example, we are supporting a study by Dr. David Armstrong
of the Scholl College of Podiatric Medicine in Chicago, Illinois
and Dr. Andrew Boulton, Head of the Manchester Diabetes
Center at the Manchester Royal Infirmary in the United Kingdom.
Drs. Armstrong and Boultons study is a study of
diabetic foot ulcers using the VersaJet, an aggressive
debridement system, in two groups of ten patients each, one
utilizing Microcyn and the other utilizing saline. The endpoints
are microbial load reduction and time to complete wound healing.
Other studies in diabetic foot infections are being conducted by
Dr Alberto Piaggesi, Director of the UO Mallatie del Metabolismo
e Diabetologia, Universitaria Pisana, Italy and Dr Robert
Frykberg, Director of Podiatry Medicine at the Carl T Hayden,
Veterans Administration Medical Center in Arizona. Dr Piaggesi
is investigating the clinical and microbiological response to
Dermacyn, with particular attention to the microscopic
anatomical changes in diseased tissue in the formation of new
blood vessels following therapy. Dr Frykberg is analyzing the
effect of Microcyn on MRSA colonized ulcers which is becoming a
public threat due to the frequency of resistance to antibiotics.
Cheryl Bongiovanni, Ph.D., Director of the Lake Wound
Clinics in Lakeview, Oregon, is conducting case report studies
focusing on blood vessel dilation effects of Microcyn and on the
potential cost savings from the use of Microcyn in treating a
variety of wounds. Dr. Matthew Regulski, who practices at
the Ocean County Foot &
12
Ankle Surgical Associates, in New Jersey, is focusing on the
combination of Microcyn and skin substitutes. Finally, Dr Amar
Pal Suri from New Dehli is investigating the effects of Microcyn
on wound healing rates with patient follow up over several
months. We provided each of these doctors with Microcyn and may
pay their expenses, including travel, hotels and meals, to
attend medical conferences to present their findings. We pay
Drs. Frykberg and Regulski an educational grant in
connection with their studies.
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of
|
|
|
|
Physician
|
|
Country
|
|
Patients
|
|
|
Publication
|
|
David Armstrong, D.P.M., PhD.(1)
|
|
U.S.
|
|
|
10
|
|
|
A prospective, multi center,
randomized, single-masked, controlled, clinical investigation of
Microcyn as a replacement solution with Versajet Jet lavage
system
|
Andrew Boulton M.D.(1)
|
|
U.K.
|
|
|
10
|
|
|
A prospective, multi center,
randomized, single-masked, controlled, clinical investigation of
Microcyn as are placement solution with Versajet Jet lavage
system
|
Alberto Piaggesi M.D.:(1)
|
|
Italy
|
|
|
40
|
|
|
Efficacy and safety of using a new
local antiseptic in managing post-surgical lesions of the
diabetic foot a prospective, randomized, open
clinical investigation
|
Robert Frykberg, D.P.M., M.P.H.(2)
|
|
US
|
|
|
30
|
|
|
A prospective clinical evaluation
of ermacyn in wounds of the lower extremity contaminated,
colonized or critically-colonized with or without MRSA
|
Matthew Regulski D.P.M.(2)
|
|
US
|
|
|
20
|
|
|
A prospective, single-center,
open-labeled, saline controlled trial to evaluate the efficacy
and compatibility of
Dermacyn®
wound care with
OASIS®
Wound Matrix for the treatment of non-infected, graft ready
venous ulcers, post-surgical, and post-traumatic wounds
|
Amar Pal Singh Suri D.P.M.(1)
|
|
India
|
|
|
100
|
|
|
Role of neutral pH, super-oxidized
solution in the healing of diabetic foot ulcers.
|
Notes
|
|
|
(1) |
|
indicates that the physician received payments, expense payments
and Microcyn to complete the study |
|
(2) |
|
indicates that the physician received an educational grant |
13
In addition to the above articles and publications, several
additional papers on the basic science of the technology have
been published or have been submitted for peer review and
publication, including:
|
|
|
|
|
Researchers
|
|
Country
|
|
Publication
|
|
Landa-Solis,
González-Espinosa
D., Guzman B, Snyder M,
Reyes-Terán G., Torres K. and
Gutiérrez A.A.(1)
|
|
México
|
|
Microcyntm
a novel super-oxidized water with neutral pH and disinfectant
activity. J Hosp Infect (UK) 61: 291-299.
|
Gutiérrez, A.A.(1)
|
|
US
|
|
The science behind stable,
super-oxidized water. Exploring the various applications of
super-oxidized solutions. Wounds. 18 (Suppl), 7-10.
|
Dalla Paola L. and Faglia E.(2)
|
|
Italy
|
|
Treatment of diabetic foot ulcer:
an overview. Strategies for clinical approach. Current
Diabetes Reviews, 2006, 2, 431-447 431
|
González-Espinosa D.,
Pérez-Romano L., Guzman Soriano
B., Arias E., Bongiovanni, C.M.
& Gutiérrez A.A.(1),(3)
|
|
Mexico US
|
|
Effects of neutral super-oxidized
water on human dermal fibroblasts in vitro. International
Wound Journal, 2007. In press.
|
Medina-Tamayo J., Balleza-Tapia
H., López, X., Cid, M.E.,
González-Espinosa, D. Gutiérrez
A.A.., and González-Espinosa C.(1)
|
|
Mexico US
|
|
Super-oxidized water inhibits
IgE-antigen- induced degranulation and cytokine release in mast
cells. International Immunophamacology 2007. In press.
|
Zahumensky E.
|
|
Czech Republic
|
|
Infections and diabetic foot
syndrome in field practice. Vnitr Lek. 2006;52:411-416.
|
Rose R., Setlow B., Monroe A.,
Mallozzi M., Driks A., Setlow P.
|
|
US
|
|
Comparison of the properties of
Bacillus subtilis spores made in liquid or on agar plates.
Submitted 2007.
|
Paul M., Setlow B. and Setlow P.
|
|
US
|
|
The killing of spores of Bacillus
subtilis by
Microcyntm,
a stable superoxided water. Submitted 2007.
|
Sauer K, Vazquez G., Thatcher
E., Northey R. and
Gutierrez A.A.(1),(4),(5)
|
|
US
|
|
Neutral super-oxidized solution is
effective in killing P. aeruginosa biofilms. Submitted
2007.
|
Notes
|
|
|
(1) |
|
Dr. Gutierrez is our Director of Medical Affairs and
conducted the study during his employment by the Company |
|
(2) |
|
Dr. Dalla Paola was a member of our Medical and Business
Advisory Board, which the Company dissolved in April 2007, and
received expense payments and Microcyn to complete the study |
|
(3) |
|
Dr. Bongiovanni received Microcyn to complete the study |
|
(4) |
|
Dr. Thatcher is a full-time consultant to us, holds shares
of our stock, previously served on our board of directors, and
received Microcyn to complete the study |
|
(5) |
|
Dr. Northey is our Director of Research &
Development and conducted the study during his employment by the
Company |
Sales and
Marketing
Our products are purchased by hospitals, physicians, nurses and
other healthcare practitioners who are the primary caregivers to
patients being treated for acute or chronic wounds, as well as
those patients undergoing surgical procedures. In the United
States, we make Microcyn available under 510(k) clearances
primarily through our website, one national distributor and
several regional distributors. We plan for a more aggressive
commercialization and product launch in the event we receive
drug approval from the FDA.
14
In Europe, we have arrangements with distributors in Germany,
Italy, and the Czech Republic. We are actively pursuing
strategic alliances with potential partners, that already have
significant sales, marketing and distribution capabilities to
hospitals and pharmacies throughout Europe. It is our intent to
use the partners capabilities to sell and distribute
Microcyn in Europe.
In Mexico, we market our products through our established
distribution network and direct sales organization. We have a
dedicated contract sales force, including salespeople, nurses
and clinical support staff responsible for selling Microcyn to
private and public hospitals and to retail pharmacies.
Throughout the rest of the world, we intend to use strategic
partners and distributors, that have a significant sales,
marketing and distribution presence in their respective
countries. We have established partners and distribution
channels for our wound care products in China, India,
Bangladesh, Pakistan, Singapore, United Arab Emirates and Saudi
Arabia.
In December 2005, we entered into an agreement with Alkem
Laboratories, a large pharmaceutical company in India. We
commenced sales to Alkem Laboratories in April 2006. Under the
terms of this agreement, Alkem has exclusive rights to market,
distribute and sell our Microcyn-based products in the Republic
of India and the Kingdom of Nepal. During the term of this
agreement, Alkem is entitled to use our patents, trade secrets,
trademarks and other intellectual property rights as to our
Microcyn-based products solely in connection with our products.
However, we will remain the owner of and reserve such patents,
trade secrets, trademarks and other intellectual property
rights. In the event we fail to timely deliver the ordered
quantities, we will be subject to certain penalties. In
addition, if either party fails to fulfill their respective
obligations under the agreement for a period of 180 days,
which is not remediated within 30 days of receiving notice,
the other party may terminate the agreement. The agreement has a
five year term and may be renewed after its initial term for
such additional term as the parties agree to in writing.
In April 2007, we entered into an exclusive distribution
agreement with China Bao Tai Investment Company, Ltd., or China
Bao Tai, for the sale of Microcyn wound care solution in China,
Hong Kong, Macau and Taiwan. China Bao Tai intends to distribute
and sell Microcyn to hospitals and pharmacies through Sinopharm,
the largest pharmaceutical group in China, and through Lianhua
Supermarkets for supermarket distribution. Lianhua Supermarkets
operates 3,609 outlets spanning 21 provinces. This agreement
provides for minimum purchases of $12 million over a five
year period, with the minimum purchases heavily weighted to the
latter years of sales. If those minimums are not met, we are not
bound by our exclusivity agreement. Sales of Microcyn wound care
solution under this agreement will commence after China Bao Tai
has obtained the required regulatory approval for distribution
of the products in the territories, which it expects to receive
in late 2009.
Other
Market Opportunities
We are searching for strategic partnerships in addition to wound
care applications in markets where Microcyn technology has
competitive advantages over antibiotics in numerous medical
indications outside of the acute and surgical wound market. Some
of these market opportunities include:
Respiratory
Our nasal product candidate is an anti-microbial solution
designed to be self-administered into a patients nasal
cavity for the treatment of chronic rhinosinusitis, or
inflammation of the nasal sinuses. In animal studies, Microcyn
has been shown to kill the bacteria that causes rhinosinusitis.
We have conducted pre-clinical animal studies that suggest the
efficacy and safety of this product candidate.
Rhinosinusitis affects an estimated 35 million people in
the United States. There is no FDA-approved therapy for chronic
rhinosinusitis. Most treatment methods have focused on the
symptoms of the disease and include the use of antibiotics,
antihistamines, corticosteroids and sinus surgery.
15
Dermatology
We believe that our Microcyn technology can be used to develop
products to treat various fungal and bacterial skin infections.
Laboratory and clinical test data support that our technology
may be effective in treating these bacterial and fungal
infections.
In February 2007, we entered into an exclusive agreement with
Dancohr Corporation B.V., a manufacturer and wholesaler of
cosmetics, to distribute Courtin oxychlorine solution to salons
in various European countries for cleaning hands and feet during
pedicures and manicures. This agreement provides for minimum
purchases of $10 million over a five year period, with
minimum purchases of 30,000 in 2007. If minimum purchases
are not met, we may terminate the agreement.
Dental
and Oral Care
We believe that our Microcyn technology may be used both as a
mouthwash and a dental rinse, and that early data from physician
studies support its safe use in oral surgery.
Ophthamology
We believe that our technology may be used to treat and prevent
eye infections such as conjunctivitis. We have conducted
in vitro and animal laboratory testing that suggests that
our product is safe when placed in the eye.
Veterinary
Medicine
Our animal wound care product based on Microcyn technology,
Vetericyn, is available for use in the United States, and
we are seeking to identify a partner with the expertise and
capability to exploit the verterinary market.
Research
and Product Development
The main goals of our research and product development program
are to design, develop and produce products to treat acute and
chronic wounds, and to identify new applications for our
technology. Our research and product development efforts with
our Microcyn-based products are divided into three areas:
science, new product development and engineering.
Our scientists work to continually improve our product
performance by evaluating variations of the formulations and
chemical structures of our products. For example, we are
evaluating alterations to Microcyn to increase the speed at
which it kills certain bacteria and viruses. Significant efforts
are also being directed towards extending our understanding of
the unique chemistry of our products.
The focus of our current development efforts is new
formulations, applications and delivery systems for Microcyn,
including the following:
|
|
|
|
|
Modification of the physical properties of our product to
improve efficiency in unique antimicrobial applications;
|
|
|
|
Development of new formulations and delivery systems that extend
the stability of the product;
|
|
|
|
Development of a surgical irrigant to control infections during
and after surgery; and
|
|
|
|
Alteration of current formulation for sinus treatments.
|
Currently, the main focus of our engineering staff is the
construction of a U.S. Good Manufacturing Practices, or
cGMP, compliant manufacturing system for our drug product. This
entails significant upgrades of our raw material, manufacturing
and bottling system.
Our technology may have application in other non-medical
markets. We intend to pursue opportunities in these markets with
third parties. We plan to increase our research and product
development staff in the future to address market demands
identified in our market research and commercial practice.
16
Manufacturing
We manufacture Microcyn through a proprietary electrolysis
process within a multi-chamber system. We are able to control
the passage of ions through proprietary membranes, yielding
electrolyzed water with only trace amounts of chlorine. This
process is fundamentally different from the processes for
manufacturing hydrogen peroxide and bleach and is the basis for
our technologys effectiveness and safety. Our
manufacturing process produces very little waste, which is
disposed of as water after a simple non-toxic chemical treatment.
We manufacture our products in Petaluma, California, Sittard,
The Netherlands and Zapopan, Mexico. We have developed an
automated manufacturing process and conduct quality assurance
testing on each production batch in accordance with current
U.S. cGMP. Our facilities are required to meet and maintain
regulatory standards applicable to the manufacture
pharmaceutical and medical device products. Our United States
and Netherlands facilities are certified and comply with cGMP
medical device Quality Systems Regulation, or QSR, and
International Organization for Standardization, or ISO,
guidelines. Our Mexico facility has been approved by the MOH.
Our machines are subjected to a series of tests, which is part
of a validation protocol mandated by cGMP, QSR and ISO
requirements. This validation is designed to ensure that the
final product is consistently manufactured in accordance with
product specifications at all manufacturing sites. Certain
materials and components used in manufacturing our machines are
proprietary to us.
We believe we have a sufficient number of machines to produce an
adequate amount of Microcyn to meet anticipated future
requirements for at least the next two years. As we expand into
new geographic markets, we may establish additional
manufacturing facilities to better serve those new markets.
Intellectual
Property
Our success depends in part on our ability to obtain and
maintain proprietary protection for our product technology and
know-how, to operate without infringing proprietary rights of
others, and to prevent others from infringing our proprietary
rights. We seek to protect our proprietary position by, among
other methods, filing, when possible, U.S. and foreign
patent applications relating to our technology, inventions and
improvements that are important to our business. We also rely on
trade secrets, know-how, continuing technological innovation,
and in-licensing opportunities to develop and maintain our
proprietary position.
As of May 31, 2007, we own one issued U.S. patent, two
issued European patents, 13 pending U.S. patent
applications and 20 foreign pending patent applications
generally relating to super-oxidized water. These applications
include six international PCT applications that have not yet
reached the deadline to file counterpart phase applications. Our
portfolio of issued and pending applications can be divided into
two groups. The first group includes one U.S. issued
patent, two issued European patents, three pending
U.S. patent applications and five foreign patent
applications that relate to early generation super-oxidized
water product, methods of using super-oxidized water, and
aspects of the method and apparatus for manufacturing
super-oxidized water. The second group includes 10 pending
U.S. patent applications and 15 foreign patent applications
that relate to Microcyn, the method and apparatus for
manufacturing Microcyn, and its uses.
In March 2003, we obtained an exclusive license to six issued
Japanese patents and five Japanese published pending patent
applications owned by Coherent Technologies, or Coherent. The
issued Japanese patents and pending Japanese patent applications
relate to an early generation of unstable, super-oxidized water
product and aspects of the method and apparatus for producing
super-oxidized water and will expire between 2011 and 2014. In
June 2006, we received written notice via email from Coherent
advising us that the patent license was terminated, citing
various reasons with which we disagree. Although we do not
believe Coherent has grounds to terminate the license, we may
have to take legal action to preserve our rights under the
license and to enjoin Coherent from breaching its terms. We do
not know whether we would prevail in any such action, which
would be costly and time consuming, and we could lose our rights
under the license, which could have a material adverse impact on
our business opportunities in Japan. In addition, we may have to
defend ourselves against infringement claims from Coherent in
Japan based on their position on termination of the license. We
do not believe the Japanese patents disclose or cover certain
innovations in our products, which we developed independently
and are the subject of our own patent applications. Neither
party has taken any formal legal action in connection with
Coherent assertions. In
17
fact, we maintain an ongoing dialogue with Coherent. To date, we
have not commercialized any products or generated any revenue in
Japan.
Although we work to protect our technology, we cannot assure you
that any patent will issue from currently pending patent
applications or from future patent applications. We also cannot
assure you that the scope of any patent protection will exclude
competitors or provide competitive advantages to us, that any of
our patents will be held valid if subsequently challenged, or
that others will not claim rights in or ownership of our patents
and proprietary rights. Furthermore, we cannot assure you that
others have not developed or will develop similar products,
duplicate any of our products or design around our patents.
We have also filed for trademark protection for marks used with
our Microcyn products in each of the United States, Europe,
Canada, certain countries in Central and South America,
including Mexico and Brazil, and certain countries in Asia,
including Japan, China, the Republic of Korea, India and
Australia. In addition to patents and trademarks, we rely on
trade secret and other intellectual property laws, nondisclosure
agreements and other measures to protect our intellectual
property rights. We believe that in order to have a competitive
advantage, we must develop and maintain the proprietary aspects
of our technologies. We require our employees, consultants and
advisors to execute confidentiality agreements in connection
with their employment, consulting or advisory relationship with
us. We also require our employees, consultants and advisors who
we expect to work on our products to agree to disclose and
assign to us all inventions made in the course of our working
relationship with them, while using our property or which relate
to our business. Despite any measures taken to protect our
intellectual property, unauthorized parties may attempt to copy
aspects of our products or to wrongfully obtain or use
information that we regard as proprietary. For more information,
please see Risk Factors, Our competitive
position depends on our ability to protect our intellectual
property and our proprietary technologies.
Competition
We believe the principal competitive factors in our target
market include improved patient outcomes, such as time in the
hospital, healing time, adverse events, safety of products, ease
of use, stability, spore killing and cost effectiveness. The
wound care market is highly competitive. We compete with a
number of large, well-established and well-funded companies that
sell a broad range of wound care products, including topical
anti-infectives and antibiotics, as well as some advanced wound
technologies, such as skin substitutes, growth factors and
sophisticated delayed release silver-based dressings.
Our products compete with a variety of products used for wound
cleaning, debriding and moistening, including sterile saline,
and chlorhexadine-based products, and they also compete with a
large number of prescription and over-the-counter products for
the prevention and treatment of infections, including topical
anti-infectives, such as Betadine, silver sulfadiazine, hydrogen
peroxide, Dakins solution and hypochlorous acid, and
topical antibiotics, such as Neosporine, Mupirocin and
Bacitracin. Currently, no single anti-infective product
dominates the chronic or acute wound markets because many of the
products have serious limitations or tend to inhibit the wound
healing process.
Our products can also replace the use of sterile saline for
debriding and moistening a dressing as well as for use as a
complementary product with many advanced wound care
technologies, such as the VACTherapy System from Kinetic
Concepts Inc., skin substitute products from Smith &
Nephew, Integra Life Sciences, Life Cell, Organogenesis and
Ortec International, and ultrasound from Celleration. We believe
that Microcyn can enhance the effectiveness of many of these
advanced wound care technologies. Because Microcyn is
competitive with some of the large wound care companies
products and complementary to others, we may compete with such
companies in some product lines and complement other product
lines.
While many companies are able to produce oxidized water, their
products, unlike ours, typically become unstable after
48 hours, and we believe they have a much higher chlorine
content that may not be suitable for treatment of infections in
wounds. One such company, PuriCore, sells electrolysis machines
used to manufacture brine-based oxidized water primarily as a
sterilant.
Some of our competitors enjoy several competitive advantages,
including:
|
|
|
|
|
significantly greater name recognition;
|
18
|
|
|
|
|
established relationships with healthcare professionals,
patients and third party payors;
|
|
|
|
established distribution networks;
|
|
|
|
additional product lines and the ability to offer rebates or
bundle products to offer discounts or incentives;
|
|
|
|
greater experience in conducting research and development,
manufacturing, obtaining regulatory approval for products and
marketing; and
|
|
|
|
greater financial and human resources for product development,
sales and marketing and patient support.
|
Government
Regulation
Government authorities in the United States at the federal,
state and local levels and foreign countries extensively
regulate, among other things, the research, development,
testing, manufacture, labeling, promotion, advertising,
distribution, sampling, marketing, and import and export of
pharmaceutical products, biologics and medical devices. All of
our products in development will require regulatory approval by
government agencies prior to commercialization. In particular,
human therapeutic products are subject to rigorous pre- clinical
and clinical trials and other approval procedures of the FDA and
similar regulatory authorities in foreign countries. Various
federal, state, local and foreign statutes and regulations also
govern testing, manufacturing, safety, labeling, storage,
distribution and record-keeping related to such products and
their marketing. The process of obtaining these approvals and
the subsequent process of maintaining substantial compliance
with appropriate federal, state, local, and foreign statutes and
regulations require the expenditure of substantial time and
financial resources. In addition, statutes, rules, regulations
and policies may change and new legislation or regulations may
be issued that could delay such approvals.
Medical
Device Regulation
In 2005, Microcyn received 510(k) clearance as a medical device
for wound cleaning, or debridement, lubricating, moistening and
dressing. Any future product candidates or new applications
using Microcyn that are classified as medical devices will need
approval or clearance by the FDA.
New medical devices, such as Microcyn, are subject to FDA
clearance and extensive regulation under the Federal Food Drug
and Cosmetic Act, or FDCA. Under the FDCA, medical devices are
classified into one of three classes: Class I,
Class II or Class III. The classification of a device
into one of these three classes generally depends on the degree
of risk associated with the medical device and the extent of
control needed to ensure safety and effectiveness.
Class I devices are those for which safety and
effectiveness can be assured by adherence to a set of general
controls. These general controls include compliance with the
applicable portions of the FDAs Quality System Regulation,
which sets forth good manufacturing practice requirements;
facility registration, device listing and product reporting of
adverse medical events; truthful and non-misleading labeling;
and promotion of the device only for its cleared or approved
intended uses. Class II devices are also subject to these
general controls, and any other special controls as deemed
necessary by the FDA to ensure the safety and effectiveness of
the device. Review and clearance by the FDA for these devices is
typically accomplished through the so-called 510(k) pre-market
notification procedure. When 510(k) clearance is sought, a
sponsor must submit a pre-market notification demonstrating that
the proposed device is substantially equivalent to a legally
marketed Class II device (for example, a device previously
cleared through the 510(k) premarket notification process). If
the FDA agrees that the proposed device is substantially
equivalent to the predicate device, then 510(k) clearance to
market will be granted. After a device receives 510(k)
clearance, any modification that could significantly affect its
safety or effectiveness, or that would constitute a major change
in its intended use, requires a new 510(k) clearance or could
require pre-market approval, or PMA.
Clinical trials are almost always required to support a PMA
application and are sometimes required for a 510(k) pre-market
notification. These trials generally require submission of an
application for an investigational device exemption, or IDE. An
IDE must be supported by pre-clinical data, such as animal and
laboratory testing results, which show that the device is safe
to test in humans and that the study protocols are
scientifically sound. The
19
IDE must be approved in advance by the FDA for a specified
number of patients, unless the product is deemed a
non-significant risk device and is eligible for more abbreviated
investigational device exemption requirements.
Both before and after a medical device is commercially
distributed, manufacturers and marketers of the device have
ongoing responsibilities under FDA regulations. The FDA reviews
design and manufacturing practices, labeling and record keeping,
and manufacturers required reports of adverse experiences
and other information to identify potential problems with
marketed medical devices. Device manufacturers are subject to
periodic and unannounced inspection by the FDA for compliance
with the Quality System Regulation, which sets forth the current
good manufacturing practice requirements that govern the methods
used in, and the facilities and controls used for, the design,
manufacture, packaging, servicing, labeling, storage,
installation and distribution of all finished medical devices
intended for human use.
FDA regulations prohibit the advertising and promotion of a
medical device for any use outside the scope of a 510(k)
clearance or PMA approval or for unsupported safety or
effectiveness claims. Although the FDA does not regulate
physicians practice of medicine, the FDA does regulate
manufacturer communications with respect to off-label use.
If the FDA finds that a manufacturer has failed to comply with
FDA laws and regulations or that a medical device is ineffective
or poses an unreasonable health risk, it can institute or seek a
wide variety of enforcement actions and remedies, ranging from a
public warning letter to more severe actions such as:
|
|
|
|
|
fines, injunctions and civil penalties;
|
|
|
|
recall or seizure of products;
|
|
|
|
operating restrictions, partial suspension or total shutdown of
production;
|
|
|
|
refusing requests for 510(k) clearance or PMA approval of new
products;
|
|
|
|
withdrawing 510(k) clearance or PMA approvals already
granted; and
|
|
|
|
criminal prosecution.
|
The FDA also has the authority to require repair, replacement or
refund of the cost of any medical device.
The FDA also administers certain controls over the export of
medical devices from the United States, as international sales
of medical devices that have not received FDA clearance are
subject to FDA export requirements. Additionally, each foreign
country subjects such medical devices to its own regulatory
requirements. In the European Union, a single regulatory
approval process has been created, and approval is represented
by the CE Mark.
Pharmaceutical
Product Regulation
We have two pharmaceutical product candidates that are regulated
by the FDA and will require approval before we can market or
sell them as drugs. Any future product candidates or new
applications using Microcyn that are classified as drugs will
need approval by the FDA.
In the United States, the FDA regulates drugs under the FDCA and
implementing regulations that are adopted under the FDCA. In the
case of biologics, the FDA regulates such products under the
Public Health Service Act. If we fail to comply with the
applicable requirements under these laws and regulations at any
time during the product development process, approval process,
or after approval, we may become subject to administrative or
judicial sanctions. These sanctions could include the FDAs
refusal to approve pending applications, withdrawals of
approvals, clinical holds, warning letters, product recalls,
product seizures, total or partial suspension of our operations,
injunctions, fines, civil penalties or criminal prosecution. Any
agency enforcement action could have a material adverse effect
on us. The FDA also administers certain controls over the export
of drugs and biologics from the United States.
|
|
|
|
|
Pre-ClinicalPhase. The pre-clinical phase
involves the discovery, characterization, product formulation
and animal testing necessary to prepare an Investigational New
Drug application, or IND, for submission to the FDA. The IND
must be accepted by the FDA before the drug can be tested in
humans.
|
20
|
|
|
|
|
Clinical Phase. The clinical phase of
development follows a successful IND submission and involves the
activities necessary to demonstrate the safety, tolerability,
efficacy, and dosage of the substance in humans, as well as the
ability to produce the substance in accordance with cGMP
requirements. Data from these activities are compiled in a New
Drug Application, or NDA, or for biologic products a Biologics
License Application, or BLA, for submission to the FDA
requesting approval to market the drug.
|
|
|
|
Post-Approval Phase. The post-approval phase
follows FDA approval of the NDA or BLA, and involves the
production and continued analytical and clinical monitoring of
the product. The post- approval phase may also involve the
development and regulatory approval of product modifications and
line extensions, including improved dosage forms, of the
approved product, as well as for generic versions of the
approved drug, as the product approaches expiration of patent or
other exclusivity protection.
|
Each of these three phases is discussed further below.
Pre-Clinical Phase. The development of a new
pharmaceutical agent begins with the discovery or synthesis of a
new molecule. These agents are screened for pharmacological
activity using various animal and tissue models, with the goal
of selecting a lead agent for further development. Additional
studies are conducted to confirm pharmacological activity, to
generate safety data, and to evaluate prototype dosage forms for
appropriate release and activity characteristics. Once the
pharmaceutically active molecule is fully characterized, an
initial purity profile of the agent is established. During this
and subsequent stages of development, the agent is analyzed to
confirm the integrity and quality of material produced. In
addition, development and optimization of the initial dosage
forms to be used in clinical trials are completed, together with
analytical models to determine product stability and
degradation. A bulk supply of the active ingredient to support
the necessary dosing in initial clinical trials must be secured.
Upon successful completion of pre-clinical safety and efficacy
studies in animals, an IND submission is prepared and provided
to the FDA for review prior to commencement of human clinical
trials. The IND consists of the initial chemistry, analytical,
formulation, and animal testing data generated during the
pre-clinical phase. The review period for an IND submission is
30 days, after which, if no comments are made by the FDA,
the product candidate can be studied in Phase I clinical trials.
Clinical Phase. Following successful
submission of an IND, the sponsor is permitted to conduct
clinical trials involving the administration of the
investigational product candidate to human subjects under the
supervision of qualified investigators in accordance with good
clinical practice. Clinical trials are conducted under protocols
detailing, among other things, the objectives of the study and
the parameters to be used in assessing the safety and the
efficacy of the drug. Each protocol must be submitted to the FDA
as part of the IND prior to beginning the trial. Each trial must
be reviewed, approved and conducted under the auspices of an
independent Institutional Review Board, and each trial, with
limited exceptions, must include the patients informed
consent. Typically, clinical evaluation involves the following
time-consuming and costly three-phase sequential process:
|
|
|
|
|
Phase I. Phase I human clinical trials are
conducted in a limited number of healthy individuals to
determine the drugs safety and tolerability and include
biological analyses to determine the availability and
metabolization of the active ingredient following
administration. The total number of subjects and patients
included in Phase I clinical trials varies, but is generally in
the range of 20 to 80 people.
|
|
|
|
Phase II. Phase II clinical trials
involve administering the drug to individuals who suffer from
the target disease or condition to determine the drugs
potential efficacy and ideal dose. These clinical trials are
typically well controlled, closely monitored, and conducted in a
relatively small number of patients, usually involving no more
than several hundred subjects. These trials require scale up for
manufacture of increasingly larger batches of bulk chemical.
These batches require validation analysis to confirm the
consistent composition of the product.
|
|
|
|
Phase III. Phase III clinical trials are
performed after preliminary evidence suggesting effectiveness of
a drug has been obtained and safety (toxicity), tolerability,
and an ideal dosing regimen have been established.
Phase III clinical trials are intended to gather additional
information about the effectiveness and safety that is needed to
evaluate the overall benefit-risk relationship of the drug and
to complete the information needed to provide adequate
instructions for the use of the drug. Phase III trials
usually include from several hundred to several thousand
subjects.
|
21
Throughout the clinical phase, samples of the product made in
different batches are tested for stability to establish shelf
life constraints. In addition, large-scale production protocols
and written standard operating procedures for each aspect of
commercial manufacture and testing must be developed.
Phase I, II, and III testing may not be completed
successfully within any specified time period, if at all. The
FDA closely monitors the progress of each of the three phases of
clinical trials that are conducted under an IND and may, at its
discretion, reevaluate, alter, suspend, or terminate the testing
based upon the data accumulated to that point and the FDAs
assessment of the risk/benefit ratio to the patient. Clinical
investigators, or IRBs, and companies may be subject to
pre-approval, routine, or for cause inspections by
the FDA for compliance with Good Clinical Practices, or GCPs,
and FDA regulations governing clinical investigations. The FDA
may suspend or terminate clinical trials, or a clinical
investigators participation in a clinical trial, at any
time for various reasons, including a finding that the subjects
or patients are being exposed to an unacceptable health risk.
The FDA can also request additional clinical trials be conducted
as a condition to product approval. Additionally, new government
requirements may be established that could delay or prevent
regulatory approval of our products under development.
Furthermore, institutional review boards, which are independent
entities constituted to protect human subjects in the
institutions in which clinical trials are being conducted, have
the authority to suspend clinical trials in their respective
institutions at any time for a variety of reasons, including
safety issues.
Post-Approval Phase. After approval, we are
still subject to continuing regulation by the FDA, including,
but not limited to, record keeping requirements, submitting
periodic reports to the FDA, reporting of any adverse
experiences with the product, and complying with drug sampling
and distribution requirements. In addition, we are required to
maintain and provide updated safety and efficacy information to
the FDA. We are also required to comply with requirements
concerning advertising and promotional labeling. In that regard,
our advertising and promotional materials must be truthful and
not misleading. We are also prohibited from promoting any
non-FDA approved or off-label indications of
products. Failure to comply with those requirements could result
in significant enforcement action by the FDA, including warning
letters, orders to pull the promotional materials, and
substantial fines. Also, quality control and manufacturing
procedures must continue to conform to cGMP after approval.
Drug and biologics manufacturers and their subcontractors are
required to register their facilities and products manufactured
annually with the FDA and certain state agencies and are subject
to periodic routine and unannounced inspections by the FDA to
assess compliance with cGMP regulations. Facilities may also be
subject to inspections by other federal, foreign, state, or
local agencies. In addition, approved biological drug products
may be subject to
lot-by-lot
release testing by the FDA before these products can be
commercially distributed. Accordingly, manufacturers must
continue to expend time, money, and effort in the area of
production and quality control to maintain compliance with cGMP
and other aspects of regulatory compliance. Future FDA
inspections may identify compliance issues at our facilities or
at the facilities that may disrupt production or distribution,
or require substantial resources to correct.
In addition, following FDA approval of a product, discovery of
problems with a product or the failure to comply with
requirements may result in restrictions on a product,
manufacturer, or holder of an approved marketing application,
including withdrawal or recall of the product from the market or
other voluntary or FDA-initiated action that could delay further
marketing. Newly discovered or developed safety or effectiveness
data may require changes to a products approved labeling,
including the addition of new warnings and contraindications.
Also, the FDA may require post-market testing and surveillance
to monitor the products safety or efficacy, including
additional clinical studies, known as Phase IV trials, to
evaluate long-term effects.
Regulation
of Disinfectants
In October 2004, we obtained EPA authorization, or registration
for the distribution and sale of our Microcyn-based product as a
hospital grade disinfectant. In August 2006, we received a
show cause letter from the EPA stating that it was
prepared to file a civil administrative complaint against us for
violation of federal pesticide legislation in connection with
the sale or distribution of a pesticide that did not meet the
labels efficacy claims. On April 5, 2007, we entered
into a Consent Agreement and Final Order with the EPA allowing
us to amend our EPA registration to a food sanitizer and pay a
$20,800 fine without admitting or denying any wrongdoing.
22
In the United States, the EPA regulates disinfectants as
antimicrobial pesticides under the Federal Insecticide,
Fungicide and Rodenticide Act, or FIFRA, and the implementing
regulations that the EPA has adopted under FIFRA. Before
marketing a disinfectant in the United States, we must satisfy
the EPAs pesticide registration requirements. That
registration process requires us to demonstrate the
disinfectants efficacy and to determine the potential
human and ecological risks associated with use of the
disinfectant. The testing and registration process could be
lengthy and could be expensive. There is no assurance, however,
that we will be able to satisfy all of the pesticide
registration requirements for a particular proposed new
disinfectant product. Once we satisfy the FIFRA registration
requirements for an individual disinfectant, additional FIFRA
regulations will apply to our various business activities,
including marketing, related to that EPA-registered product.
Failure to comply with FIFRAs requirements could expose us
to various enforcement actions. FIFRA empowers the EPA to seek
administrative or judicial sanctions against those who violate
FIFRA. Among the potential FIFRA penalties are civil
administrative penalties, stop sale orders, cancellation of our
registration, seizures, injunctions and criminal sanctions. If
EPA were to initiate a FIFRA enforcement action against us, it
could have a material adverse effect on us.
Other
Regulation in the United States
Health
Care Coverage and Reimbursement by Third-Party Payors
Commercial success in marketing and selling our products
depends, in part, on the availability of adequate coverage and
reimbursement from third-party health care payors, such as
government and private health insurers and managed care
organizations. Third-party payers are increasingly challenging
the pricing of medical products and services. Government and
private sector initiatives to limit the growth of health care
costs, including price regulation, competitive pricing, and
managed-care arrangements, are continuing in many countries
where we do business, including the United States. These changes
are causing the marketplace to be more cost-conscious and
focused on the delivery of more cost-effective medical products.
Government programs, including Medicare and Medicaid, private
health care insurance companies, and managed-care plans control
costs by limiting coverage and the amount of reimbursement for
particular procedures or treatments. This has created an
increasing level of price sensitivity among customers for our
products. Some third-party payors also require that a favorable
coverage determination be made for new or innovative medical
devices or therapies before they will provide reimbursement of
those medical devices or therapies. Even though a new medical
product may have been cleared or approved for commercial
distribution, we may find limited demand for the product until
adequate coverage and reimbursement have been obtained from
governmental and other third-party payors.
Fraud and
Abuse Laws
In the United States, we are subject to various federal and
state laws pertaining to healthcare fraud and abuse, which,
among other things, prohibit the offer or acceptance of
remuneration intended to induce or in exchange for the purchase
of products or services reimbursed under a federal healthcare
program and the submission of false or fraudulent claims with
the government. These laws include the federal Anti-Kickback
Statute, the False Claim Act and comparable state laws. These
laws regulate the activities of entities involved in the
healthcare industry, such as us, by limiting the kinds of
financial arrangements such entities may have with healthcare
providers who use or recommend the use of medical products
(including for example, sales and marketing programs, advisory
boards and research and educational grants). In addition, in
order to ensure that healthcare entities comply with healthcare
laws, the Office of Inspector General, or OIG, of the
U.S. Department of Health and Human Services recommends
that healthcare entities institute effective compliance
programs. To assist in the development of effective compliance
programs, the OIG has issued model Compliance Program Guidance,
or CPG, materials for a variety of healthcare entities which,
among other things, identify practices to avoid that may
implicate the federal Anti-Kickback Statute and other relevant
laws and describes elements of an effective compliance program.
While compliance with the CPG materials is voluntary, a recent
California law requires pharmaceutical and devices manufacturers
to initiate compliance programs that incorporate the CPG and the
July 2002 Pharmaceuticals Research and Manufacturers of America
Code on Interactions with Healthcare Professionals.
23
Due to the scope and breadth of the provisions of some of these
laws, it is possible that some of our practices might be
challenged by the government under one or more of these laws in
the future. Violations of these laws, which are discussed more
fully below, can lead to civil and criminal penalties, damages,
imprisonment, fines, exclusion from participation in Medicare,
Medicaid and other federal health care programs, and the
curtailment or restructuring of our operations. Any such
violations could have a material adverse effect on our business,
financial condition, results of operations or cash flows.
Anti-Kickback Laws. Our operations are subject
to federal and state anti-kickback laws. The federal
Anti-Kickback Statute prohibits persons from knowingly and
willfully soliciting, receiving, offering or providing
remuneration directly or indirectly to induce either the
referral of an individual for a good or service reimbursed under
a federal healthcare program, or the furnishing, recommending,
or arranging of a good or service, for which payment may be made
under a federal healthcare program, such as Medicare or
Medicaid. The definition of remuneration has been
broadly interpreted to include anything of value, including such
items as gifts, discounts, the furnishing of supplies or
equipment, waiver of co-payments, and providing anything at less
than its fair market value. Because the Anti-Kickback Statute
makes illegal a wide variety of common (even beneficial)
business arrangements, the OIG was tasked with issuing
regulations, commonly known as safe harbors, that
describe arrangements where the risk of illegal remuneration is
minimal. As long as all of the requirements of a particular safe
harbor are strictly met, the entity engaging in that activity
will not be prosecuted under the federal Anti-Kickback Statute.
The failure of a transaction or arrangement to fit precisely
within one or more safe harbors does not necessarily mean that
it is illegal or that prosecution will be pursued. However,
business arrangements that do not fully satisfy an applicable
safe harbor may result in increased scrutiny by government
enforcement authorities, such as the OIG. Our agreements to pay
compensation to our advisory board members and physicians who
conduct clinical trials or provide other services for us may be
subject to challenge to the extent they do not fall within
relevant safe harbors under state and federal anti-kickback
laws. In addition, many states have adopted laws similar to the
federal Anti-Kickback Statute which apply to the referral of
patients for healthcare services reimbursed by Medicaid, and
some have adopted such laws with respect to private insurance.
Violations of the Anti-Kickback Statute are subject to
significant fines and penalties and may lead to a company being
excluded from participating in federal health care programs.
False Claims Laws. The federal False Claims
Act prohibits knowingly filing a false claim, knowingly causing
the filing of a false claim, or knowingly using false statements
to obtain payment from the federal government. Under the False
Claims Act, such suits are known as qui tam actions,
and those who bring such suits. Individuals may file suit on
behalf of the government share in any amounts received by the
government pursuant to a settlement. In addition, certain states
have enacted laws modeled after the federal False Claims Act
under the Deficit Reduction Act of 2005, the federal government
created financial incentives for states to enact false claims
laws consistent with the federal False Claims Act. As more
states enact such laws, we expect the number of qui tam lawsuits
to increase. Qui tam actions have increased significantly in
recent years, causing greater numbers of healthcare companies to
have to defend a false claims action, pay fines or be excluded
from Medicare, Medicaid or other federal or state government
healthcare programs as a result of investigations arising out of
such actions.
HIPAA. Two federal crimes were created under
the Health Insurance Portability and Accountability Act of 1996,
or HIPAA: healthcare fraud and false statements relating to
healthcare matters. The healthcare fraud statute prohibits
knowingly and willfully executing a scheme to defraud any
healthcare benefit program, including private payors. The false
statements statute prohibits knowingly and willfully falsifying,
concealing or covering up a material fact or making any
materially false, fictitious or fraudulent statement in
connection with the delivery of or payment for healthcare
benefits, items or services.
Health
Information Privacy and Security
Individually identifiable health information is subject to an
array of federal and state regulation. Federal rules promulgated
pursuant to HIPAA regulate the use and disclosure of health
information by covered entities. Covered entities
include individual and institutional health care providers from
which we may receive individually identifiable health
information. These regulations govern, among other things, the
use and disclosure of health information for research purposes,
and require the covered entity to obtain the written
authorization of the individual before using or disclosing
health information for research. Failure of the covered entity
to obtain such
24
authorization could subject the covered entity to civil and
criminal penalties. We may experience delays and complex
negotiations as we deal with each entitys differing
interpretation of the regulations and what is required for
compliance. Also, where our customers or contractors are covered
entities, including hospitals, universities, physicians or
clinics, we may be required by the HIPAA regulations to enter
into business associate agreements that subject us
to certain privacy and security requirements. In addition, many
states have laws that apply to the use and disclosure of health
information, and these laws could also affect the manner in
which we conduct our research and other aspects of our business.
Such state laws are not preempted by the federal privacy law
where they afford greater privacy protection to the individual.
While activities to assure compliance with health information
privacy laws are a routine business practice, we are unable to
predict the extent to which our resources may be diverted in the
event of an investigation or enforcement action with respect to
such laws.
Foreign
Regulation
Whether or not we obtain FDA approval for a product, we must
obtain approval of a product by the applicable regulatory
authorities of foreign countries before we can commence clinical
trials or marketing of the product in those countries. The
approval process varies from country to country, and the time
may be longer or shorter than that required for FDA approval.
The requirements governing the conduct of clinical trials,
product licensing, pricing, and reimbursement also vary greatly
from country to country. Although governed by the applicable
country, clinical trials conducted outside of the United States
typically are administered under a three-phase sequential
process similar to that discussed above for pharmaceutical
products.
European
Union Regulation
Medical Device Regulation. Our Microcyn
products are classified as medical devices in the European
Union. In order to sell our medical device products within the
European Union, we are required to comply with the requirements
of the Medical Devices Directive, or MDD, and its national
implementations, including affixing CE Marks on our
products. In order to comply with the MDD, we must meet certain
requirements relating to the safety and performance of our
products and, prior to marketing our products, we must
successfully undergo verification of our products
regulatory compliance, or conformity assessment.
Medical devices are divided into three regulatory classes:
Class I, Class IIb and Class III. The nature of
the conformity assessment procedures depends on the regulatory
class of the product. We executed the conformity assessment for
production quality assurance for Class IIb products for
Dermacyn Wound Care. Compliance with production quality
assurance is audited every year by a private entity certified by
government regulators. In order to comply with the examination,
we completed, among other things, a risk analysis and presented
clinical data, which demonstrated that our products met the
performance specifications claimed by us, provided sufficient
evidence of adequate assessment of unwanted side effects and
demonstrated that the benefits to the patient outweigh the risks
associated with the device. We will be subject to continued
supervision and will be required to report any serious adverse
incidents to the appropriate authorities. We will also be
required to comply with additional national requirements that
are beyond the scope of the MDD.
We received our CE certificate for Dermacyn Wound Care as a
Class IIb medical device in February 2005. There can be no
assurance that we will be able to maintain the requirements
established for CE Marks for any or all of our products or that
we will be able to produce these products in a timely and
profitable manner while complying with the requirements of the
MDD and other regulatory requirements.
Marketing Authorizations for Drugs. In order
to obtain marketing approval of any of our drug products in
Europe, we must submit for review an application similar to a
U.S. NDA to the relevant authority. In contrast to the
United States, where the FDA is the only authority that
administers and approves NDAs, in Europe there are multiple
authorities that administer and approve these applications.
Marketing authorizations in Europe expire after five years but
may be renewed.
We believe that our Microcyn-based drugs will be reviewed by the
Committee for Medicinal Products for Human Use, or CHMP, on
behalf of the European Medicines Agency, or EMEA. Based upon the
review of the CHMP, the EMEA provides an opinion to the European
Commission on the safety, quality and efficacy of the drug. The
decision to grant or refuse an authorization is made by the
European Commission.
25
Approval of applications can take several months to several
years, or may be denied. This approval process can be affected
by many of the same factors relating to safety, quality and
efficacy as in the approval process for NDAs in the United
States. As in the United States, European drug regulatory
authorities can require us to perform additional non-clinical
studies and clinical trials. The need for such studies or
trials, if imposed, may delay marketing approval and involve
unanticipated costs. Inspection of clinical investigation sites
by a competent authority may also be required as part of the
regulatory approval procedure. In addition, as a condition of
marketing approval, regulatory agencies in Europe may require
post-marketing surveillance to monitor for adverse effects, or
other additional studies as deemed appropriate. The terms of any
approval, including labeling content, may be more restrictive
than expected and could affect the marketability of a product.
In addition, after approval for the initial indication, further
clinical studies are usually necessary to gain approval for any
additional indications.
European GMP. In the European Union, the
manufacture of pharmaceutical products and clinical trial
supplies is subject to good manufacturing practice, or GMP, as
set forth in the relevant laws and guidelines. Compliance with
GMP is generally assessed by the competent regulatory
authorities. They may conduct inspections of relevant
facilities, and review manufacturing procedures, operating
systems and personnel qualifications. In addition to obtaining
approval for each product, in many cases each drug manufacturing
facility must be approved. Further inspections may occur over
the life of the product.
Mexico
The MOH is the authority in charge of sanitary controls in
Mexico. Sanitary controls are a group of practices related to
the orientation, education, testing, verification and
application of security measures and sanctions exercised by the
MOH. The MOH acts by virtue of the Federal Commission for the
Protection against Sanitary Risks, or COFEPRIS, a decentralized
entity of the MOH whose mission is to protect the population
against sanitary risks, by means of centralized sanitary
regulations, controls and by raising public awareness.
The MOH is responsible for the issuance of Official Mexican
Standards and specifications for drugs subject to the provisions
of the General Health Law, which govern the process and
specifications of drugs, including the obtaining, preparation,
manufacturing, maintenance, mixture, conditioning, packaging,
handling, transport, distribution, storage and supply of
products to the public at large. In addition, a medical device
is defined as a device that may contain antiseptics or
germicides used in surgical practice or in the treatment of
continuity solutions, skin injuries or its attachments.
Regulations applicable to medical devices and drugs are divided
into two sections: the business that manufactures the medical
device or drug and the product itself.
Manufacturing a Medical Device or Drug. Under
the General Health Law, a business that manufactures drugs is
either required to obtain a Sanitary Authorization or to file an
Operating Notice. Our Mexico subsidiary is considered a business
that manufactures medical devices and therefore is not subject
to a Sanitary Authorization, but rather only an Operating Notice.
In addition to its Operating Notice, our Mexico subsidiary has
obtained a Good Processing Practices Certificate
issued by COFEPRIS, which demonstrates that the manufacturing of
Microcyn at the facility located in Zapopan, Mexico, operates in
accordance with the applicable official standards.
Commercialization of Drugs and Medical
Devices. Drugs and medical devices should be
commercialized in appropriate packaging containing labels
printed in accordance with specific official standards. For
medical devices, there are no specific standards or regulations
related to the labeling of the product, but rather only a
general standard related to the labeling for all types of
products to be commercialized in Mexico. Advertising of medical
devices is regulated in the General Health Law and in the
specific regulations of the General Health Law related to
advertising. Generally, the advertising of medical devices is
subject to a permit only in the case that such advertising is
directed to the general public.
Medical Devices and Drugs as a Product. To
produce, sell or distribute medical devices, a Sanitary Registry
is required in accordance with the General Health Law and the
Regulation for Drugs. Such registry is granted for a term of
five years, and this term may be extended. The Sanitary Registry
may be revoked if the interested party does not request the
extension in the term or the product or the manufacturer or the
raw material is changed without the permission of the MOH.
26
The MOH classifies the medical devices in three classes:
|
|
|
|
|
Class I. Devices for which safety and
effectiveness have been duly proved and are generally not used
inside the body;
|
|
|
|
Class II. Devices that may vary with
respect to the material used for its fabrication or in its
concentration and generally used in the inside of the body for a
period no greater than 30 days; and
|
|
|
|
Class III. New devices or recently
approved devices in the medical practice or those used inside
the body and which shall remain inside the body for a period
greater than 30 days.
|
Violation of these regulations may result in the revocation of
the registrations or approvals, and, in addition, economic
fines. In some cases, such violations may constitute criminal
actions.
In addition, regulatory approval of prices is required in most
countries other than the United States, which could result in
lengthy negotiations delaying our ability to commercialize our
products. We face the risk that the prices which result from the
regulatory approval process would be insufficient to generate an
acceptable return.
Executive
Officers
The names of our executive officers and their ages as of
March 31, 2007, are as follows:
|
|
|
|
|
|
|
Name
|
|
Age
|
|
Position
|
|
Hojabr Alimi
|
|
|
45
|
|
|
President, Chief Executive Officer
and Chairman of the Board
|
James Schutz
|
|
|
44
|
|
|
Vice President Corporate
Development, Secretary, General Counsel and Director
|
Michael Wokasch
|
|
|
55
|
|
|
Chief Operating Officer
|
Robert Miller
|
|
|
64
|
|
|
Chief Financial Officer
|
Bruce Thornton
|
|
|
42
|
|
|
Vice President International
Operations and Sales
|
Hojabr Alimi, one of our founders, has served as our
Chief Executive Officer, President and director since 1999 and
was appointed as Chairman of the board of directors in June
2006. Prior to co-founding our company with his spouse in 1999,
Mr. Alimi was a Corporate Microbiologist for Arterial
Vascular Engineering. Mr. Alimi received a B.A. in biology
from Sonoma State University.
Michael Wokasch has served as our Chief Operating Officer
since June 2006. From July 2004 to May 2006, Mr. Wokasch
served as Senior Vice President Global Commercial Operations for
the Biopharmaceuticals division of Chiron Corporation, a
biotechnology company. He served as Chief Operating Officer of
Impax Laboratories, a pharmaceutical company, from January 2003
to June 2004. Prior to Impax, Mr. Wokasch served as
President of PanVera Corporation and then Aurora Biosciences
Corporation, both drug discovery subsidiary companies of Vertex
Pharmaceuticals, from July 2001 to December 2002, and as Chief
Executive Officer of Gala Design, a biotechnology company, from
June 2000 to July 2001. Prior to this, Mr. Wokasch also
served as a President and Corporate Senior Vice President at
Covance from 1997 to 1999, a contract research organization. In
this capacity, Mr. Wokasch managed the global Early
Development operations at Covance responsible for providing drug
development services including preclinical toxicology,
bioanalytical chemistry, regulatory, and Phase I clinical
services to pharmaceutical and biotechnology companies. Prior to
this, he held sales and marketing positions at Abbott
Laboratories, Merck & Co., and Miles Inc.
Mr. Wokasch received a B.S. from the University of
Minnesota, College of Pharmacy.
Robert Miller has served as our Chief Financial Officer
since June 2004 and was a consultant to us from March 2003 to
May 2004. Mr. Miller has served as a director of Scanis,
Inc. since 1998 and served as acting Chief Financial Officer
from 1998 to June 2006. He was a Chief Financial Officer
consultant to Evit Labs from June 2003 to December 2004,
Wildlife International Network from October 2002 to December
2005, Endoscopic Technologies from November 2002 to March 2004,
Biolog from January 2000 to December 2002 and Webware from
August 2000 to August 2002. Prior to this, Mr. Miller was
the Chief Financial Officer for GAF Corporation, Penwest Ltd.
27
and Bugle Boy and Treasurer of Mead Corporation. He received a
B.A. in economics from Stanford University and an M.B.A. in
finance from Columbia University.
James Schutz has served as our Vice President of
Corporate Development and General Counsel since
August 2003, as a director since May 2004 and Corporate
Secretary since June 2006. From August 2001 to August 2003,
Mr. Schutz served as General Counsel at Jomed (formerly
EndoSonic Corp.), an international medical device company. From
1999 to July 2001, Mr. Schutz served as in-house counsel at
Urban Media Communications Corporation, an Internet/telecom
company based in Palo Alto, California. Mr. Schutz received
a B.A. in economics from the University of California,
San Diego and a J.D. from the University of
San Francisco School of Law.
Bruce Thornton has served as our Vice President of
International Operations and Sales since June 2005.
Mr. Thornton served as our General Manager for
U.S. Operations from March 2004 to July 2005. He served as
Vice President of Operations for Jomed (formerly EndoSonic
Corp.) from January 1999 to September 2003, and as Vice
President of Manufacturing for Volcano Therapeutics, an
international medical device company, following its acquisition
of Jomed, until March 2004. Mr. Thornton received a B.S. in
aeronautical science from Embry-Riddle Aeronautical University
and an M.B.A. from National University.
Robert Northey, Ph.D. has served as our
Director of Research and Development since July 2005.
Dr. Northey served as a consultant to us from May 2001
to June 2005. From August 1998 until June 2005, he was an
Assistant Professor in the Paper Science and Engineering
Department at the University of Washington. Dr. Northey
received a B.S. in wood and fiber science and a Ph.D. in wood
chemistry, each from the University of Washington.
Andres
Gutiérrez, M.D., Ph.D. has served
as our Director of Medical Affairs since August 2005.
Dr. Gutiérrez served as a consultant to us from April
2003 to July 2005. He served as the Head of the Cell Therapy
Unit at the National Institute of Rehabilitation in Mexico City
from September 2000 to July 2005 and as a consulting physician
with the Department of Medicine at Hospital Angeles del
Pederegal in Mexico City from 1996 to July 2005. He received an
M.D. with a specialty in internal medicine, and a Ph.D. in
biomedical sciences, each from the National University of Mexico
in Mexico City.
Gerard de Nies has served as Director of Marketing and
Sales Europe, Middle East and Africa of our
Netherlands subsidiary, since August 2005. Mr. de Nies held a
similar position in Kimberly-Clark for the
Scientific & Industrial division, where he was
responsible for sales and marketing in Europe from July 1999
through August 2005. He was the Sales Manager in the Ethicon
Endo-Surgery division of Johnson & Johnson from June
1993 to July 1999. Mr. de Nies received a Bachelor of nursing
and of healthcare management, each from the University of
Amsterdam, The Netherlands.
Sergio Caleti has served as Commercial Director for our
Mexican subsidiary since February 2005. Mr. Caleti served
as the Mexico National Sales Manager of Darier Laboratories, a
dermatological laboratory, from July 2003 to January 2005. He
served as the Regional Sales Manager, Hospital Products Division
for the central region for Abbott Laboratories from 1999 until
June 2003. Mr. Caleti received an engineering degree from
the Engineering School of Universidad Iberoamericana, Mexico.
Employees
As of March 31, 2007, we had 69 full-time
employees, including 15 in manufacturing, 12 in research and
development, 6 in regulatory and clinical, 12 in sales and
marketing and 14 in executive or administrative functions in the
U.S., 3 in administrative functions in Europe, 5 in
administrative functions in Mexico, and 2 in information
technology function. None of our employees is covered by
collective bargaining arrangements, and we consider our
relationship with our employees to be good.
Available
Information
Our website is located at www.oculusis.com. We make available
free of charge on our website our annual reports on
Form 10-K,
quarterly reports on
Form 10-Q,
current reports on
Form 8-K
and amendments to those reports, as soon as reasonably
practicable after we electronically file or furnish such
materials to the Securities and Exchange Commission. Our website
and the information contained therein or connected thereto are
not intended to be incorporated into this Annual Report on
Form 10-K.
28
Factors
that May Affect Results
Risks
Related to Our Business
We
have a history of losses, we expect to continue to incur losses
and we may never achieve profitability.
We have incurred significant net losses in each fiscal year
since our inception, including losses of $19.8 million,
$21.1 million and $16.5 million for the years ended
March 31, 2007, 2006 and 2005 respectively. Our accumulated
deficit as of March 31, 2007 was $70.5 million. We
have yet to demonstrate that we can generate sufficient sales of
our products to become profitable. The extent of our future
operating losses and the timing of profitability are highly
uncertain, and we may never achieve profitability. Even if we do
generate significant revenues from our product sales, we expect
that increased operating expenses will result in significant
operating losses in the near term as we, among other things:
|
|
|
|
|
conduct preclinical studies and clinical trials on our products
and product candidates;
|
|
|
|
seek FDA clearance to market Microcyn as a drug in the United
States;
|
|
|
|
increase our research and development efforts to enhance our
existing products, commercialize new products and develop new
product candidates;
|
|
|
|
establish additional and expand existing manufacturing
facilities; and
|
|
|
|
grow our sales and marketing capabilities in the United States
and internationally.
|
As a result of these activities, we will need to generate
significant revenue in order to achieve profitability and may
never become profitable. We must also maintain specified cash
reserves in connection with our loan and security agreement
which may limit our investment opportunities. Failure to
maintain these reserves could result in our secured lenders
foreclosing against our assets or imposing significant
restrictions on our operations. Even if we do achieve
profitability, we may not be able to sustain or increase
profitability on an ongoing basis.
Without raising additional capital, we would curtail certain
operational activities in order to reduce costs. We cannot
provide any assurance that we will secure any commitments for
new financing on acceptable terms, if at all.
Because
all of our products are based on our Microcyn platform
technology, we will need to generate sufficient revenues from
the sale of Microcyn to execute our business plan.
All of our products are based on our Microcyn platform
technology, and we do not have any non-Microcyn product
candidates that will generate revenues in the foreseeable
future. Accordingly, we expect to derive substantially all of
our future revenues from sales of our current Microcyn products.
We have only been selling our products since July 2004, and
substantially all of our historical product revenues have been
from sales of Microcyn in Mexico. Although we began selling in
Europe in October 2004, in the United States in June 2005, and
in India in July 2006, our product revenues outside of Mexico
were not significant prior to fiscal year 2007. For example,
product revenues from countries outside of Mexico were just 9%
of our product revenues for the year ended March 31, 2006.
However, during the year ended March 31, 2007, the
percentage of product revenues from outside of Mexico increased
to 32%. Microcyn has not been adopted as a standard of care for
wound treatment in any country and may not gain acceptance among
physicians, nurses, patients, third-party payors and the medical
community. Existing protocols for wound care are well
established within the medical community and tend to vary
geographically, and healthcare providers may be reluctant to
alter their protocols to include the use of Microcyn. If
Microcyn does not achieve an adequate level of acceptance, we
will not generate sufficient revenues to become profitable. We
recently decreased our sales and marketing activities in Europe
and Mexico, which could materially affect our revenues in the
geographic areas in the future.
29
Our
inability to raise additional capital on acceptable terms in the
future may cause us to curtail certain operational activities,
including regulatory trials, sales and marketing, and
international operations, in order to reduce costs and sustain
the business, and would have a material adverse effect on our
business and financial condition.
We expect capital outlays and operating expenditures to increase
over the next several years as we work to conduct regulatory
trials, commercialize our products and expand our
infrastructure. We have entered into debt financing arrangements
which are secured by all of our assets. We may need to raise
additional capital to, among other things:
|
|
|
|
|
fund our clinical trials and preclinical studies;
|
|
|
|
sustain commercialization of our current products or new
products;
|
|
|
|
expand our manufacturing capabilities;
|
|
|
|
increase our sales and marketing efforts to drive market
adoption and address competitive developments;
|
|
|
|
acquire or license technologies; and
|
|
|
|
finance capital expenditures and our general and administrative
expenses.
|
Our present and future funding requirements will depend on many
factors, including:
|
|
|
|
|
the progress and timing of our clinical trials;
|
|
|
|
the level of research and development investment required to
maintain and improve our technology position;
|
|
|
|
cost of filing, prosecuting, defending and enforcing patent
claims and other intellectual property rights;
|
|
|
|
our efforts to acquire or license complementary technologies or
acquire complementary businesses;
|
|
|
|
changes in product development plans needed to address any
difficulties in commercialization;
|
|
|
|
competing technological and market developments; and
|
|
|
|
changes in regulatory policies or laws that affect our
operations.
|
If we raise additional funds by issuing equity securities,
dilution to our stockholders could result. Any equity securities
issued also may provide for rights, preferences or privileges
senior to those of holders of our common stock. If we raise
additional funds by issuing debt securities, these debt
securities would have rights, preferences and privileges senior
to those of holders of our common stock, and the terms of the
debt securities issued could impose significant restrictions on
our operations. If we raise additional funds through
collaborations and licensing arrangements, we might be required
to relinquish significant rights to our technologies or
products, or grant licenses on terms that are not favorable to
us. A failure to obtain adequate funds may cause us to curtail
certain operational activities, including regulatory trials,
sales and marketing, and international operations, in order to
reduce costs and sustain the business, and would have a material
adverse effect on our business and financial condition.
We do
not have the necessary regulatory approvals to market Microcyn
as a drug in the United States.
We have obtained three 510(k) clearances in the United States
that permit us to sell Microcyn as a medical device to clean,
moisten and debride wounds. However, we do not have the
necessary regulatory approvals to market Microcyn in the United
States as a drug, which we will need to obtain in order to
execute our business plan. Before we are permitted to sell
Microcyn as a drug in the United States, we must, among other
things, successfully complete additional preclinical studies and
well-controlled clinical trials, submit a New Drug Application,
or NDA, to the FDA and obtain FDA approval. In July 2006, we
completed a controlled clinical trial for pre-operative skin
preparation. After completion of this trial, the FDA advised us
that it is considering adopting new heightened performance
requirements for evaluating efficacy of products designed to be
used in pre-operative skin preparation such as ours. In
discussions with the FDA, the FDA has not provided us with the
definitive timing for, or parameters of, any such requirements,
and has informally stated that it is uncertain during what time
frame it will be able to do
30
so. We plan to continue our discussions with the FDA regarding
the possible timing and parameters of any new guidelines for
evaluating efficacy for pre-operative skin preparations.
Depending on the ultimate position of the FDA regarding
performance criteria for pre-operative skin preparations, we may
reassess our priorities, clinical timelines and schedules for
pursuing a pre-operative skin preparation indication or may
decide not to pursue this indication. We also intend to seek FDA
approval for the use of Microcyn to treat infections in wounds.
We have sponsored the majority of physicians performing
physician clinical studies of Microcyn and in some cases, the
physicians who performed these studies also hold equity in our
company. The physician clinical studies were performed in the
United States, Mexico and Italy, and used various endpoints,
methods and controls. These studies were not intended to be
rigorously designed or controlled clinical trials and, as such,
did not have all of the controls required for clinical trials
used to support an NDA submission to the FDA in that they did
not include blinding, randomization, predefined clinical
endpoints, use of placebo and active control groups or
U.S. good clinical practice requirements. Consequently, the
results of these physician clinical studies may not be used by
us to support an NDA submission for Microcyn to the FDA. In
addition, any results obtained from clinical trials designed to
support an NDA submission for Microcyn to the FDA may not be as
favorable as results from such physician clinical studies and
otherwise may not be sufficient to support an NDA submission or
FDA approval of any Microcyn NDA.
The FDA approval process is expensive and uncertain, requires
detailed and comprehensive scientific and other data and
generally takes several years. Despite the time and expense
exerted, approval is never guaranteed. We do not know whether we
will obtain favorable results in our preclinical and clinical
studies or whether we will obtain the necessary regulatory
approvals to market Microcyn as a drug in the United States. We
anticipate that obtaining approval for the use of Microcyn to
treat infections in wounds in the United States will take
several years. Even if we obtain FDA approval to sell Microcyn
as a drug, we may not be able to successfully commercialize
Microcyn as a drug in the United States and may never recover
the substantial costs we have invested in the development of our
Microcyn products.
Delays
or adverse results in clinical trials could result in increased
costs to us and delay our ability to generate
revenue.
Clinical trials can be long and expensive, and the outcome of
clinical trials is uncertain and subject to delays. It may take
several years to complete clinical trials, if at all, and a
product candidate may fail at any stage of the clinical trial
process. The length of time required varies substantially
according to the type, complexity, novelty and intended use of
the product candidate. Interim results of a preclinical study or
clinical trial do not necessarily predict final results, and
acceptable results in preclinical studies or early clinical
trials may not be repeatable in later subsequent clinical
trials. The commencement or completion of any of our clinical
trials may be delayed or halted for a variety of reasons,
including the following:
|
|
|
|
|
FDA requirements for approval, including requirements for
testing efficacy or safety, may change;
|
|
|
|
the FDA or other regulatory authorities do not approve a
clinical trial protocol;
|
|
|
|
patients do not enroll in clinical trials at the rate we expect;
|
|
|
|
delays in reaching agreement on acceptable clinical trial
agreement terms with prospective sites;
|
|
|
|
delays in obtaining institutional review board approval to
conduct a study at a prospective site;
|
|
|
|
third party clinical investigators do not perform our clinical
trials on our anticipated schedule or consistent with the
clinical trial protocol and good clinical practices, or the
third party organizations do not perform data collection and
analysis in a timely or accurate manner;
|
|
|
|
governmental regulations or administrative actions are
changed; and
|
|
|
|
insufficient funds to continue our clinical trials.
|
We do not know whether our existing or any future clinical
trials will demonstrate safety and efficacy sufficiently to
result in additional FDA approvals. While a number of physicians
have conducted clinical studies assessing the safety and
efficacy of Microcyn for various indications, the data from
these studies is not sufficient to
31
support approval of Microcyn as a drug in the United States. In
addition, further studies and trials could show different
results. For example, in an independent physician study of
10 patients in which procedures were not fully delineated,
published in February 2007, four patients discontinued treatment
with Demacyn due to pain, and beneficial change in wound
microbiology was found in only one of the six remaining
patients. We will be required to conduct additional clinical
trials prior to seeking approval of Microcyn for additional
indications. Our failure to adequately demonstrate the safety
and efficacy of our product candidates to the satisfaction of
the FDA will prevent our receipt of FDA approval for additional
indications and, ultimately, impact commercialization of our
products in the United States. If we experience significant
delays or adverse results in clinical trials, our financial
results and the commercial prospects for products based on
Microcyn will be harmed, our costs would increase and our
ability to generate revenue would be delayed.
One of
our non-commercialized products, when tested by the
U.S. Environmental Protection Agency, or EPA, did not meet
certain efficacy standards based on an EPA test protocol that
used parameters that differed from those parameters previously
used by us when we originally registered this product as an EPA
registered disinfectant product.
In October 2004, after EPA review of our registration filing,
including the results of disinfectant efficacy testing conducted
by an independent laboratory retained by us, we obtained EPA
authorization, or registration, for the distribution and sale of
our Microcyn-based product, which we call Cidalcyn, as a
hospital grade disinfectant. Although we have not commercialized
Cidalcyn, we previously provided samples to potential marketing
partners and other entities for product evaluation.
Subsequently, in July 2006, we were informed by the EPA that in
more recent tests conducted by the EPA, Cidalcyn did not meet
efficacy standards when tested against three specified pathogens
(Pseudomonas aeruginosa, Staphylococcus aureus and
Mycobacterium tuberculosis) when used according to label
directions. We believe the EPA test protocol utilizes a
bacterial culture to challenge a disinfectant in a test method
which does not replicate a human wound environment and which is
not used to evaluate the safety or efficacy of wound care
products by the FDA or CE Mark. We believe the EPA test made use
of a bacterial culture which contained a significantly higher
concentration of pathogens than the culture used in the
independent test, the results of which we submitted to the EPA
for registration purposes. This increased concentration of
bacteria might have overwhelmed our Cidalcyn product. Subsequent
testing we have conducted appears to have confirmed the
EPAs results against two of the three pathogens. Based on
the EPAs own testing, the EPA strongly recommended that we
immediately recall all Cidalcyn distributed on and after
September 28, 2005. Accordingly, we promptly and
voluntarily ceased all distribution of Cidalcyn to end users,
and we are not providing the product to distributors or
retailers for re-distribution to third parties or end users; we
have ceased promoting Cidalcyn; and we have contacted the
entities and small number of individuals in the United States
who are not our employees, to whom the Cidalcyn product had been
provided for evaluation purposes during the one-year period (the
products shelf-life) prior to our receipt of the
EPAs recent notification to ensure they have been informed
not to use any remaining quantities they might have in their
possession. In August 2006, we received a show cause
letter from the EPA stating that it was prepared to file a civil
administrative complaint against us for violation of federal
pesticide legislation in connection with the sale or
distribution of a pesticide that did not meet the labels
efficacy claims, and it gave us the opportunity to advise the
EPA of any factors we believe the EPA should consider before
issuing a civil complaint. We have engaged in discussions with
the EPA and since that time and worked cooperatively with the
EPA to resolve this matter. Unless and until we provide new
information to support the original label claims of Cidalcyn to
the EPA, there will not be any sales or other distributions of
the product in the United States as a hospital grade
disinfectant. On April 5, 2007, we entered into a Consent
Agreement and Final Order with the EPA allowing us to amend our
EPA registration to a food sanitizer and pay a $20,800 fine
without admitting or denying any wrongdoing.
If we
fail to obtain, or experience significant delays in obtaining
additional regulatory clearances or approvals to market our
current or future products, we may be unable to commercialize
these products.
Developing, testing, manufacturing, marketing and selling of
medical technology products are subject to extensive regulation
by numerous governmental authorities in the United States and
other countries. The process of obtaining regulatory clearance
and approval of medical technology products is costly and time
consuming. Even though the underlying product formulation may be
the same or similar, our products are subject to different
regulations and approval processes depending upon their intended
use. In the United States, use of Microcyn to
32
cleanse and debride a wound comes within the medical device
regulation framework, while use of Microcyn to treat infections
in wounds will require us to seek FDA approval of Microcyn as a
drug in the United States.
To obtain regulatory approval of our products as drugs in the
United States, we must first show that our products are safe and
effective for target indications through preclinical studies
(laboratory and animal testing) and clinical trials (human
testing). The FDA generally clears marketing of a medical device
through the 510(k) pre-market clearance process if it is
demonstrated that the new product has the same intended use and
the same or similar technological characteristics as another
legally marketed Class II device, such as a device already
cleared by the FDA through the 510(k) premarket notification
process, and otherwise meets the FDAs requirements.
Product modifications, including labeling the product for a new
intended use, may require the submission of a new 510(k)
clearance and FDA approval before the modified product can be
marketed.
We do not know whether our products based on Microcyn will
receive approval from the FDA as a drug. The data from clinical
studies of Microcyn conducted by physicians to date will not
satisfy the FDAs regulatory criteria for approval of an
NDA. In order for us to seek approval for the use of Microcyn as
a drug in the treatment of infections in wounds, we will be
required to conduct additional preclinical and clinical trials
and submit applications for approval to the FDA. For example, we
are currently planning to conduct a pilot study of Microcyn for
the treatment of wound infections, and we will need to conduct
additional non-clinical and well-controlled clinical trials in
order to generate data to support FDA approval of Microcyn for
this indication.
The outcomes of clinical trials are inherently uncertain. In
addition, we do not know whether the necessary approvals or
clearances will be granted or delayed for future products. The
FDA could request additional information or clinical testing
that could adversely affect the time to market and sale of
products as drugs. If we do not obtain the requisite regulatory
clearances and approvals, we will be unable to commercialize our
products as drugs or devices and may never recover any of the
substantial costs we have invested in the development of
Microcyn.
Distribution of our products outside the United States is
subject to extensive government regulation. These regulations,
including the requirements for approvals or clearance to market,
the time required for regulatory review and the sanctions
imposed for violations, vary from country to country. We do not
know whether we will obtain regulatory approvals in such
countries or that we will not be required to incur significant
costs in obtaining or maintaining these regulatory approvals. In
addition, the export by us of certain of our products that have
not yet been cleared for domestic commercial distribution may be
subject to FDA export restrictions. Failure to obtain necessary
regulatory approvals, the restriction, suspension or revocation
of existing approvals or any other failure to comply with
regulatory requirements would have a material adverse effect on
our future business, financial condition, and results of
operations.
If our
products do not gain market acceptance, our business will suffer
because we might not be able to fund future
operations.
A number of factors may affect the market acceptance of our
products or any other products we develop or acquire, including,
among others:
|
|
|
|
|
the price of our products relative to other treatments for the
same or similar treatments;
|
|
|
|
the perception by patients, physicians and other members of the
health care community of the effectiveness and safety of our
products for their indicated applications and treatments;
|
|
|
|
our ability to fund our sales and marketing efforts; and
|
|
|
|
the effectiveness of our sales and marketing efforts.
|
If our products do not gain market acceptance, we may not be
able to fund future operations, including developing, testing
and obtaining regulatory approval for new product candidates and
expanding our sales and marketing efforts for our approved
products, which would cause our business to suffer.
33
We
have agreed to change the brand name of our product in Mexico,
which may result in the loss of any brand recognition that we
have established with users of our products.
In accordance with the settlement of a trademark infringement
lawsuit filed against us in Mexico, we have agreed to stop using
the name Microcyn60 in Mexico by September 2007. In addition, in
May 2006, a complaint was filed against us for trademark
confusion in connection with the same tradename, and we are in
settlement negotiations concerning such claim. We have marketed
our products in Mexico under the brand name of Microcyn60 since
2004. During the year ended March 31, 2007, 68% of our
product revenues were derived from Mexico. As a result of our
agreement to change our product name, we may lose the benefit of
the brand name recognition we have generated in the region and
our product sales in Mexico could decline. In locations where we
have distributed our products, we believe that the brand names
of those products have developed name recognition among
consumers who purchase them. Any change to the brand name of our
other products may cause us to lose such name recognition, which
may lead to confusion in the marketplace and a decline in sales
of our products.
If our
competitors develop products similar to Microcyn, we may need to
modify or alter our business strategy, which may delay the
achievement of our goals.
Competitors may develop products with similar characteristics as
Microcyn. Such similar products marketed by larger competitors
can hinder our efforts to penetrate the market. As a result, we
may be forced to modify or alter our business and regulatory
strategy and sales and marketing plans, as a response to changes
in the market, competition and technology limitations, among
others. Such modifications may pose additional delays in
achieving our goals.
We
intend to license or collaborate with third parties in various
potential markets, and events involving these strategic partners
or any future collaborations could delay or prevent us from
developing or commercializing products.
Our business strategy and our short- and long-term operating
results will depend in part on our ability to execute on
existing strategic collaborations and to license or partner with
new strategic partners. We believe collaborations allow us to
leverage our resources and technologies and to access markets
that are compatible with our own core areas of expertise while
avoiding the cost of establishing a direct sales force in each
market. We may incur significant costs in the use of third
parties to identify and assist in establishing relationships
with potential collaborators.
To penetrate our target markets, we may need to enter into
additional collaborative agreements to assist in the development
and commercialization of future products. For example, depending
upon our analysis of the time and expense involved in obtaining
FDA approval to sell a product to treat open wounds, we may
choose to license our technology to a third party as opposed to
pursuing commercialization ourselves. Establishing strategic
collaborations is difficult and time-consuming. Potential
collaborators may reject collaborations based upon their
assessment of our financial, regulatory or intellectual property
position and our internal capabilities. Our discussions with
potential collaborators may not lead to the establishment of new
collaborations on favorable terms. We have limited control over
the amount and timing of resources that our current
collaborators or any future collaborators devote to our
collaborations or potential products. These collaborators may
breach or terminate their agreements with us or otherwise fail
to conduct their collaborative activities successfully and in a
timely manner. Further, our collaborators may not develop or
commercialize products that arise out of our collaborative
arrangements or devote sufficient resources to the development,
manufacture, marketing or sale of these products. By entering
into a collaboration, we may preclude opportunities to
collaborate with other third parties who do not wish to
associate with our existing third party strategic partners.
Moreover, in the event of termination of a collaboration
agreement, termination negotiations may result in less favorable
terms.
If we
are unable to expand our direct domestic sales force, we may not
be able to successfully sell our products in the United
States.
We have very limited commercialization capability and make
Microcyn-based products available primarily through our website,
one national distributor and several regional distributors. We
plan for a more aggressive
34
commercialization and product launch in the event we obtain drug
approval from the FDA. Developing a sales force is expensive and
time consuming, and the lack of qualified sales personnel could
delay or limit the success of our product launch. Our domestic
sales force, if established, will be competing with the sales
operations of our competitors, which are better funded and more
experienced. We may not be able to develop domestic sales
capacity on a timely basis or at all.
We may
incur significant liabilities in connection with our
relationship with a former distributor in Mexico.
On June 16, 2005, we entered into a series of agreements
with Quimica Pasteur, or QP, a Mexico-based distributor of
pharmaceutical products to hospitals and health care entities
owned or operated by the Mexican Ministry of Health, or MOH.
These agreements provided, among other things, for QP to act as
our exclusive distributor of Microcyn to the MOH for a period of
three years. We were granted an option to acquire all except a
minority share of the equity of QP directly from its principals.
In addition, two of our employees were appointed as officers of
QP, which resulted in the establishment of financial control of
QP by our company under applicable accounting literature. As a
result of our agreements, we were required to consolidate
QPs operations with our financial results for a portion of
our year ended March 31, 2006. In connection with our audit
of QPs financial statements in late 2005, we were made
aware of a number of facts that suggested that QP or its
principals may have engaged in some form of tax avoidance
practice in Mexico prior to the execution of the agreements
between our company and QP. We did not discover these facts
prior to our execution of these agreements or for several months
thereafter. Our prior independent auditors informed us that we
did not have effective anti-fraud programs designed to detect
the type of activities in which QPs principals engaged or
the personnel to effectively evaluate and determine the
appropriate accounting for non-routine or complex accounting
transactions. Our audit committee engaged an outside law firm to
conduct an investigation whose findings implicated QPs
principals in a systemic tax avoidance practice prior to
June 16, 2005. We estimate that QPs liability for
taxes, interest and penalties related to these practices could
amount to $7 million or more. Based on the results of this
investigation, we terminated our agreements with QP effective
March 26, 2006.
Although we do not believe that we are responsible for any tax
avoidance practices of QPs principals prior to
June 16, 2005, the Mexican taxing authority could make a
claim against us or our Mexican subsidiary. We have been
informed by counsel in Mexico that the statute of limitations,
including for actions for fraud, is five years from
March 31, 2006.
Our
dependence on distributors for sales could limit or prevent us
from selling our products and from realizing long-term revenue
growth.
We currently depend on distributors to sell Microcyn in the
United States, Europe and other countries and intend to continue
to sell our products primarily through distributors in Europe
and the United States for the foreseeable future. If we are
unable to expand our direct sales force, we will continue to
rely on distributors to sell Microcyn. Our existing distribution
agreements are generally short-term in duration, and we may need
to pursue alternate distributors if the other parties to these
agreements terminate or elect not to renew their agreements. If
we are unable to retain our current distributors for any reason,
we must replace them with alternate distributors experienced in
supplying the wound care market, which could be time-consuming
and divert managements attention from other operational
matters. In addition, we will need to attract additional
distributors to expand the geographic areas in which we sell
Microcyn. Distributors may not commit the necessary resources to
market and sell our products to the level of our expectations,
which could harm our ability to generate revenues. In addition,
some of our distributors may also sell products that compete
with ours. In some countries, regulatory licenses must be held
by residents of the country. For example, the regulatory
approval for one product in India is owned and held by our
Indian distributor. If the licenses are not in our name or under
our control, we might not have the power to ensure their ongoing
effectiveness and use by us. If current or future distributors
do not perform adequately, or we are unable to locate
distributors in particular geographic areas, we may not realize
long-term revenue growth.
We
depend on a contract sales force to sell our products in
Mexico.
We currently depend on a contract sales force to sell Microcyn
in Mexico. Our existing agreement is short-term in duration and
can be terminated by either party upon 30 days written
notice. If we are unable to retain our current
35
agreement for any reason, we may need to build our own internal
sales force or find an alternate source for contract sales
people. We may be unable to find an alternate source, or the
alternate sources sales force may not generate sufficient
revenue. If our current or future contract sales force does not
perform adequately, we may not realize long-term revenue growth
in Mexico.
If we
fail to comply with ongoing regulatory requirements, or if we
experience unanticipated problems with our products, these
products could be subject to restrictions or withdrawal from the
market.
Regulatory approvals or clearances that we currently have and
that we may receive in the future are subject to limitations on
the indicated uses for which the products may be marketed, and
any future approvals could contain requirements for potentially
costly post-marketing
follow-up
studies. If the FDA determines that our promotional materials or
activities constitute promotion of an unapproved use or we
otherwise fail to comply with FDA regulations, we may be subject
to regulatory enforcement actions, including a warning letter,
injunction, seizure, civil fine or criminal penalties. In
addition, the manufacturing, labeling, packaging, adverse event
reporting, storage, advertising, promotion, distribution and
record-keeping for approved products are subject to extensive
regulation. Our manufacturing facilities, processes and
specifications are subject to periodic inspection by the FDA,
European and other regulatory authorities and from time to time,
we may receive notices of deficiencies from these agencies as a
result of such inspections. Our failure to continue to meet
regulatory standards or to remedy any deficiencies could result
in restrictions being imposed on products or manufacturing
processes, fines, suspension or loss of regulatory approvals or
clearances, product recalls, termination of distribution or
product seizures or the need to invest substantial resources to
comply with various existing and new requirements. In the more
egregious cases, criminal sanctions, civil penalties,
disgorgement of profits or closure of our manufacturing
facilities are possible. The subsequent discovery of previously
unknown problems with Microcyn, including adverse events of
unanticipated severity or frequency, may result in restrictions
on the marketing of our products, and could include voluntary or
mandatory recall or withdrawal of products from the market.
New government regulations may be enacted and changes in FDA
policies and regulations, their interpretation and enforcement,
could prevent or delay regulatory approval of our products. We
cannot predict the likelihood, nature or extent of adverse
government regulation that may arise from future legislation or
administrative action, either in the United States or abroad.
Therefore, we do not know whether we will be able to continue to
comply with any regulations or that the costs of such compliance
will not have a material adverse effect on our future business,
financial condition, and results of operations. If we are not
able to maintain regulatory compliance, we will not be permitted
to market our products and our business would suffer.
We may
experience difficulties in manufacturing Microcyn, which could
prevent us from commercializing one or more of our
products.
The machines used to manufacture our Microcyn-based products are
complex, use complicated software and must be monitored by
highly trained engineers. Slight deviations anywhere in our
manufacturing process, including quality control, labeling and
packaging, could lead to a failure to meet the specifications
required by the FDA, the EPA, European notified bodies, Mexican
regulatory agencies and other foreign regulatory bodies, which
may result in lot failures or product recalls. In August 2006,
we received a show cause letter from the EPA, which
stated that, in tests conducted by the EPA, Cidalcyn was found
to be ineffective in killing specified pathogens when used
according to label directions. We gathered records for review to
determine if there might have been any problems in production of
the lot tested by the EPA. We have also quarantined all
remaining quantities of the production lot in question. If we
are unable to obtain quality internal and external components,
mechanical and electrical parts, if our software contains
defects or is corrupted, or if we are unable to attract and
retain qualified technicians to manufacture our products, our
manufacturing output of Microcyn, or any other product candidate
based on our platform that we may develop, could fail to meet
required standards, our regulatory approvals could be delayed,
denied or revoked, and commercialization of one or more of our
Microcyn-based products may be delayed or foregone.
Manufacturing processes that are used to produce the smaller
quantities of Microcyn needed for our clinical test and current
commercial sales may not be successfully scaled up to allow
production of significant commercial quantities. Any failure to
manufacture our products to required standards on a commercial
scale could result in reduced revenues, delays in generating
revenue and increased costs.
36
Our
competitive position depends on our ability to protect our
intellectual property and our proprietary
technologies.
Our ability to compete and to achieve and maintain profitability
depends on our ability to protect our intellectual property and
proprietary technologies. We currently rely on a combination of
patents, patent applications, trademarks, trade secret laws,
confidentiality agreements, license agreements and invention
assignment agreements to protect our intellectual property
rights. We also rely upon unpatented know-how and continuing
technological innovation to develop and maintain our competitive
position. These measures may not be adequate to safeguard our
Microcyn technology. In addition, we granted a security interest
in our assets, including our intellectual property, under two
loan and security agreements. If we do not protect our rights
adequately, third parties could use our technology, and our
ability to compete in the market would be reduced.
Although we have filed U.S. and foreign patent applications
related to our Microcyn based products, the manufacturing
technology for making the products, and their uses, only one
patent has been issued from these applications to date.
Our pending patent applications and any patent applications we
may file in the future may not result in issued patents, and we
do not know whether any of our in-licensed patents or any
additional patents that might ultimately be issued by the
U.S. Patent and Trademark Office or foreign regulatory body
will protect our Microcyn technology. Any claims that issue may
not be sufficiently broad to prevent third parties from
producing competing substitutes and may be infringed, designed
around, or invalidated by third parties. Even issued patents may
later be found to be invalid, or may be modified or revoked in
proceedings instituted by third parties before various patent
offices or in courts.
The degree of future protection for our proprietary rights is
more uncertain in part because legal means afford only limited
protection and may not adequately protect our rights, and we
will not be able to ensure that:
|
|
|
|
|
we were the first to invent the inventions described in patent
applications;
|
|
|
|
we were the first to file patent applications for inventions;
|
|
|
|
others will not independently develop similar or alternative
technologies or duplicate our products without infringing our
intellectual property rights;
|
|
|
|
any patents licensed or issued to us will provide us with any
competitive advantages;
|
|
|
|
we will develop proprietary technologies that are
patentable; or
|
|
|
|
the patents of others will not have an adverse effect on our
ability to do business.
|
The policies we use to protect our trade secrets may not be
effective in preventing misappropriation of our trade secrets by
others. In addition, confidentiality and invention assignment
agreements executed by our employees, consultants and advisors
may not be enforceable or may not provide meaningful protection
for our trade secrets or other proprietary information in the
event of unauthorized use or disclosures. We cannot be certain
that the steps we have taken will prevent the misappropriation
and use of our intellectual property, particularly in foreign
countries where the laws may not protect our proprietary rights
as fully as in the United States. For example, one of our former
contract partners, Nofil Corporation, whom we relied upon to
manufacture our proprietary machines had access to our
proprietary information and we believe undertook the development
and manufacture of the machines to be sold to third parties in
violation of our agreement with such company. We have brought a
claim against Nofil Corporation in the U.S. District Court
for the Northern District of California. We believe that a
former officer of our Mexico subsidiary collaborated in these
acts, misappropriated our trade secrets, and is currently
selling products in Mexico that are competitive with our
products. In addition, we believe that, through the licensor of
the patents that we in-license and who has also assigned patents
to us, a company in Japan obtained one of our patent
applications, translated it into Hangul and filed it under such
companys and the licensors name in South Korea.
These and any other leak of confidential data into the public
domain or to third parties could allow our competitors to learn
our trade secrets.
37
We are
in a dispute with the Japanese entity that licenses to us
certain rights under Japanese patents, which could result in our
losing such rights and may have a material adverse impact on our
business opportunities in Japan.
In March 2003, we obtained an exclusive license to six issued
Japanese patents and five Japanese published pending patent
applications owned by Coherent Technologies. The issued Japanese
patents and pending Japanese patent applications relate to an
earlier generation of super-oxidized water product with an
acidic pH and not the current commercialized Microcyn. The
patents that cover the method and apparatus for the production
of the earlier generation of super-oxidized water will expire
between 2011 and 2014. In June 2006, we received written notice
from Coherent Technologies advising us that the patent license
was terminated, citing various reasons with which we disagree.
Since that time we have engaged in discussions with Coherent
Technologies concerning the license agreement and our continued
business relationship. Although we do not believe Coherent
Technologies has grounds to terminate the license, we may have
to take legal action to preserve our rights under the license
and to enjoin Coherent Technologies from breaching its terms. We
do not know whether we would prevail in any such action, which
would be costly and time consuming, and we could lose our rights
under the license, which could have a material adverse impact on
our business opportunities in Japan. In addition, we could have
to defend ourselves against infringement claims from Coherent
Technologies in Japan based on their position on termination of
the license.
We may
face intellectual property infringement claims that could be
time-consuming, costly to defend and could result in our loss of
significant rights and, in the case of patent infringement
claims, the assessment of treble damages.
On occasion, we may receive notices of claims of infringement,
misappropriation or misuse of other parties proprietary
rights. We may have disputes regarding intellectual property
rights with the parties that have licensed those rights to us.
Some claims received from third parties may lead to litigation.
We cannot assure you that we will prevail in these actions, or
that other actions alleging misappropriation or misuse by us of
third-party trade secrets, infringement by us of third-party
patents and trademarks or the validity of our patents, will not
be asserted or prosecuted against us. We may also initiate
claims to defend our intellectual property. For example, we
brought a claim against Nofil Corporation for misappropriation
of our trade secrets and Nofil Corporation filed a
cross-complaint against us in February 2007 claiming ownership
of our technology. Intellectual property litigation, regardless
of outcome, is expensive and time-consuming, could divert
managements attention from our business and have a
material negative effect on our business, operating results or
financial condition. In addition, the outcome of such litigation
may be unpredictable. If there is a successful claim of
infringement against us, we may be required to pay substantial
damages (including treble damages if we were to be found to have
willfully infringed a third partys patent) to the party
claiming infringement, develop non-infringing technology, stop
selling our products or using technology that contains the
allegedly infringing intellectual property or enter into royalty
or license agreements that may not be available on acceptable or
commercially practical terms, if at all. Our failure to develop
non-infringing technologies or license the proprietary rights on
a timely basis could harm our business. In addition, modifying
our products to include the non-infringing technologies could
require us to seek re-approval or clearance from various
regulatory bodies for our products, which would be costly and
time consuming. Also, we may be unaware of pending patent
applications that relate to our technology. Parties making
infringement claims on future issued patents may be able to
obtain an injunction that would prevent us from selling our
products or using technology that contains the allegedly
infringing intellectual property, which could harm our business.
In September 2005, a complaint was filed against us in Mexico
claiming trademark infringement with respect to our Microcyn60
mark. To settle this claim we have agreed to cease marketing our
product in Mexico under the name Microcyn60 by September 2007. A
second unrelated claim was filed against us in Mexico in May
2006, claiming trademark infringement with respect to our
Microcyn60 mark in Mexico. We are in discussions with the
claimant to settle the matter.
In addition to the infringement claims in Mexico, we are
currently involved in several pending trademark opposition
proceedings in connection with our applications to register the
marks Microcyn, Oculus Microcyn and Dermacyn in
the European Union, Argentina, Guatemala, Honduras, Nicaragua
and Paraguay. If we are unable to settle these disputes or
prevail in these opposition proceedings, we will not be able to
obtain registrations for the
38
Microcyn, Oculus Microcyn and Dermacyn
marks in those countries, and that may impair our ability to
enforce our trademark rights against infringers in those
countries. Although no such legal proceedings have been brought
or threats of such legal proceedings have been made, we cannot
rule out the possibility that any of these opposing parties will
also file a trademark infringement lawsuit seeking to prevent
our use and seek monetary damages based on our use of the
Microcyn, Oculus Microcyn and Dermacyn
marks in the European Union, Argentina, Guatemala, Honduras,
Nicaragua and Paraguay.
We have also entered into agreements with third parties to
settle trademark opposition proceedings in which we have agreed
to certain restrictions on our use and registration of certain
marks. In March 2006, we entered into an agreement with an
opposing party that places restrictions on the manner in which
we can use and register our Microcyn and Microcyn60
marks in countries where the opposing party has superior
rights, including in Europe and Singapore. These restrictions
include always using Microcyn along with the word
technology and another distinctive trademark such as
Cidalcyn, Dermacyn and Vetericyn. In
addition, we have entered into an agreement with an opposing
party in which we agreed to limit our use and registration of
the Microcyn mark in Uruguay to disinfectant, antiseptic
and sterilizing agents. Moreover, we have entered into an
agreement with an opposing party in Europe in which we agreed to
specifically exclude ophthalmologic products for our Oculus
Microcyn application in the European Union.
Our
ability to generate revenue will be diminished if we are unable
to obtain acceptable prices or an adequate level of
reimbursement from third-party payors of healthcare
costs.
The continuing efforts of governmental and other third-party
payors, including managed care organizations such as health
maintenance organizations, or HMOs, to contain or reduce costs
of health care may affect our future revenue and profitability,
and the future revenue and profitability of our potential
customers, suppliers and collaborative or license partners and
the availability of capital. For example, in certain foreign
markets, pricing or profitability of prescription
pharmaceuticals is subject to government control. In the United
States, governmental and private payors have limited the growth
of health care costs through price regulation or controls,
competitive pricing programs and drug rebate programs. Our
ability to commercialize our products successfully will depend
in part on the extent to which appropriate coverage and
reimbursement levels for the cost of our Microcyn products and
related treatment are obtained from governmental authorities,
private health insurers and other organizations, such as HMOs.
There is significant uncertainty concerning third-party coverage
and reimbursement of newly approved medical products and drugs.
Third-party payors are increasingly challenging the prices
charged for medical products and services. Also, the trend
toward managed healthcare in the United States and the
concurrent growth of organizations such as HMOs, as well as
legislative proposals to reform healthcare or reduce government
insurance programs, may result in lower prices for or rejection
of our products. The cost containment measures that health care
payors and providers are instituting and the effect of any
health care reform could materially and adversely affect our
ability to generate revenues.
In addition, given ongoing federal and state government
initiatives directed at lowering the total cost of health care,
the United States Congress and state legislatures will likely
continue to focus on health care reform, the cost of
prescription pharmaceuticals and the reform of the Medicare and
Medicaid payment systems. While we cannot predict whether any
proposed cost-containment measures will be adopted, the
announcement or adoption of these proposals could reduce the
price that we receive for our Microcyn products in the future.
We
could be required to indemnify third parties for alleged
infringement, which could cause us to incur significant
costs.
Some of our distribution agreements contain commitments to
indemnify our distributors against liability arising from
infringement of third party intellectual property such as
patents. We may be required to indemnify our customers for
claims made against them or license fees they are required to
pay. If we are forced to indemnify for claims or to pay license
fees, our business and financial condition could be
substantially harmed.
39
A
significant part of our business is conducted outside of the
United States, exposing us to additional risks that may not
exist in the United States, which in turn could cause our
business and operating results to suffer.
We have international operations in Mexico and Europe. For the
fiscal years ended March 31, 2007, 2006 and 2005,
approximately 78%, 72% and 35%, respectively, of our total
revenue was generated from sales outside of the United States.
Our business is highly regulated for the use, marketing and
manufacturing of our Microcyn products both domestically and
internationally. Our international operations are subject to
risks, including:
|
|
|
|
|
local political or economic instability;
|
|
|
|
changes in governmental regulation;
|
|
|
|
changes in import/export duties;
|
|
|
|
trade restrictions;
|
|
|
|
lack of experience in foreign markets;
|
|
|
|
difficulties and costs of staffing and managing operations in
certain foreign countries;
|
|
|
|
work stoppages or other changes in labor conditions;
|
|
|
|
difficulties in collecting accounts receivables on a timely
basis or at all; and
|
|
|
|
adverse tax consequences or overlapping tax structures.
|
We plan to continue to market and sale our products
internationally to respond to customer requirements and market
opportunities. We currently have international manufacturing
facilities in Mexico and The Netherlands. Establishing
operations in any foreign country or region presents risks such
as those described above as well as risks specific to the
particular country or region. In addition, until a payment
history is established over time with customers in a new
geography or region, the likelihood of collecting receivables
generated by such operations could be less than our
expectations. As a result, there is a greater risk that reserves
set with respect to the collection of such receivables may be
inadequate. If our operations in any foreign country are
unsuccessful, we could incur significant losses and we may not
achieve profitability.
In addition, changes in policies or laws of the United States or
foreign governments resulting in, among other things, changes in
regulations and the approval process, higher taxation, currency
conversion limitations, restrictions on fund transfers or the
expropriation of private enterprises, could reduce the
anticipated benefits of our international expansion. If we fail
to realize the anticipated revenue growth of our future
international operations, our business and operating results
could suffer.
Our
sales in international markets subject us to foreign currency
exchange and other risks and costs which could harm our
business.
A substantial portion of our revenues are derived from outside
the United States, primarily from Mexico. We anticipate that
revenues from international customers will continue to represent
a substantial portion of our revenues for the foreseeable
future. Because we generate revenues in foreign currencies, we
are subject to the effects of exchange rate fluctuations. The
functional currency of our Mexican subsidiary is the Mexican
Peso, and the functional currency of our subsidiary in The
Netherlands is the Euro. For the preparation of our consolidated
financial statements, the financial results of our foreign
subsidiaries are translated into U.S. dollars on average
exchange rates during the applicable period. If the
U.S. dollar appreciates against the Mexican Peso or the
Euro, as applicable, the revenues we recognize from sales by our
subsidiaries will be adversely impacted. Foreign exchange gains
or losses as a result of exchange rate fluctuations in any given
period could harm our operating results and negatively impact
our revenues. Additionally, if the effective price of our
products were to increase as a result of fluctuations in foreign
currency exchange rates, demand for our products could decline
and adversely affect our results of operations and financial
condition.
40
The
loss of key members of our senior management team, one of our
directors or our inability to retain highly skilled scientists,
technicians and salespeople could adversely affect our
business.
Our success depends largely on the skills, experience and
performance of key members of our executive management team,
including Hojabr Alimi, our Chief Executive Officer, and a
member of our Board of Directors and Robert Northey, our Vice
President of Research and Development.. The efforts of these
people will be critical to us as we continue to develop our
products and attempt to commercialize products in the chronic
and acute wound care market. If we were to lose one or more of
these individuals, we may experience difficulties in competing
effectively, developing our technologies and implementing our
business strategies.
Our research and development programs depend on our ability to
attract and retain highly skilled scientists and technicians. We
may not be able to attract or retain qualified scientists and
technicians in the future due to the intense competition for
qualified personnel among medical technology businesses,
particularly in the San Francisco Bay Area. We also face
competition from universities and public and private research
institutions in recruiting and retaining highly qualified
personnel. In addition, our success depends on our ability to
attract and retain salespeople with extensive experience in
wound care and close relationships with the medical community,
including physicians and other medical staff. We may have
difficulties locating, recruiting or retaining qualified
salespeople, which could cause a delay or decline in the rate of
adoption of our products. If we are not able to attract and
retain the necessary personnel to accomplish our business
objectives, we may experience constraints that will adversely
affect our ability to support our research, development and
sales programs.
We maintain key-person life insurance only on Mr. Alimi. We
may discontinue this insurance in the future, it may not
continue to be available on commercially reasonable terms or, if
continued, it may prove inadequate to compensate us for the loss
of Mr. Alimis services.
We may
be unable to manage our future growth effectively, which would
make it difficult to execute our business
strategy.
We may experience periods of rapid growth as we expand our
business, which will likely place a significant strain on our
limited personnel and other resources. Any failure by us to
manage our growth effectively could have an adverse effect on
our ability to achieve our commercialization goals.
Furthermore, we conduct business in a number of geographic
regions and are seeking to expand to other regions. We have not
established a physical presence in many of the international
regions in which we conduct or plan to conduct business, but
rather we manage our business from our headquarters in Northern
California. As a result, we conduct business at all times of the
day and night with limited personnel. If we fail to
appropriately target and increase our presence in these
geographic regions, we may not be able to effectively market and
sell our Microcyn products in these locations or we may not meet
our customers needs in a timely manner, which could
negatively affect our operating results.
Future growth will also impose significant added
responsibilities on management, including the need to identify,
recruit, train and integrate additional employees. In addition,
rapid and significant growth will place strain on our
administrative and operational infrastructure, including sales
and marketing and clinical and regulatory personnel. Our ability
to manage our operations and growth will require us to continue
to improve our operational, financial and management controls,
reporting systems and procedures. If we are unable to manage our
growth effectively, it may be difficult for us to execute our
business strategy.
The
wound care industry is highly competitive and subject to rapid
technological change. If our competitors are better able to
develop and market products that are less expensive or more
effective than any products that we may develop, our commercial
opportunity will be reduced or eliminated.
The wound care industry is highly competitive and subject to
rapid technological change. Our success depends, in part, upon
our ability to stay at the forefront of technological change and
maintain a competitive position.
We compete with large healthcare, pharmaceutical and
biotechnology companies, along with smaller or early-stage
companies that have collaborative arrangements with larger
pharmaceutical companies, academic institutions, government
agencies and other public and private research organizations.
Many of our competitors have
41
significantly greater financial resources and expertise in
research and development, manufacturing, pre-clinical testing,
conducting clinical trials, obtaining regulatory approvals and
marketing approved products than we do. Our competitors may:
|
|
|
|
|
develop and patent processes or products earlier than we will;
|
|
|
|
develop and commercialize products that are less expensive or
more efficient than any products that we may develop;
|
|
|
|
obtain regulatory approvals for competing products more rapidly
than we will; and
|
|
|
|
improve upon existing technological approaches or develop new or
different approaches that render our technology or products
obsolete or non-competitive.
|
As a result, we may not be able to successfully commercialize
any future products.
The
success of our research and development efforts may depend on
our ability to find suitable collaborators to fully exploit our
capabilities. If we are unable to establish collaborations or if
these future collaborations are unsuccessful, our research and
development efforts may be unsuccessful, which could adversely
affect our results of operations and financial
condition.
An important element of our business strategy will be to enter
into collaborative or license arrangements under which we
license our Microcyn technology to other parties for development
and commercialization. We expect that while we may initially
seek to conduct initial clinical trials on our drug candidates,
we may need to seek collaborators for a number of our potential
products because of the expense, effort and expertise required
to conduct additional clinical trials and further develop those
potential products candidates. Because collaboration
arrangements are complex to negotiate, we may not be successful
in our attempts to establish these arrangements. If we need
third party assistance in identifying and negotiating one or
more acceptable arrangements, it might be costly. Also, we may
not have products that are desirable to other parties, or we may
be unwilling to license a potential product because the party
interested in it is a competitor. The terms of any arrangements
that we establish may not be favorable to us. Alternatively,
potential collaborators may decide against entering into an
agreement with us because of our financial, regulatory or
intellectual property position or for scientific, commercial or
other reasons. If we are not able to establish collaborative
agreements, we may not be able to develop and commercialize new
products, which would adversely affect our business and our
revenues.
In order for any of these collaboration or license arrangements
to be successful, we must first identify potential collaborators
or licensees whose capabilities complement and integrate well
with ours. We may rely on these arrangements for, not only
financial resources, but also for expertise or economies of
scale that we expect to need in the future relating to clinical
trials, manufacturing, sales and marketing, and for licenses to
technology rights. However, it is likely that we will not be
able to control the amount and timing of resources that our
collaborators or licensees devote to our programs or potential
products. If our collaborators or licensees prove difficult to
work with, are less skilled than we originally expected, or do
not devote adequate resources to the program, the relationship
will not be successful. If a business combination, involving a
collaborator or licensee and a third party were to occur, the
effect could be to diminish, terminate or cause delays in
development of a potential product.
We may
acquire other businesses or form joint ventures that could harm
our operating results, dilute your ownership of us, increase our
debt or cause us to incur significant expense.
As part of our business strategy, we may pursue acquisitions of
complementary businesses and assets, as well as technology
licensing arrangements. We also intend to pursue strategic
alliances that leverage our core technology and industry
experience to expand our product offerings or distribution. We
have no experience with respect to acquiring other companies and
limited experience with respect to the formation of
collaborations, strategic alliances and joint ventures. If we
make any acquisitions, we may not be able to integrate these
acquisitions successfully into our existing business, and we
could assume unknown or contingent liabilities. Any future
acquisitions by us also could result in significant write-offs
or the incurrence of debt and contingent liabilities, any of
which could harm our operating results. Integration of an
acquired company also may require management resources that
otherwise would be available for ongoing development of our
existing business. We may not identify or complete these
transactions
42
in a timely manner, on a cost-effective basis, or at all, and we
may not realize the anticipated benefits of any acquisition,
technology license, strategic alliance or joint venture.
To finance any acquisitions, we may choose to issue shares of
our common stock as consideration, which would dilute your
ownership interest in us. If the price of our common stock is
low or volatile, we may not be able to acquire other companies
for stock. Alternatively, it may be necessary for us to raise
additional funds for acquisitions through public or private
financings. Additional funds may not be available on terms that
are favorable to us, or at all.
If we are unable to comply with broad and complex federal and
state fraud and abuse laws, including state and federal
anti-kickback laws, we could face substantial penalties and our
products could be excluded from government healthcare programs.
We are subject to various federal and state laws pertaining to
healthcare fraud and abuse, which include, among other things,
anti-kickback laws that prohibit payments to induce
the referral of products and services, and false
claims statutes that prohibit the fraudulent billing of
federal healthcare programs. Our operations are subject to the
federal anti-kickback statute, a criminal statute that, subject
to certain statutory exceptions, prohibits any person from
knowingly and willfully offering, paying, soliciting or
receiving remuneration, directly or indirectly, to induce or
reward a person either (i) for referring an individual for
the furnishing of items or services for which payment may be
made in whole or in part by a government healthcare program such
as Medicare or Medicaid, or (ii) for purchasing, leasing,
or ordering or arranging for or recommending the purchasing,
leasing or ordering of an item or service for which payment may
be made under a government healthcare program. Because of the
breadth of the federal anti-kickback statute, the Office of
Inspector General of the U.S. Department of Health and
Human Services, or the OIG, was authorized to adopt regulations
setting forth additional exceptions to the prohibitions of the
statute commonly known as safe harbors. If all of
the elements of an applicable safe harbor are fully satisfied,
an arrangement will not be subject to prosecution under the
federal anti-kickback statute.
We previously had agreements to pay compensation to our advisory
board members and physicians who conduct clinical trials or
provide other services for us. Currently, these agreements have
been terminated. The agreements may be subject to challenge to
the extent they do not fall within relevant safe harbors under
federal and similar state anti-kickback laws. If our past or
present operations, including, but not limited to, our
consulting arrangements with our advisory board members or
physicians conducting clinical trials on our behalf, or our
promotional or discount programs, are found to be in violation
of these laws, we or our officers may be subject to civil or
criminal penalties, including large monetary penalties, damages,
fines, imprisonment and exclusion from government healthcare
program participation, including Medicare and Medicaid.
In addition, if there is a change in law, regulation or
administrative or judicial interpretations of these laws, we may
have to change our business practices or our existing business
practices could be challenged as unlawful, which could have a
negative effect on our business, financial condition and results
of operations.
Healthcare fraud and abuse laws are complex and even minor,
inadvertent irregularities can potentially give rise to claims
that a statute or regulation has been violated.
The frequency of suits to enforce these laws have increased
significantly in recent years and have increased the risk that a
healthcare company will have to defend a false claim action, pay
fines or be excluded from the Medicare, Medicaid or other
federal and state healthcare programs as a result of an
investigation arising out of such action. We cannot assure you
that we will not become subject to such litigation. Any
violations of these laws, or any action against us for violation
of these laws, even if we successfully defend against it, could
harm our reputation, be costly to defend and divert
managements attention from other aspects of our business.
Similarly, if the physicians or other providers or entities with
whom we do business are found to have violated abuse laws, they
may be subject to sanctions, which could also have a negative
impact on us.
Our
efforts to discover and develop potential products may not lead
to the discovery, development, commercialization or marketing of
actual drug products.
We are currently engaged in a number of different approaches to
discover and develop new product applications and product
candidates. At the present time, we have one Microcyn-based drug
candidate in clinical trials. We also have a non-Microcyn-based
compound in the research and development phase. We believe this
43
compound has potential applications in oncology. Discovery and
development of potential drug candidates are expensive and
time-consuming, and we do not know if our efforts will lead to
discovery of any drug candidates that can be successfully
developed and marketed. If our efforts do not lead to the
discovery of a suitable drug candidate, we may be unable to grow
our clinical pipeline or we may be unable to enter into
agreements with collaborators who are willing to develop our
drug candidates.
We
must implement additional and expensive finance and accounting
systems, procedures and controls as we grow our business and
organization and to satisfy new reporting requirements, which
will increase our costs and require additional management
resources.
As a public reporting company, we are required to comply with
the Sarbanes-Oxley Act of 2002 and the related rules and
regulations of the Securities and Exchange Commission, or the
Commission, including expanded disclosures and accelerated
reporting requirements and more complex accounting rules for the
reporting period ending March 31, 2008. Compliance with
Section 404 of the Sarbanes-Oxley Act of 2002 and other
requirements will increase our costs and require additional
management resources. In a letter following their dismissal, our
prior independent auditors informed us that we did not have the
appropriate financial management and reporting structure in
place to meet the demands of a public company and that our
accounting and financial personnel lacked the appropriate level
of accounting knowledge, experience and training. Our current
independent auditors recommended certain changes in our internal
controls, which we are working on. We have upgraded our finance
and accounting systems, procedures and controls and will need to
continue to implement additional finance and accounting systems,
procedures and controls as we grow our business and
organization, enter into complex business transactions and take
actions designed to satisfy new reporting requirements.
Specifically, our experience with QP indicated that we need to
better plan for complex transactions and the application of
complex accounting principles relating to those transactions. If
we are unable to complete the required Section 404
assessment as to the adequacy of our internal control over
financial reporting, if we fail to maintain or implement
adequate controls, or if our independent registered public
accounting firm is unable to provide us with an unqualified
report as to the effectiveness of our internal control over
financial reporting as of the date of our second Annual Report
on
Form 10-K
for which compliance is required and thereafter, our ability to
obtain additional financing could be impaired. In addition,
investors could lose confidence in the reliability of our
internal control over financial reporting and in the accuracy of
our periodic reports filed under the Securities Exchange Act of
1934. A lack of investor confidence in the reliability and
accuracy of our public reporting could cause our stock price to
decline.
We may
not be able to maintain sufficient product liability insurance
to cover claims against us.
Product liability insurance for the healthcare industry is
generally expensive to the extent it is available at all. We may
not be able to maintain such insurance on acceptable terms or be
able to secure increased coverage if the commercialization of
our products progresses, nor can we be sure that existing or
future claims against us will be covered by our product
liability insurance. Moreover, the existing coverage of our
insurance policy or any rights of indemnification and
contribution that we may have may not be sufficient to offset
existing or future claims. A successful claim against us with
respect to uninsured liabilities or in excess of insurance
coverage and not subject to any indemnification or contribution
could have a material adverse effect on our future business,
financial condition, and results of operations.
Risks
Related to Our Common Stock
Our
operating results may fluctuate, which could cause our stock
price to decrease.
Fluctuations in our operating results may lead to fluctuations,
including declines, in our share price. Our operating results
and our share price may fluctuate from period to period due to a
variety of factors, including:
|
|
|
|
|
demand by physicians, other medical staff and patients for our
Microcyn products;
|
|
|
|
reimbursement decisions by third-party payors and announcements
of those decisions;
|
|
|
|
clinical trial results and publication of results in
peer-reviewed journals or the presentation at medical
conferences;
|
44
|
|
|
|
|
the inclusion or exclusion of our Microcyn products in large
clinical trials conducted by others;
|
|
|
|
actual and anticipated fluctuations in our quarterly financial
and operating results;
|
|
|
|
developments or disputes concerning our intellectual property or
other proprietary rights;
|
|
|
|
issues in manufacturing our product candidates or products;
|
|
|
|
new or less expensive products and services or new technology
introduced or offered by our competitors or us;
|
|
|
|
the development and commercialization of product enhancements;
|
|
|
|
changes in the regulatory environment;
|
|
|
|
delays in establishing new strategic relationships;
|
|
|
|
costs associated with collaborations and new product candidates;
|
|
|
|
introduction of technological innovations or new commercial
products by us or our competitors;
|
|
|
|
litigation or public concern about the safety of our product
candidates or products;
|
|
|
|
changes in recommendations of securities analysts or lack of
analyst coverage;
|
|
|
|
failure to meet analyst expectations regarding our operating
results;
|
|
|
|
additions or departures of key personnel; and
|
|
|
|
general market conditions.
|
Variations in the timing of our future revenues and expenses
could also cause significant fluctuations in our operating
results from period to period and may result in unanticipated
earning shortfalls or losses. In addition, the Nasdaq Global
Market, in general, and the market for life sciences companies,
in particular, have experienced significant price and volume
fluctuations that have often been unrelated or disproportionate
to the operating performance of those companies.
If an
active, liquid trading market for our common stock does not
develop, you may not be able to sell your shares quickly or at
or above the initial offering price.
Prior to our initial public offering, there was no public market
for our common stock. Although we listed our common stock listed
on the Nasdaq Global Market, an active and liquid trading market
for our common stock has not yet and may not ever develop or be
sustained. You may not be able to sell your shares quickly or at
or above the initial offering price if trading in our stock is
not active.
Future
sales of shares by our stockholders could cause the market price
of our common stock to drop significantly, even if our business
is doing well.
We had 11,844,411 outstanding shares of common stock-based on
the number of shares outstanding at March 31, 2007. The
outstanding shares will become available for resale in the
public market as shown in the chart below.
|
|
|
Number of Restricted Shares
|
|
|
7,976,604 shares.
|
|
Date Available for Sale Into
Public Market Immediately upon expiration of the
180-day lock
up period
|
193,580 shares
|
|
At some point after expiration of
the 180-day
lock up period
|
Additional sales of our common stock in the public market, or
the perception that these sales could occur, could cause the
market price of our common stock to decline.
45
We do
not expect to pay dividends in the foreseeable future. As a
result, you must rely on stock appreciation, if any, for a
return on your investment.
We do not anticipate paying cash dividends on our common stock
in the foreseeable future. Any payment of cash dividends will
depend on our financial condition, results of operations,
capital requirements and other factors and will be at the
discretion of our Board of Directors. In addition, under two of
our secured loans, we will not pay any dividends without our
secured lenders prior written consent for as long as we
have any outstanding obligations to the secured lenders.
Accordingly, you will have to rely on appreciation in the price
of our common stock, if any, to earn a return on your investment
in our common stock. Furthermore, we may in the future become
subject to contractual restrictions on, or prohibitions against,
the payment of dividends.
We may
allocate our cash and cash equivalents in ways with which you
may not agree.
Our management has broad discretion in using our cash and cash
equivalents and may use them in ways with which you may
disagree. For example, we have deposited $2 million into a
segregated account to which we do not have access to assure
payment under one of our secured loan agreements. You and other
stockholders may not agree with our decisions about the use of
our reserves. Because we are not required to allocate our cash
and cash equivalents to any specific investment or transaction,
you cannot determine at this time the value or propriety of our
application of our cash position. Moreover, you will not have
the opportunity to evaluate the economic, financial or other
information on which we base our decisions on how to use our
cash and cash equivalents. As a result, we may use our cash and
cash equivalents for corporate purposes that do not immediately
enhance our prospects for the future or increase the value of
your investment.
Anti-takeover
provisions in our charter, by-laws and Delaware law may make it
more difficult for you to change our management and may also
make a takeover difficult.
Our corporate documents and Delaware law contain provisions that
limit the ability of stockholders to change our management and
may also enable our management to resist a takeover. These
provisions include:
|
|
|
|
|
the ability of our Board of Directors to issue and designate the
rights of, without stockholder approval, up to
5,000,000 shares of convertible preferred stock, which
rights could be senior to those of common stock;
|
|
|
|
limitations on persons authorized to call a special meeting of
stockholders; and
|
|
|
|
advance notice procedures required for stockholders to make
nominations of candidates for election as directors or to bring
matters before an annual meeting of stockholders.
|
These provisions might discourage, delay or prevent a change of
control in our management. These provisions could also
discourage proxy contests and make it more difficult for you and
other stockholders to elect directors and cause us to take other
corporate actions. In addition, the existence of these
provisions, together with Delaware law, might hinder or delay an
attempted takeover other than through negotiations with our
Board of Directors.
Our
stockholders may experience substantial dilution in the value of
their investment if we issue additional shares of our capital
stock.
Our charter documents allow us to issue up to
100,000,000 shares of our common stock and to issue and
designate the rights of, without stockholder approval, up to
5,000,000 shares of convertible preferred stock. In the
event we issue additional shares of our capital stock, dilution
to our stockholders could result. In addition, if we issue and
designate a class of convertible preferred stock, these
securities may provide for rights, preferences or privileges
senior to those of holders of our common stock.
|
|
ITEM 1B:
|
Unresolved
Staff Comments
|
None.
46
We currently lease approximately 12,000 square feet of
office, research and manufacturing space in Petaluma,
California, which serves as our principal executive offices. We
also lease approximately 28,000 square feet of office space
in an adjacent building for manufacturing and research and
development. Both leases expire in September 2007. We are
currently in negotiations with our landlord and expect to extend
both leases.
We lease approximately 4,000 square feet of office space
and approximately 14,000 square feet of manufacturing and
warehouse space in Zapopan, Mexico, under a lease that expires
in April 2011. We lease approximately 5,000 square feet of
office space and approximately 14,000 square feet of
manufacturing and warehouse space in Sittard, The Netherlands,
under leases that expire in January 2009. As we expand, we may
need to establish manufacturing facilities in other countries.
We believe that, once we have determined whether to extend our
leases in Petaluma or to lease space elsewhere, our properties
will be adequate to meet our needs through March 2008.
|
|
ITEM 3.
|
Legal
Proceedings
|
In November 2005, the Company identified a possible criminal
misappropriation of its technology in Mexico, and it notified
the Mexican Attorney Generals office. The Company believes
the Mexican Attorney General is currently conducting an
investigation.
On March 14, 2006, the Company filed suit in the
U.S. District Court for the Northern District of California
against Nofil Corporation and Naoshi Kono, Chief Executive
Officer of Nofil for breach of contract, misappropriation of
trade secrets and trademark infringement. The Company believes
that Nofil Corporation violated key terms of both an exclusive
purchase agreement and non-disclosure agreement by contacting
and working with a potential competitor in Mexico. In the
complaint, the Company seeks damages of $3,500,000 and immediate
injunctive relief. On February 13, 2007, Nofil filed an
answer and cross-complaint, and it subsequently filed two
amendments to the cross complaint. The cross-complaint, which
alleges fraudulent inducement to enter contracts, breach of
non-disclosure contract, trade secret misappropriation,
conversion and violation under civil RICO statutes by the
Company, seeks damages of $4.5 million and equitable
relief. The Company believes that Nofils claims are
without merit and intends to defend its position with respect to
this matter. No trial date has been set.
The Company settled a trademark matter in Mexico in August 2006
asserting confusion in trademarks with respect to the
Companys use of the name Microcyn60 in Mexico. Although
the Company believes that the nature and intended use of its
products are different from those with the similar names, it has
agreed with one of the parties to stop using the name Microcyn60
by September 2007. Company management believes that the name
change will satisfy an assertion that the Companys
trademark use has caused confusion. Company management believes
that the Company could incur a possible loss of approximately
$100,000 for the use of the name Microcyn60 during the year
following the date of settlement.
On June 2, 2006, Oculus Technologies of México SA de
CV (OTM) filed an executory action in the Second Mercantile
Court at Guadalajara, Mexico, an action used to secure payment
of a commercial debt based on a promissory note signed by
Quimica Pasteur S de RL (QP) for approximately $770,000. The
attachment took place on February 7, 2007 and allowed OTM
to attach accounts receivables, bank accounts and some vehicles
of QP to secure the debt. No trial date has been set.
In June 2006, the Company received a written communication from
the grantor of a license to an earlier generation of its
technology indicating that such license was terminated due to an
alleged breach of the license agreement by the Company. The
license agreement extends to the Companys use of the
technology in Japan only. While the Company does not believe
that the grantors revocation is valid under the terms of
the license agreement and no legal claim has been threatened to
date, the Company cannot provide any assurance that the grantor
will not take legal action to restrict the Companys use of
the technology in the licensed territory.
47
While the Company management does not anticipate that the
outcome of this matter is likely to result in a material loss,
there can be no assurance that if the grantor pursues legal
action, such legal action would not have a material adverse
effect on the Companys financial position or results of
operations.
In October 2004, we obtained EPA authorization, or registration,
for the distribution and sale of our Microcyn- based product as
a hospital grade disinfectant. In August 2006, we received a
show cause letter from the EPA stating that it was
prepared to file a civil administrative complaint against us for
violation of federal pesticide legislation in connection with
the sale or distribution of a pesticide that did not meet the
labels efficacy claims. On April 5, 2007, we entered
into a Consent Agreement and Final Order with the EPA allowing
us to amend our EPA registration to a food sanitizer and pay a
$20,800 fine without admitting or denying any wrongdoing.
In April 2005, the Company was named as a defendant in an
employment related matter under a complaint filed by one of its
former employees in the Superior Court of the State of
California in the County of Sonoma. The Company entered into a
settlement agreement with the plaintiff in November 2006, which
provides for the payment of $250,000 cash and the issuance of a
warrant, valued at $365,000, to purchase 50,000 shares of
our common stock exercisable at $3.00 per share, and the
plaintiff has agreed to dismiss his claim and has waived any
other previous claims against us.
In September 2006, a consulting firm in Mexico City contacted
the Company threatening legal action in Mexico, alleging breach
of contract and claiming damages of $225,000. In December 2006,
the Company entered into a settlement agreement with the
consulting firm under which the Company paid $115,000 for the
dismissal of the consulting firms claim and release of all
claims against the Company.
The Company, on occasion, is involved in legal matters arising
in the ordinary course of its business. While management
believes that such matters are currently insignificant, there
can be no assurance that matters arising in the ordinary course
of business for which the Company is or could become involved in
litigation, will not have a material adverse effect on its
business, financial condition or results of operations.
|
|
ITEM 4.
|
Submission
of Matters to a Vote of Security Holders
|
None.
PART II
|
|
ITEM 5.
|
Market
for Registrants Common Equity, Related Stockholder Matters
and Issuer Purchases of Equity Securities
|
(a) Our common stock is traded on the Nasdaq Global Market
under the symbol OCLS and has been trading since our
initial public offering on January 25, 2007. The following
table sets forth the range of high and low sale prices for our
common stock, based on the last daily sale, in each of the
quarters since our stock began trading:
|
|
|
|
|
|
|
|
|
|
|
Low
|
|
|
High
|
|
|
2007:
|
|
|
|
|
|
|
|
|
Fourth Quarter (from
January 25, 2007)
|
|
$
|
5.66
|
|
|
$
|
8.40
|
|
According to the records of our transfer agent, we had 680
stockholders of record as of May 31, 2007.
(b) We have never declared or paid any cash dividends on
our capital stock, and we do not currently intend to pay any
cash dividends on our common stock in the foreseeable future.
Pursuant to our Loan and Security Agreement dated March 25,
2004 with Venture Lending & Leasing III, Inc. and
our Loan and Security Agreement dated June 14, 2006 with
Venture Lending & Leasing IV, Inc., each as amended,
we will not pay any dividends without our secured lenders
prior written consent for so long as we have any outstanding
obligations to the secured lenders.
48
(c) Information regarding the securities authorized for
issuance under our equity compensation plans can be found under
Item 12 of Part III of this Report.
(d) On January 24, 2007, a Registration Statement on
Form S-1
(File
No. 333-135584)
relating to our initial public offering was declared effective
by the SEC. Roth Capital Partners acted as the managing
underwriter. The closing was January 30, 2007, and on
February 16, 2007, our underwriters exercised their option
to sell over-allotment shares. In total, the net offering
proceeds to us including over-allotment shares were
approximately $21.9 million (after deducting underwriting
discounts, commissions and offering expenses). Through
March 31, 2007, $3.7 million of the net proceeds were
used, including $845,000 for working capital and general
corporate purposes, $1.6 million for clinical trials and
related research and development, and $1.2 million for
sales and marketing activities worldwide. A portion of the net
proceeds may also be used to acquire or invest in complementary
businesses, technologies, services or products. Pending use for
these or other purposes, net proceeds have been invested in
interest bearing, investment grade securities.
(e) During the three months ended March 31, 2007, we
did not sell any equity securities that were not registered with
the Securities Act, nor did we purchase any of our equity
securities. However, during the fiscal year ended March 31,
2007 the period covered by this report, we had sales of
unregistered equity securities.
49
(f) Stock Performance Graph
The following information is not deemed to be soliciting
material or to be filed with the Securities
and Exchange Commission or subject to Regulation 14A or 14C
under the Securities Exchange Act of 1934 or to the liabilities
of Section 18 of the Securities Exchange Act of 1934, and
will not be deemed to be incorporated by reference into any
filing under the Securities Act of 1933 or the Securities
Exchange Act of 1934, except to the extent we specifically
incorporate it by reference into such a filing.
Set forth below is a line graph showing the cumulative total
stockholder return (change in stock price plus reinvested
dividends) assuming the investment of $100 on January 25,
2007 (the day of our initial public offering) in each of our
common stock, the NASDAQ Market Index and the NASDAQ
Biotechnology Index for the period commencing on
January 25, 2007 and ending on March 31, 2007. The
comparisons in the table are required by the Securities and
Exchange Commission and are not intended to forecast or be
indicative of future performance of our common stock.
COMPARISON
OF CUMULATIVE TOTAL RETURN
AMONG OCULUS INNOVATIVE SCIENCES, INC.,
NASDAQ COMPOSITE AND NASDAQ BIOTECH INDEX
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1/25/07
|
|
|
3/31/07
|
Oculus Innovative Sciences,
Inc.
|
|
|
$
|
100.00
|
|
|
|
$
|
76.28
|
|
NASDAQ Biotechnology Index
|
|
|
$
|
100.00
|
|
|
|
$
|
94.81
|
|
NASDAQ Composite Index
|
|
|
$
|
100.00
|
|
|
|
$
|
99.48
|
|
|
|
|
|
|
|
|
|
|
|
|
50
|
|
ITEM 6.
|
Selected
Financial Data
|
You should read the following selected consolidated financial
data together with Managements Discussion and
Analysis of Financial Condition and Results of Operations
and our consolidated financial statements and related notes
included elsewhere in this
Form 10-K.
The selected consolidated statements of operations data for each
of the years ended March 31, 2007, 2006 and 2005 and the
selected consolidated balance sheet data as of March 31,
2007 and 2006 have been derived from our audited consolidated
financial statements and related notes included elsewhere in
this
Form 10-K.
The selected consolidated statements of operations data for the
years ended March 31, 2004 and 2003 and the selected
consolidated balance sheet data as of March 31, 2005, 2004
and 2003 have been derived from our consolidated financial
statements and related notes not included in this Annual Report
on
Form 10-K.
The selected consolidated statement of operations data for the
year ended March 31, 2003 and the selected consolidated
balance sheet data as of March 31, 2003 have not been
audited. The unaudited financial statements include, in the
opinion of management, all adjustments that management considers
necessary for the fair presentation of the financial information
set forth in those statements. Our historical results are not
necessarily indicative of the results that may be expected in
the future.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
2004
|
|
|
2003
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited)
|
|
|
Consolidated statement of
operations data (in thousands, except per share data):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product
|
|
$
|
3,679
|
|
|
$
|
1,966
|
|
|
$
|
473
|
|
|
$
|
95
|
|
|
$
|
|
|
Service
|
|
|
864
|
|
|
|
618
|
|
|
|
883
|
|
|
|
807
|
|
|
|
2,470
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
4,543
|
|
|
|
2,584
|
|
|
|
1,356
|
|
|
|
902
|
|
|
|
2,470
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product(1)
|
|
|
2,104
|
|
|
|
3,899
|
|
|
|
2,211
|
|
|
|
1,403
|
|
|
|
|
|
Service(1)
|
|
|
895
|
|
|
|
1,003
|
|
|
|
1,311
|
|
|
|
1,265
|
|
|
|
1,768
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total cost of revenues
|
|
|
2,999
|
|
|
|
4,902
|
|
|
|
3,522
|
|
|
|
2,668
|
|
|
|
1,768
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit (loss)
|
|
|
1,544
|
|
|
|
(2,318
|
)
|
|
|
(2,166
|
)
|
|
|
(1,766
|
)
|
|
|
702
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development(1)
|
|
|
4,508
|
|
|
|
2,600
|
|
|
|
1,654
|
|
|
|
1,413
|
|
|
|
68
|
|
Selling, general and
administrative(1)
|
|
|
16,520
|
|
|
|
15,933
|
|
|
|
12,492
|
|
|
|
3,918
|
|
|
|
2,102
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
21,028
|
|
|
|
18,533
|
|
|
|
14,146
|
|
|
|
5,331
|
|
|
|
2,170
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(19,484
|
)
|
|
|
(20,851
|
)
|
|
|
(16,312
|
)
|
|
|
(7,097
|
)
|
|
|
(1,468
|
)
|
Interest expense
|
|
|
(956
|
)
|
|
|
(172
|
)
|
|
|
(372
|
)
|
|
|
(178
|
)
|
|
|
(123
|
)
|
Interest income
|
|
|
312
|
|
|
|
282
|
|
|
|
8
|
|
|
|
3
|
|
|
|
|
|
Other income (expense), net
|
|
|
345
|
|
|
|
(377
|
)
|
|
|
146
|
|
|
|
(26
|
)
|
|
|
(4
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss from continuing operations
|
|
|
(19,783
|
)
|
|
|
(21,118
|
)
|
|
|
(16,530
|
)
|
|
|
(7,298
|
)
|
|
|
(1,595
|
)
|
Loss from operations of
discontinued business
|
|
|
|
|
|
|
(818
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss on disposal of discontinued
business
|
|
|
|
|
|
|
(1,163
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss on discontinued operations
|
|
|
|
|
|
|
(1,981
|
)
|
|
|
|
|
|
|
(7,298
|
)
|
|
|
(1,595
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
(19,783
|
)
|
|
|
(23,099
|
)
|
|
|
(16,530
|
)
|
|
|
(7,298
|
)
|
|
|
(1,595
|
)
|
Preferred stock dividends
|
|
|
(404
|
)
|
|
|
(121
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss available to common
stockholders
|
|
$
|
(20,187
|
)
|
|
$
|
(23,220
|
)
|
|
$
|
(16,530
|
)
|
|
$
|
(7,298
|
)
|
|
$
|
(1,595
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share: basic
and diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
(3.71
|
)
|
|
$
|
(5.12
|
)
|
|
$
|
(4.22
|
)
|
|
$
|
(1.87
|
)
|
|
$
|
(0.42
|
)
|
Discontinued operations
|
|
|
|
|
|
|
(0.48
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
(3.71
|
)
|
|
$
|
(5.60
|
)
|
|
$
|
(4.22
|
)
|
|
$
|
(1.87
|
)
|
|
$
|
(0.42
|
)
|
Weighted-average number of shares
used in per common share calculations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted
|
|
|
5,448
|
|
|
|
4,150
|
|
|
|
3,914
|
|
|
|
3,911
|
|
|
|
3,827
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Includes the following stock-based compensation charges (in
thousands): |
51
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
2004
|
|
|
2003
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited)
|
|
|
Cost of revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product
|
|
$
|
|
|
|
$
|
2
|
|
|
$
|
2
|
|
|
$
|
|
|
|
$
|
|
|
Service
|
|
|
4
|
|
|
|
1
|
|
|
|
3
|
|
|
|
10
|
|
|
|
55
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
|
70
|
|
|
|
52
|
|
|
|
5
|
|
|
|
56
|
|
|
|
|
|
Selling, general and administrative
|
|
|
1,508
|
|
|
|
542
|
|
|
|
2,339
|
|
|
|
358
|
|
|
|
186
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
2004
|
|
|
2003
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited)
|
|
|
Consolidated Balance Sheet Data
(in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
19,050
|
|
|
$
|
7,448
|
|
|
$
|
3,287
|
|
|
$
|
869
|
|
|
$
|
177
|
|
Working capital
|
|
|
13,834
|
|
|
|
5,127
|
|
|
|
663
|
|
|
|
(1,186
|
)
|
|
|
(145
|
)
|
Total assets
|
|
|
26,9
|
|
|
|
12,689
|
|
|
|
6,940
|
|
|
|
2,992
|
|
|
|
961
|
|
Total liabilities
|
|
|
12,049
|
|
|
|
5,351
|
|
|
|
4,738
|
|
|
|
3,374
|
|
|
|
1,040
|
|
Total stockholders equity
(deficit)
|
|
|
14,901
|
|
|
|
7,338
|
|
|
|
2,202
|
|
|
|
(382
|
)
|
|
|
(79
|
)
|
|
|
ITEM 7.
|
Managements
Discussion and Analysis of Financial Condition and Results of
Operations
|
Managements
Discussion and Analysis of Financial Condition and Results of
Operations
Business
Overview
Oculus Innovative Sciences is a biopharmaceutical company that
develops, manufactures and markets a family of products, based
on its platform technology called Microcyn, intended to help
prevent and treat infections in chronic and acute wounds.
Microcyn is a non-irritating oxychlorine compound designed to
treat a wide range of pathogens, including antibiotic-resistant
strains of bacteria, viruses, fungi and spores.
Financial
Operations Overview
Revenues
We derive our revenues from product sales and service
arrangements. Product revenues are generated from the sale of
Microcyn products to hospitals, medical centers, doctors,
pharmacies, distributors and strategic partners, and are
generally recorded upon shipment following receipt of a purchase
order or upon obtaining proof of sell-through by a distributor.
Product sales are made either through direct sales personnel or
distributors.
Service revenues are derived from consulting and testing
contracts. Service revenues are generally recorded upon
performance under the service contract. Revenues generated from
testing contracts are recorded upon completion of the test and
when the final report is sent to the customer. We have refocused
our business efforts away from consulting and testing services
toward the completion of our clinical trials and eventual
commercialization of Microcyn. As a result, we expect service
revenues to continue to significantly decline in future periods.
Cost of
Revenues
Cost of product revenues represents the costs associated with
the manufacturing of our products, including expenses for our
various facilities which are fixed, and related personnel cost
and the cost of materials used to produce our products. Cost of
service revenues consists primarily of personnel related
expenses and supplies.
52
Research
and Development Expense
Research and development expense consists of costs related to
the research and development of Microcyn and our manufacturing
process, the development of new products and new delivery
systems for our products and to carry out preclinical studies
and clinical trials to obtain various regulatory approvals.
Research and development expense is charged as incurred.
Selling,
General and Administrative Expense
Selling, general and administrative expense consists of
personnel related costs, including salaries and sales
commissions, and education and promotional expenses associated
with Microcyn and costs related to administrative personnel and
senior management. These expenses also include the costs of
educating physicians and other healthcare professionals
regarding our products and participating in industry conferences
and seminars. Selling, general and administrative expense also
includes travel costs, outside consulting services, legal and
accounting fees and other professional and administrative costs.
Stock-Based
Compensation Expense
Prior to April 1, 2006, we accounted for stock-based
employee compensation arrangements in accordance with the
provisions of APB No. 25, Accounting for Stock Issued
to Employees, and its related interpretations and applied
the disclosure requirements of SFAS No. 148,
Accounting for Stock-Based Compensation-Transition and
Disclosure, an amendment of FASB Statement No. 123.
We used the minimum value method to measure the fair value of
awards issued prior to April 1, 2006 with respect to its
application of the disclosure requirements under SFAS 123.
Effective April 1, 2006, we adopted
SFAS No. 123(R) Share Based Payment
(SFAS 123(R)). This statement is a revision of
SFAS Statement No. 123, and supersedes APB Opinion
No. 25, and its related implementation guidance.
SFAS 123(R) addresses all forms of share based payment
(SBP) awards including shares issued under employee
stock purchase plans, stock options, restricted stock and stock
appreciation rights. Under SFAS 123(R), SBP awards result
in a cost that will be measured at fair value on the
awards grant date, based on the estimated number of awards
that are expected to vest and will result in a charge to
operations.
We had a choice of two attribution methods for allocating
compensation costs under SFAS 123(R): the
straight-line method, which allocates expense on a
straight-line basis over the requisite service period of the
last separately vesting portion of an award, or the graded
vesting attribution method, which allocates expense on a
straight-line basis over the requisite service period for each
separately vesting portion of the award as if the award was, in
substance, multiple awards. We chose the former method and
amortized the fair value of each option on a straight-line basis
over the requisite period of the last separately vesting portion
of each award.
Under SFAS 123(R), nonpublic entities, including those that
become public entities after June 15, 2005, that used the
minimum value method of measuring equity share options and
similar instruments for either recognition or pro forma
disclosure purposes under Statement 123 are required to
apply SFAS 123(R)prospectively to new awards and to awards
modified, repurchased, or cancelled after the date of adoption.
In addition, SFAS 123(R), requires such entities to
continue accounting for any portion of awards outstanding at the
date of initial application using the accounting principles
originally applied to those awards. Accordingly, stock-based
compensation expense relating to awards granted prior to
April 1, 2006 that are expected to vest in periods ending
after April 1, 2006 are being recorded in accordance with
the provisions of APB 25 and its related interpretive
guidance.
We have adopted the prospective method with respect to
accounting for its transition to SFAS 123(R). Accordingly,
we recognized in salaries and related expense in the statement
of operations $158,000 of stock-based compensation expense
during the year ended March 31, 2007, which represents the
intrinsic value amortization of options granted prior to
April 1, 2006 that we are continuing to account for using
the recognition and measurement principles prescribed under
APB 25. We also recognized in salaries and related expense
in the statement of operations $815,000 of stock-based
compensation expense during the year ended March 31, 2007
which represents the amortization of the fair value of options
granted subsequent to adoption of SFAS 123(R). During the
year ended March 31, 2007, we reclassified certain
components of our stockholders equity section to reflect
the elimination of
53
deferred compensation arising from unvested share-based
compensation pursuant to the requirements of Staff Accounting
Bulletin No. 107, regarding Statement of Financial
Accounting Standards No. 123(R), Share-Based
Payment. This deferred compensation was previously
recorded as an increase to additional paid-in capital with a
corresponding reduction to stockholders equity for such
deferred compensation. This reclassification has no effect on
net income or total stockholders equity as previously
reported. We will record an increase to additional paid-in
capital as the share-based payments vest.
Total non-cash stock-compensation charges were
$1.6 million, $597,000, and $2.3 million for the years
ended March 31, 2007, 2006, and 2005 respectively. The
losses from operations excluding non-cash stock-compensation
charges were $17.9 million, $20.3 million, and
$14.0 million for the years ended March 31, 2007,
2006, and 2005 respectively.
Comparison
of Years Ended March 31, 2007 and 2006
Revenues
We experienced growth in revenues in both our product and
services businesses resulting in reported revenues of
$4.5 million in the year ended March 31, 2007, an
increase of 76% from the prior year level of $2.6 million.
The $1.7 million, or 87%, increase in product revenues was
due primarily to higher sales volumes in Mexico and Europe, and
sales to a new customer, Alkem Laboratories Limited, in India.
The following table shows our product revenues by country (in
thousands); note that sales in India are reported as part of our
Europe business:
|
|
|
|
|
|
|
|
|
|
|
Year Ended March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
(In thousands)
|
|
|
U.S
|
|
$
|
140
|
|
|
$
|
109
|
|
Mexico
|
|
|
2,513
|
|
|
|
1,788
|
|
India
|
|
|
604
|
|
|
|
|
|
Europe
|
|
|
422
|
|
|
|
69
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
3,679
|
|
|
$
|
1,966
|
|
|
|
|
|
|
|
|
|
|
The $246,000, or 40%, increase in service revenues was due
primarily to an increase in the volume of tests provided by our
services business. We expect that our service revenues will
significantly decline in future periods, as we continue to
implement our strategy of focusing primarily on our Microcyn
business.
Gross
Profit/Loss
We reported gross profit from our Microcyn products business of
$1.6 million, or 43% of product revenues, in the year ended
March 31, 2007, compared to the prior year reported gross
loss of $1.9 million, or -98% of product revenues. The
gross loss in the year ended March 31, 2006 was adversely
affected by $1.0 million of non-recurring inventory
write-downs and approximately $200,000 of non-recurring charges
associated with the relocation of our Mexico manufacturing
facility during the year. Excluding these charges, our gross
loss from product sales in the year ended March 31, 2006
would have been $685,000, or -35% of product revenues. The
increase in product gross margin, excluding these non-recurring
charges, from -35% in the year ended March 31, 2006, to 43%
in the year ended March 31, 2007, was primarily due to
improvements in manufacturing efficiencies through the
consolidation of our worldwide manufacturing from three sites to
two during the year. In April 2006, we transitioned the United
States facility from a product manufacturing site into a
research and development facility, and began producing all
products for sales outside of Mexico in our facility in Europe.
The remaining improvements in gross profits were due to a full
year of benefit from the relocation of our Mexican manufacturing
site during the year ended March 31, 2006 from Morelia,
Mexico into a lower-cost manufacturing facility in Zapopan,
Mexico.
We reported a gross loss from our services business of $31,000,
or -4% of service revenues, in the year ended March 31,
2007, compared to the prior year reported gross loss of
$385,000, or -62% of service revenues. This improvement in
margin from -62% to -4% was due primarily to the growth in sales
volume of our services which
54
moved our service revenues closer to exceeding the relatively
high fixed cost of our laboratory facility. Additionally, we
discontinued our consulting service business during the year
ended March 31, 2006 which had a positive impact on our
services margin.
We expect gross profits to increase as a percentage of sales in
future periods as we continue to implement our strategy of
focusing on our Microcyn business, and we move away from our
lower-margin services business.
Research
and Development Expense
Research and development expense increased $1.9 million, or
73%, to $4.5 million for the year ended March 31,
2007, from $2.6 million for the year ended March 31,
2006. This increase was primarily the result of higher personnel
costs associated with the expansion of our research and
development teams. The expansion of these teams was through both
an internal shift of focus in our United States operations from
product manufacturing to research and development, as well as
through the hiring of outside personnel. The expansion of the
research and development teams helps support our increased
attention to product development and the management of
regulatory trials designed to obtain FDA drug approvals for our
Microcyn products.
We expect research and development expenses to increase
significantly in future periods as we incur the costs associated
with our FDA trials for the treatment of diabetic foot ulcer
infections with Dermacyn, and as we expand the scope of our new
product development.
Selling,
General and Administrative Expense
Selling, general and administrative expense increased $587,000,
or 4%, to $16.5 million for the year ended March 31,
2007, from $15.9 million for the year ended March 31,
2006. This increase was primarily due to a $966,000 increase in
non-cash stock-based compensation expense recorded during the
year ended March 31, 2007. This increase in stock
compensation charges was primarily the result of charges
incurred for the warrants issued to a new board member, which
are amortized over the two-year agreement, and for the warrants
issued for the settlement of litigation with a past employee.
This increase was offset in the current year by lower outside
service expenses, primarily in legal and accounting fees.
We expect that general and administrative costs will increase in
future periods due to the added expenses of being a public
company, including insurance, legal, accounting, and fees
associated with Sarbanes Oxley compliance. These increases may
be offset in part by lower selling expenses as we shift our
company resources from the opening of new markets worldwide to
the completion of our FDA regulatory trials, and as we expand
the scope of our new product development.
Interest
income and expense and other income and expense
Interest expense increased $784,000 to $956,000 for the year
ended March 31, 2007, from $172,000 in the year ended
March 31, 2006, primarily due to the issuance of
$8.2 million of new debt during the year. The new debt had
amortized debt issuance costs booked as non-cash interest of
$402,000, and normal interest expense of $441,000 during the
year ended March 31, 2007.
Other income and expense primarily consists of non-cash charges
due to the fluctuation of foreign exchange rates, and the
resulting gain or loss booked for the revaluation of our
intercompany notes payable denominated in non-local currencies.
During the year ended March 31, 2007, the U.S. dollar
became stronger in relation to the Mexican peso and the Euro,
and a net $407,000 gain on foreign exchange was recorded
accordingly. In comparison, during the year ended March 31,
2006, the U.S. Dollar became weaker in relation to the
Mexican Peso and the Euro, and a $283,000 loss on foreign
exchange was recorded. Additionally, during the year ended
March 31, 2006, we incurred $113,000 in loss on the
disposal of assets.
Due to the difficulty of predicting foreign currency
fluctuations, we do not know the affect that such fluctuations
may have on our operating results in future periods.
55
Comparison
of Years Ended March 31, 2006 and March 31,
2005
Revenues
Revenues increased $1.2 million, or 91%, to
$2.6 million for the year ended March 31, 2006, from
$1.4 million for the year ended March 31, 2005.
Product revenues increased $1.5 million, or 316%, to
$2.0 million for the year ended March 31, 2006, from
$473,000 for the year ended March 31, 2005. This increase
was primarily due to a $1.4 million increase in sales of
Microcyn60 in Mexico following the expansion of our sales force
in that country and the receipt of product reimbursement by the
Mexican Ministry of Health.
The increase in product revenues was partially offset by a
$265,000 decrease in service revenues during the year ended
March 31, 2006, as compared to the prior year. The decrease
in service revenues was a result of a shift in our focus from
services to the development of our Microcyn products during the
year ended March 31, 2006.
Gross
Profit/Loss
We reported a gross loss from our Microcyn products business of
$1.9 million, or -98% of revenues, in the year ended
March 31, 2006, compared to the prior year reported gross
loss of $1.7 million, or -367% of product revenues. The
gross loss in the year ended March 31, 2006 was adversely
affected by $1.0 million of non-recurring inventory
write-downs and approximately $200,000 of non-recurring charges
associated with the relocation of our Mexico manufacturing
facility during the year. Excluding these charges, our gross
loss from product sales in the year ended March 31, 2006
would have been $685,000, or -35% of product revenues. The
increase in margin, excluding these non-recurring charges, from
-367% in the year ended March 31, 2005, to -35% in the year
ended March 31, 2006, was primarily due to the growth in
sales volume which moved our product revenues closer to
exceeding our relatively high fixed cost of manufacturing. The
remaining improvements in gross profits were due to the
relocation of our Mexican manufacturing site during the year
ended March 31, 2006 from Morelia, Mexico into a lower-cost
manufacturing facility in Zapopan, Mexico.
We reported a gross loss from our services business of $385,000,
or -62% of service revenues, during the year ended
March 31, 2007, compared to the prior year reported gross
loss of $428,000, or -48% of service revenues. This decrease in
margin from -48% to -62% was due primarily to the decline in
sales volume of our services which moved our service revenues
further away from exceeding the relatively high fixed cost of
our laboratory facility.
Research
and Development Expense
Research and development expense increased $946,000, or 57%, to
$2.6 million during the year ended March 31, 2006,
from $1.7 million in the year ended March 31, 2005.
This increase was primarily attributable to the expansion of our
regulatory team, which focused on FDA and KEMA approvals for
Microcyn products during the period. Additionally, in September
2005, we commenced our pre-operative skin preparation pilot
studies to support our application for an FDA drug clearance
indicating microbial load reduction. Total spending on
regulatory trials, other clinical studies, and related expenses
increased $1.2 million, or 164%, to $1.9 million for
the year ended March 31, 2006, from $735,000 during the
year ended March 31, 2005. This increase was partially
offset by a $418,000 decrease in spending on new product
development to $497,000 in the year ended March 31, 2006,
from $915,000 in the year ended March 31, 2005.
Selling,
General and Administrative Expense
Selling, general and administrative expense increased
$3.4 million, or 28%, to $15.9 million during the year
ended March 31, 2006, from $12.5 million during the
year ended March 31, 2005. This increase was partially due
to a $1.5 million increase in United States selling,
general and administrative expense primarily as a result of
higher outside consulting and service fees during the year ended
March 31, 2006. Specifically, outside accounting fees
increased by $653,000 due to the preparation and completion of
an audit of our last four fiscal years, legal fees increased by
$507,000 due to expanded intellectual property and general legal
support, and outside consulting and service fees increased by
$294,000 due to consulting expenses related to the marketing of
our products in Asia.
In addition, sales and marketing expense in Europe increased
$429,000 due to the hiring of additional sales and marketing
personnel during the year ended March 31, 2006.
56
Selling, general and administrative expense in Mexico increased
$3.3 million during the year ended March 31, 2006
compared to the prior year primarily due to expanded sales and
marketing efforts in Mexico, as well as non-recurring charges
associated with the relocation of our Mexican subsidiarys
facility. During the year ended March 31, 2006, we began
utilizing 75 full-time, direct sales personnel in the major
districts of Mexico, dedicated to the sale of Microcyn60 in the
hospital and pharmacy markets in Mexico. As a result, sales and
marketing expense in Mexico increased $2.7 million during
the year ended March 31, 2006, compared to the prior year.
The increase in selling, general and administrative expense was
offset by a $1.8 million decrease in non-cash stock
compensation expense in the year ended March 31, 2006
compared to the prior year. Approximately $1.7 million of
non-cash stock-based compensation expense incurred during the
year ended March 31, 2005 was related to the grant of an
option to purchase 300,000 shares of common stock to our
Chief Executive Officer.
Interest
income and expense and other income and expense
Interest expense decreased $200,000 to $172,000 for the year
ended March 31, 2006, from $372,000 during the year ended
March 31, 2005. This decrease was primarily the result of
lower average borrowings during the year as our outstanding debt
was paid down. Interest income increased $274,000, to $282,000
during the year ended March 31, 2006, from $8,000 in the
year ended March 31, 2005. This increase was primarily the
result of higher balances of interest-bearing instruments during
the year ended March 31, 2006.
Other income and expense primarily consists of non-cash charges
due to the fluctuation of foreign exchange rates, and the
resulting gain or loss booked for the revaluation of our
intercompany notes payable denominated in non-local currencies.
During the year ended March 31, 2006 the U.S. dollar
became weaker in relation to the Mexican peso and the Euro, and
a $283,000 loss on foreign exchange was booked accordingly. In
comparison, during the year ended March 31, 2005, the
U.S. dollar became stronger in relation to the Mexican Peso
and the Euro, and a $134,000 gain on foreign exchange was
booked. Additionally, during the year ended March 31, 2006,
Oculus incurred $113,000 in loss on the disposal of assets.
Discontinued
Operations
Loss on discontinued operations was $2.0 million during the
year ended March 31, 2006. This loss consisted of $818,000
classified as a loss from operations of discontinued business
and $1.2 million of loss on the disposal of discontinued
business. The loss from operations of discontinued business
represents the net operating loss of QP, which was consolidated
with our financial results. The relationship was terminated in
the fourth quarter of the year ended March 31, 2006 and the
loss was classified as a discontinued operation on our
consolidated statements of operations. As no relationship
existed with this entity prior to the year ended March 31,
2006, no charges were recognized in prior years.
Liquidity
and Capital Resources
Since our inception, we have incurred significant losses and, as
of March 31, 2007, we had an accumulated deficit of
approximately $70.5 million. We have not yet achieved
profitability, and we expect that our operating expenses will
continue to increase and, as a result, we will need to generate
significant product revenues to achieve profitability in the
future.
Sources
of Liquidity
Since our inception, substantially all of our operations have
been financed through the sale of our common and convertible
preferred stock. Through March 31, 2007, we had received
net proceeds of $21.9 million through the sale of our
common stock in our initial public offering in January 2007,
$3.5 million from prior sales of common stock,
$6.7 million from the sale of Series A convertible
preferred stock, $43.7 million from the sale of
Series B convertible preferred stock, $2.9 million
from the sales of Series C convertible preferred stock, and
$304,000 from the issuance of common stock to employees,
consultants and directors in connection with the exercise of
stock options. We have received additional funding through
various debt and financing transactions, as described below. We
have also used our revenues to date as a source of additional
liquidity. As of March 31, 2007, we had unrestricted
57
cash and cash equivalents of $19.1 million, and restricted
cash of $2.0 million reserved for the pay-down of
particular debt.
In June 2006, we entered into a loan and security agreement with
a financial institution to borrow a maximum of
$5.0 million. Under this facility we have borrowed
$4.2 million, and have paid back $852,000 in principle as
of March 31, 2007. The terms of this facility include
monthly principal repayment over three years, and an annual
interest rate of 8.5%. In conjunction with this agreement, we
issued warrants to purchase up to 75,000 shares of our
Series B preferred stock at an exercise price of
$18.00 per share. Warrants to purchase 53,750 shares
were earned and exercisable at execution of the agreement.
On November 7, 2006, we signed a loan agreement with Robert
Burlingame, one of the Companys directors, under which
Mr. Burlingame advanced to us $4.0 million, which was
funded on November 10, 2006, and which accrues interest at
an annual interest rate of 7%. The principal and all accrued
interest under the loan agreement will become due and payable in
full on November 10, 2007. The loan is secured by all of
our assets, other than our intellectual property, but is
subordinate to the security interest held by our secured lender.
Brookstreet Securities Corporation, a placement agent, was paid
a fee in the amount of $50,000 and granted a warrant to purchase
25,000 shares of our common stock at an exercise price of
$18.00 per share in connection with this loan.
Additionally, in May 2007, we deposited $2 million into a
segregated, interest-bearing account on which
Mr. Burlingame, has sole signature authority. Under our
arrangement with Mr. Burlingame, the interest on the
account is paid to us each month, and the $2 million
principal will be used to satisfy a part of our obligation to
Mr. Burlingame under the loan agreement. We have also
agreed to deposit an additional $2 million into this
segregated account should our total cash and restricted cash
balances drop to below $10 million in total.
Cash
Flows
As of March 31, 2007, we had unrestricted cash and cash
equivalents of $19.1 million, compared to $7.4 million
at March 31, 2006 and $3.3 million at March 31,
2005.
Net cash used in operating activities was $18.1 million,
$19.7 million and $13.5 million during the years ended
March 31, 2007, 2006 and 2005, respectively. Net cash used
in each of these periods primarily reflects net loss for these
periods, offset in part by non-cash charges in operating assets
and liabilities, non-cash stock-based compensation and
depreciation and amortization.
Net cash used in investing activities was $877,000, $419,000 and
$1.1 million for the years ended March 31, 2007, 2006
and 2005, respectively. Primarily this cash was used to invest
in fixed assets and other capital expenditures to support
increased personnel and manufacturing facility expansion in
Europe and Mexico during the years ended March 31, 2007,
2006 and 2005.
Net cash provided by financing activities was
$30.6 million, $26.1 million and $17.2 million
for the years ended March 31, 2007, 2006 and 2005,
respectively. The net cash provided by financing activities for
the year ended March 31, 2007 was primarily due to our
initial public offering, which raised net cash of
$21.9 million. This amount includes $24.2 million of
net cash raised in our initial public offering on
January 30, 2007 (net of underwriters commissions,
and expenses), and $2.4 million of net cash raised when our
underwriters exercised their option to sell over allotment
shares on February 16, 2007. These amounts were offset by
$2.8 million of additional accounting, legal, and other
expenses directly related to the initial public offering.
Additionally, the sale of convertible preferred stock, generated
$2.9 million, $27.0 million and $16.7 million for
the years ended March 31, 2007, 2006 and 2005,
respectively. In addition, net proceeds from debt financing
added $7.2 million and $541,000 during the years ended
March 31, 2007 and 2005, respectively, and net payments on
debt were $696,000 during the year ended March 31, 2006.
During the year ended March 31, 2007, the activity was also
related to the $2.0 million reclassification of cash to
restricted cash per the terms of the Burlingame loan agreement,
as described above.
58
Contractual
Obligations
As of March 31, 2007, we had contractual obligations as
follows (long-term debt and capital lease amounts include
principal payments only):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due by Period
|
|
|
|
|
|
|
Less Than
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
1 Year
|
|
|
1-3 Years
|
|
|
4-5 Years
|
|
|
After 5 Years
|
|
|
Long-term debt
|
|
$
|
8,035
|
|
|
$
|
6,045
|
|
|
$
|
1,952
|
|
|
$
|
23
|
|
|
$
|
15
|
|
Capital leases
|
|
|
42
|
|
|
|
17
|
|
|
|
25
|
|
|
|
|
|
|
|
|
|
Operating leases
|
|
|
660
|
|
|
|
296
|
|
|
|
261
|
|
|
|
103
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
8,737
|
|
|
$
|
6,358
|
|
|
$
|
2,238
|
|
|
$
|
126
|
|
|
$
|
15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
We have operating leases covering approximately
40,000 square feet of office and manufacturing space in
Petaluma, California, expiring in September 2007, and our
monthly rent is $23,493. We also have operating leases covering
approximately 19,000 square feet of office and
manufacturing space in Sittard, The Netherlands expiring in
2009, and approximately 12,000 square feet of office and
manufacturing space and 5,000 square feet of warehouse
space in Zapopan, Mexico, expiring in 2011 and 2007,
respectively.
We do not have any off-balance sheet arrangements as such term
is defined in rules promulgated by the SEC.
Operating
Capital and Capital Expenditure Requirements
We expect to continue to incur substantial operating losses in
the future as we continue our FDA clinical trials on our
Microcyn technology to treat diabetic foot ulcers, and the
subsequent commercialization of an FDA approved drug. It may
take several years to obtain the necessary regulatory approvals
to commercialize Microcyn as a drug in the United States.
We currently anticipate that our cash, cash equivalents, and
restricted cash balances, together with our future revenues and
interest we earn on these balances will be sufficient to meet
our anticipated cash requirements through March 31, 2008.
We currently anticipate a need to raise additional funds prior
to March 31, 2008, and in periods following, through public
or private equity offerings, debt financings, corporate
collaborations or other means in order to complete our
Phase 3 clinical trials, execute our product development
strategy, and to commercialize Microcyn as a drug product in the
United States. The sale of additional equity or convertible debt
securities could result in dilution to our stockholders. To the
extent that we raise additional funds through collaborative
arrangements, it may be necessary to relinquish some rights to
our technologies or grant licenses on terms that are not
favorable to us. We do not know whether additional funding will
be available on acceptable terms, or at all. A failure to secure
additional funding when needed may require us to curtail certain
operational activities, including regulatory trials, sales and
marketing, and international operations and would have a
material adverse effect on our future business and financial
condition.
Our future funding requirements will depend on many factors,
including:
|
|
|
|
|
the scope, rate of progress and cost of our clinical trials and
other research and development activities;
|
|
|
|
future clinical trial results;
|
|
|
|
the terms and timing of any collaborative, licensing and other
arrangements that we may establish;
|
|
|
|
the cost and timing of regulatory approvals;
|
|
|
|
the cost and delays in product development as a result of any
changes in regulatory oversight applicable to our products;
|
|
|
|
the cost and timing of establishing sales, marketing and
distribution capabilities;
|
|
|
|
the effect of competing technological and market developments;
|
59
|
|
|
|
|
the cost of filing, prosecuting, defending and enforcing any
patent claims and other intellectual property rights; and
|
|
|
|
the extent to which we acquire or invest in businesses, products
and technologies.
|
Use of
Estimates
The preparation of consolidated financial statements in
conformity with United States generally accepted accounting
principles requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and
disclosures of contingent liabilities at the dates of the
consolidated financial statements and the reported amounts of
revenues and expenses during the reporting periods. Actual
results could differ from these estimates. These estimates and
assumptions include reserves and write-downs related to
receivables and inventories, the recoverability of long-term
assets, deferred taxes and related valuation allowances and
valuation of equity instruments.
Recent
Accounting Pronouncements
In March 2006, the FASB issued SFAS No. 156
Accounting for Servicing of Financial Assets
an amendment of FASB Statement No. 140
(SFAS 156). SFAS 156 is effective for the
first fiscal year beginning after September 15, 2006.
SFAS 156 changes the way entities account for servicing
assets and obligations associated with financial assets acquired
or disposed of. We have not yet completed our evaluation of the
impact of adopting SFAS 156 on our results of consolidated
operations or financial position, and do not expect that the
adoption of SFAS 156 will have a material impact on our
consolidated financial statements.
In June 2006, the Financial Accounting Standards Board issued
FASB Interpretation No. 48, Accounting for Uncertainty in
Income Taxes. This Interpretation prescribes a recognition
threshold and measurement attribute for the financial statement
recognition and measurement of a tax position taken or expected
to be taken in a tax return. This Interpretation also provides
guidance on derecognition, classification, interest and
penalties, accounting in interim periods, disclosure, and
transition. The Interpretation is effective for fiscal years
beginning after December 15, 2006. The Company has not yet
completed its analysis of the impact this Interpretation will
have on its financial condition, results of operations, cash
flows or disclosures.
In February 2007, the FASB issued SFAS 159, The Fair
Value Option for Financial Assets and Financial
Liabilities (SFAS 159). SFAS 159
provides companies with an option to report selected financial
assets and liabilities at fair value and establishes
presentation and disclosure requirements designed to facilitate
comparisons between companies that choose different measurement
attributes for similar types of assets and liabilities.
SFAS 159 is effective for fiscal years beginning after
November 15, 2007. The Company is in the process of
evaluating the impact of the adoption of this statement on the
Companys results of operations and financial condition.
In September 2006, the FASB issued SFAS No. 157,
Accounting for Fair Value Measurements
(SFAS 157). SFAS 157 defines fair value,
and establishes a framework for measuring fair value in
generally accepted accounting principles and expands disclosure
about fair value measurements. SFAS 157 is effective for
financial statements issued subsequent to November 15,
2007. We do not expect that the adoption of this standard will
have a material impact on our consolidated financial position,
results of operations or cash flows.
In September 2006, the Securities and Exchange Commission
(SEC) issued Staff Accounting Bulletin 108,
Considering the Effects on Prior Year Misstatements when
Quantifying Misstatements in Current Year Financial Statements,
(SAB 108). SAB 108 requires registrants to
quantify errors using both the income statement method (i.e.
iron curtain method) and the rollover method and requires
adjustment if either method indicates a material error. If a
correction in the current year relating to prior year errors is
material to the current year, then the prior year financial
information needs to be corrected. A correction to the prior
year results that are not material to those years, would not
require a restatement process where prior financials would be
amended. SAB 108 is effective for fiscal years ending after
November 15, 2006. Our adoption of SAB 108 did not
have a material effect on our financial position, results of
operations or cash flows.
In December 2006, the FASB issued FSP
EITF 00-19-2
Accounting for Registration Payment Arrangements
(FSP
EITF 00-19-2).
FSP
EITF 00-19-2
addresses an issuers accounting for registration payment
arrangements.
60
This pronouncement specifies that the contingent obligation to
make future payments or otherwise transfer consideration under a
registration payment arrangement, whether issued as a separate
agreement or included as a provision of a financial instrument,
should be separately recognized and accounted for as a
contingency in accordance with SFAS 5 Accounting for
Contingencies. FSP
EITF 00-19-2
amending previous standards relating to rights agreements became
effective on December 21, 2006 with respect to arrangements
entered into or modified beginning on such date and for the
first fiscal year beginning after December 15, 2006 with
respect to those arrangements entered into prior to
December 21, 2006. We are in the process of evaluating the
impact of the adoption of this statement on our results of
operations and financial condition.
Other accounting standards that have been issued or proposed by
the FASB or other standards-setting bodies that do not require
adoption until a future date are not expected to have a material
impact on the consolidated financial statements upon adoption.
ITEM 7A. Quantitative
and Qualitative Disclosures About Market Risk
Interest
Rate Market Risk
Our exposure to interest rate risk is confined to our excess
cash in highly liquid money market funds denominated in
U.S. dollars. The primary objective of our investment
activities is to preserve our capital to fund operations. We
also seek to maximize income from our investments without
assuming significant risk. We do not use derivative financial
instruments in our investment portfolio. Our cash and
investments policy emphasizes liquidity and preservation of
principal over other portfolio considerations.
Foreign
Currency Market Risks
We have two significant subsidiaries, one each in Europe and
Mexico. Revenues and expenses associated with these subsidiaries
are denominated in foreign currency. Accordingly, our operating
results are affected by exchange rate fluctuations between the
U.S. dollar and these foreign currencies In order to
mitigate our exposure to foreign currency rate fluctuations, we
maintain minimal cash balances in the foreign subsidiaries.
However, if we are successful in our efforts to grow
internationally, our exposure to foreign currency rate
fluctuations, primarily the Euro and Mexican Peso, may increase.
We are also exposed to foreign currency risk related to the Euro
denominated and Mexican Peso denominated intercompany
receivables. Because our intercompany receivables are accounted
for in Euros and US dollars, any appreciation or devaluation of
the Euro or Mexican Peso will result in a gain or loss to the
consolidated statements of operations.
We do not currently enter into forward exchange contracts to
hedge exposure denominated in foreign currencies or any other
derivative financial instrument for trading or speculative
purposes. In the future, if we believe our currency exposure
merits, we may consider entering into transactions to help
mitigate the risk.
61
|
|
ITEM 8.
|
Consolidated
Financial Statements and Supplementary Data
|
Oculus
Innovative Sciences, Inc.
Index to
Consolidated Financial Statements
62
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board
of Directors and Stockholders of
Oculus Innovative Sciences, Inc. and Subsidiaries
We have audited the accompanying consolidated balance sheets of
Oculus Innovative Sciences, Inc. and Subsidiaries (the
Company) as of March 31, 2007 and 2006, and the
related consolidated statements of operations and comprehensive
loss and stockholders equity (deficit) and cash flows for
each of the three years in the period ended March 31, 2007.
These financial statements are the responsibility of the
Companys management. Our responsibility is to express an
opinion on these consolidated financial statements based on our
audit.
We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are
free of material misstatement. The Company is not required to
have, nor were we engaged to perform, an audit of its internal
control over financial reporting. Our audit included
consideration of internal control over financial reporting as a
basis for designing audit procedures that are appropriate in the
circumstances, but not for the purpose of expressing an opinion
on the effectiveness of the Companys internal control over
financial reporting. Accordingly, we express no such opinion. An
audit also includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and
significant estimates made by management, as well as evaluating
the overall financial statement presentation. We believe that
our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred
to above present fairly, in all material respects, the
consolidated financial position of Oculus Innovative Sciences,
Inc. and Subsidiaries as of March 31, 2007 and 2006, and
the results of their operations and their cash flows for each of
the three years in the period ended March 31, 2007 in
conformity with United States generally accepted accounting
principles.
/s/
Marcum & Kliegman LLP
New York, New York
June 13, 2007
63
OCULUS
INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES
CONSOLIDATED
BALANCE SHEETS
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
(In thousands, except per share amounts)
|
|
|
ASSETS
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
19,050
|
|
|
$
|
7,448
|
|
Restricted cash
|
|
|
2,000
|
|
|
|
|
|
Accounts receivable, net
|
|
|
1,364
|
|
|
|
1,076
|
|
Inventories
|
|
|
282
|
|
|
|
317
|
|
Prepaid expenses and other current
assets
|
|
|
1,172
|
|
|
|
1,386
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
23,868
|
|
|
|
10,227
|
|
Property and equipment, net
|
|
|
2,207
|
|
|
|
1,940
|
|
Restricted cash
|
|
|
49
|
|
|
|
44
|
|
Deferred offering costs
|
|
|
|
|
|
|
478
|
|
Debt issue costs, net
|
|
|
826
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
26,950
|
|
|
$
|
12,689
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS
EQUITY
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
2,551
|
|
|
$
|
2,774
|
|
Accrued expenses and other current
liabilities
|
|
|
1,421
|
|
|
|
1,686
|
|
Dividends payable
|
|
|
|
|
|
|
121
|
|
Current portion of long-term debt
|
|
|
6,045
|
|
|
|
504
|
|
Current portion of capital lease
obligations
|
|
|
17
|
|
|
|
15
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
10,034
|
|
|
|
5,100
|
|
Long-term debt, less current
portion
|
|
|
1,990
|
|
|
|
210
|
|
Capital lease obligations, less
current portion
|
|
|
25
|
|
|
|
41
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
12,049
|
|
|
|
5,351
|
|
|
|
|
|
|
|
|
|
|
Commitments and Contingencies
|
|
|
|
|
|
|
|
|
Stockholders Equity
|
|
|
|
|
|
|
|
|
Convertible preferred stock,
$0.0001 par value; 30,000,000 shares authorized,
Series A, none and 1,347,709 shares issued and
outstanding at March 31, 2007 and 2006, respectively
|
|
|
|
|
|
|
6,668
|
|
Series B, none and
2,635,744 shares issued and outstanding at March 31,
2007 and 2006, respectively
|
|
|
|
|
|
|
43,722
|
|
Common stock, $0.0001 par
value; 100,000,000 shares authorized,
|
|
|
|
|
|
|
|
|
11,844,411 and
4,218,981 shares issued and outstanding at March 31,
2007 and
|
|
|
|
|
|
|
|
|
2006, respectively
|
|
|
1
|
|
|
|
3,399
|
|
Additional paid-in capital
|
|
|
85,751
|
|
|
|
4,644
|
|
Deferred compensation
|
|
|
|
|
|
|
(798
|
)
|
Accumulated other comprehensive
income (loss)
|
|
|
(364
|
)
|
|
|
3
|
|
Accumulated deficit
|
|
|
(70,487
|
)
|
|
|
(50,300
|
)
|
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
|
14,901
|
|
|
|
7,338
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and
stockholders equity
|
|
$
|
26,950
|
|
|
$
|
12,689
|
|
|
|
|
|
|
|
|
|
|
The accompanying footnotes are an integral part of these
financial statements.
64
OCULUS
INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
|
(In thousands, except
|
|
|
|
per share amounts)
|
|
|
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
Product
|
|
$
|
3,679
|
|
|
$
|
1,966
|
|
|
$
|
473
|
|
Service
|
|
|
864
|
|
|
|
618
|
|
|
|
883
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
4,543
|
|
|
|
2,584
|
|
|
|
1,356
|
|
Cost of revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
Product
|
|
|
2,104
|
|
|
|
3,899
|
|
|
|
2,211
|
|
Service
|
|
|
895
|
|
|
|
1,003
|
|
|
|
1,311
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total cost of revenues
|
|
|
2,999
|
|
|
|
4,902
|
|
|
|
3,522
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit (loss)
|
|
|
1,544
|
|
|
|
(2,318
|
)
|
|
|
(2,166
|
)
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
|
4,508
|
|
|
|
2,600
|
|
|
|
1,654
|
|
Selling, general and administrative
|
|
|
16,520
|
|
|
|
15,933
|
|
|
|
12,492
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
21,028
|
|
|
|
18,533
|
|
|
|
14,146
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(19,484
|
)
|
|
|
(20,851
|
)
|
|
|
(16,312
|
)
|
Interest expense
|
|
|
(956
|
)
|
|
|
(172
|
)
|
|
|
(372
|
)
|
Interest income
|
|
|
312
|
|
|
|
282
|
|
|
|
8
|
|
Other income (expense), net
|
|
|
345
|
|
|
|
(377
|
)
|
|
|
146
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss from continuing operations
|
|
|
(19,783
|
)
|
|
|
(21,118
|
)
|
|
|
(16,530
|
)
|
Loss from operations of
discontinued business
|
|
|
|
|
|
|
(818
|
)
|
|
|
|
|
Loss on disposal of discontinued
business
|
|
|
|
|
|
|
(1,163
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss on discontinued operations
|
|
|
|
|
|
|
(1,981
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
(19,783
|
)
|
|
|
(23,099
|
)
|
|
|
(16,530
|
)
|
Preferred stock dividends
|
|
|
(404
|
)
|
|
|
(121
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss available to common
stockholders
|
|
$
|
(20,187
|
)
|
|
$
|
(23,220
|
)
|
|
$
|
(16,530
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share: basic
and diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
(3.71
|
)
|
|
$
|
(5.12
|
)
|
|
$
|
(4.22
|
)
|
Discontinued operations
|
|
|
|
|
|
|
(0.48
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
(3.71
|
)
|
|
$
|
(5.60
|
)
|
|
$
|
(4.22
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average number of shares
used in per common share calculations:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted
|
|
|
5,448
|
|
|
|
4,150
|
|
|
|
3,914
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive loss, net of
tax
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(19,783
|
)
|
|
$
|
(23,099
|
)
|
|
$
|
(16,530
|
)
|
Foreign currency translation
adjustments
|
|
|
(367
|
)
|
|
|
144
|
|
|
|
(127
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss
|
|
$
|
(20,150
|
)
|
|
$
|
(22,955
|
)
|
|
$
|
(16,657
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying footnotes are an integral part of these
financial statements.
65
OCULUS
INNOVATIVE SCIENCES, INC.
CONSOLIDATED
STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumu-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred
|
|
|
lated
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Addi-
|
|
|
Stock-
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
Convertible Preferred Stock
|
|
|
|
|
|
|
|
|
tional
|
|
|
Based
|
|
|
Comprehensive
|
|
|
Accum-
|
|
|
|
|
|
|
Series A ($0.0001 par Value)
|
|
|
Series B ($0.0001 par Value)
|
|
|
Series C ($0.0001 par Value)
|
|
|
Common Stock ($0.0001 par Value)
|
|
|
Paid in
|
|
|
Compen-
|
|
|
Income
|
|
|
ulated
|
|
|
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
sation
|
|
|
(Loss)
|
|
|
Deficit
|
|
|
Total
|
|
|
|
(In thousands, except share and per share amounts)
|
|
|
Balance, March 31, 2004
|
|
|
1,337,709
|
|
|
$
|
6,628
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,914,653
|
|
|
$
|
3,101
|
|
|
$
|
661
|
|
|
$
|
(208
|
)
|
|
$
|
(14
|
)
|
|
$
|
(10,550
|
)
|
|
$
|
(382
|
)
|
Deferred stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,765
|
|
|
|
(2,765
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of stock-based
compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,297
|
|
|
|
|
|
|
|
|
|
|
|
2,297
|
|
Non-employee stock-based
compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30
|
|
Reclassification of options subject
to cash settlement
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
113
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
113
|
|
Issuance of common stock warrants
in connection with debt financing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28
|
|
Issuance of Series A
convertible preferred stock warrants in connection with debt
financing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
77
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
77
|
|
Issuance of Series B
convertible preferred stock, net of offering costs
|
|
|
|
|
|
|
|
|
|
|
1,014,093
|
|
|
|
16,696
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16,696
|
|
Foreign currency translation
adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(127
|
)
|
|
|
|
|
|
|
(127
|
)
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(16,530
|
)
|
|
|
(16,530
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, March 31, 2005
|
|
|
1,337,709
|
|
|
|
6,628
|
|
|
|
1,014,093
|
|
|
|
16,696
|
|
|
|
|
|
|
|
|
|
|
|
3,914,653
|
|
|
|
3,101
|
|
|
|
3,674
|
|
|
|
(676
|
)
|
|
|
(141
|
)
|
|
|
(27,080
|
)
|
|
|
2,202
|
|
Issuance of common stock upon
exercise of stock options
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
291,828
|
|
|
|
298
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
298
|
|
Deferred stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
401
|
|
|
|
(401
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of stock-based
compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
279
|
|
|
|
|
|
|
|
|
|
|
|
279
|
|
Non-employee stock-based
compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32
|
|
Fair value related to common stock
warrants with service conditions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
153
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
153
|
|
Issuance of common stock in
exchange for services
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,500
|
|
|
|
|
|
|
|
127
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
127
|
|
Reclassification of options subject
to cash settlement
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
257
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
257
|
|
Issuance of Series B
convertible preferred stock, net of offering costs
|
|
|
|
|
|
|
|
|
|
|
1,621,651
|
|
|
|
27,026
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27,026
|
|
Issuance of Series A
convertible preferred stock in connections with convertible debt
|
|
|
10,000
|
|
|
|
40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
40
|
|
Dividend payable to Series A
convertible preferred stockholders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(121
|
)
|
|
|
(121
|
)
|
Foreign currency translation
adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
144
|
|
|
|
|
|
|
|
144
|
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(23,099
|
)
|
|
|
(23,099
|
)
|
Balance, March 31, 2006
|
|
|
1,347,709
|
|
|
$
|
6,668
|
|
|
|
2,635,744
|
|
|
$
|
43,722
|
|
|
|
|
|
|
|
|
|
|
|
4,218,981
|
|
|
$
|
3,399
|
|
|
$
|
4,644
|
|
|
$
|
(798
|
)
|
|
$
|
3
|
|
|
$
|
(50,300
|
)
|
|
$
|
7,338
|
|
66
OCULUS
INNOVATIVE SCIENCES, INC.
CONSOLIDATED
STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumu-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred
|
|
|
lated
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Addi-
|
|
|
Stock-
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
Convertible Preferred Stock
|
|
|
|
|
|
|
|
|
tional
|
|
|
Based
|
|
|
Comprehensive
|
|
|
Accum-
|
|
|
|
|
|
|
Series A ($0.0001 par Value)
|
|
|
Series B ($0.0001 par Value)
|
|
|
Series C ($0.0001 par Value)
|
|
|
Common Stock ($0.0001 par Value)
|
|
|
Paid in
|
|
|
Compen-
|
|
|
Income
|
|
|
ulated
|
|
|
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
sation
|
|
|
(Loss)
|
|
|
Deficit
|
|
|
Total
|
|
|
|
(In thousands, except share and per share amounts)
|
|
|
Issuance of common stock in
connection with IPO and exercise of over-allotment, net of
discounts, commissions, expenses and other offering costs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,353,550
|
|
|
|
|
|
|
|
21,936
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21,936
|
|
Issuance of common stock in
connection with exercise of warrants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,138
|
|
|
|
|
|
|
|
21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21
|
|
Issuance of common stock in
connection with services rendered
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,750
|
|
|
|
|
|
|
|
43
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
43
|
|
Issuance of Series C
convertible preferred stock, net of offering costs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
193,045
|
|
|
|
2,903
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,903
|
|
Conversion of convertible preferred
stock into common stock at the closing of the IPO on
January 30, 2007
|
|
|
(1,347,709
|
)
|
|
|
(6,668
|
)
|
|
|
(2,635,744
|
)
|
|
|
(43,722
|
)
|
|
|
(193,045
|
)
|
|
|
(2,903
|
)
|
|
|
4,176,498
|
|
|
|
|
|
|
|
53,293
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reclassification to APIC in
connection with Delaware reincorporation due to change in par
value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,398
|
)
|
|
|
3,398
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reclassification of deferred
stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(798
|
)
|
|
|
798
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of stock-based
compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
158
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
158
|
|
Non-employee stock-based
compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11
|
|
Employee stock-based compensation
expense recognized under SFAS No. 123R, net of
forfeitures
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
815
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
815
|
|
Fair value adjustment related to
common stock warrants with service conditions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
555
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
555
|
|
Issuance of common warrants in
connection with debt financing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,150
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,150
|
|
Dividend payable to Series A
convertible preferred stockholders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(404
|
)
|
|
|
(404
|
)
|
Common stock dividend paid to
Series A convertible preferred stockholders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
87,494
|
|
|
|
|
|
|
|
525
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
525
|
|
Foreign currency translation
adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(367
|
)
|
|
|
|
|
|
|
(367
|
)
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(19,783
|
)
|
|
|
(19,783
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, March 31, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,844,411
|
|
|
$
|
1
|
|
|
$
|
85,751
|
|
|
|
|
|
|
$
|
(364
|
)
|
|
$
|
(70,487
|
)
|
|
$
|
14,901
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying footnotes are an integral part of these
financial statements.
67
OCULUS
INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF CASH FLOWS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
|
(In thousands)
|
|
|
Cash flows from operating
activities
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss from continuing operations
|
|
$
|
(19,783
|
)
|
|
$
|
(21,118
|
)
|
|
$
|
(16,530
|
)
|
Adjustments to reconcile net loss
to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
672
|
|
|
|
651
|
|
|
|
434
|
|
Stock-based compensation
|
|
|
1,582
|
|
|
|
597
|
|
|
|
2,349
|
|
Non-cash interest expense
|
|
|
547
|
|
|
|
21
|
|
|
|
131
|
|
Unrealized foreign exchange gain
|
|
|
(407
|
)
|
|
|
|
|
|
|
|
|
Loss on disposal of assets
|
|
|
|
|
|
|
113
|
|
|
|
2
|
|
Changes in operating assets and
liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(287
|
)
|
|
|
(849
|
)
|
|
|
217
|
|
Inventories
|
|
|
53
|
|
|
|
551
|
|
|
|
(748
|
)
|
Prepaid expenses and other current
assets
|
|
|
219
|
|
|
|
(887
|
)
|
|
|
(278
|
)
|
Accounts payable
|
|
|
(245
|
)
|
|
|
1,868
|
|
|
|
(165
|
)
|
Accrued expenses and other
liabilities
|
|
|
(433
|
)
|
|
|
(649
|
)
|
|
|
1,055
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in operating
activities
|
|
|
(18,082
|
)
|
|
|
(19,702
|
)
|
|
|
(13,533
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing
activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases of property and equipment
|
|
|
(873
|
)
|
|
|
(475
|
)
|
|
|
(1,042
|
)
|
Issuance of note receivable
|
|
|
|
|
|
|
55
|
|
|
|
(55
|
)
|
Changes in restricted cash
|
|
|
(4
|
)
|
|
|
1
|
|
|
|
(21
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing
activities
|
|
|
(877
|
)
|
|
|
(419
|
)
|
|
|
(1,118
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing
activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred offering costs
|
|
|
478
|
|
|
|
(478
|
)
|
|
|
|
|
Proceeds from issuance of common
stock, net of offering costs
|
|
|
21,936
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of common
stock upon exercise of stock options and warrants
|
|
|
21
|
|
|
|
298
|
|
|
|
|
|
Proceeds from issuance of
convertible preferred stock
|
|
|
2,903
|
|
|
|
27,026
|
|
|
|
16,696
|
|
Debt issuance costs
|
|
|
(77
|
)
|
|
|
|
|
|
|
|
|
Cash restricted for repayment of
debt
|
|
|
(2,000
|
)
|
|
|
|
|
|
|
|
|
Proceeds from issuance of debt
|
|
|
9,056
|
|
|
|
257
|
|
|
|
1,205
|
|
Principal payments on debt
|
|
|
(1,734
|
)
|
|
|
(953
|
)
|
|
|
(664
|
)
|
Payments on capital lease
obligations
|
|
|
(15
|
)
|
|
|
(31
|
)
|
|
|
(41
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing
activities
|
|
|
30,568
|
|
|
|
26,119
|
|
|
|
17,196
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from discontinued
operations
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating cash flows
|
|
|
|
|
|
|
(818
|
)
|
|
|
|
|
Investing cash flows
|
|
|
|
|
|
|
(1,163
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in discontinued
operations
|
|
|
|
|
|
|
(1,981
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate on cash
and cash equivalents
|
|
|
(7
|
)
|
|
|
144
|
|
|
|
(127
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase in cash and cash
equivalents
|
|
|
11,602
|
|
|
|
4,161
|
|
|
|
2,418
|
|
Cash and cash equivalents,
beginning of year
|
|
|
7,448
|
|
|
|
3,287
|
|
|
|
869
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, end of
year
|
|
$
|
19,050
|
|
|
$
|
7,448
|
|
|
$
|
3,287
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash
flow information:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$
|
391
|
|
|
$
|
125
|
|
|
$
|
221
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash investing and
financing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Equipment acquired under capital
leases
|
|
|
|
|
|
|
|
|
|
$
|
37
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion of note payable into
Series A convertible preferred stock
|
|
|
|
|
|
$
|
40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of warrants issued in
connection with debt
|
|
$
|
1,150
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying footnotes are an integral part of these
financial statements.
68
OCULUS
INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Organization
Oculus Innovative Sciences, Inc. (the Company) was
incorporated under the laws of the State of California in April
1999 and was reincorporated under the laws of the State of
Delaware in December 2006. The Companys principal office
is located in Petaluma, California. The Company develops,
manufactures and markets a family of products intended to
prevent and treat infections in chronic and acute wounds. The
Companys platform technology, called Microcyn, is a
proprietary oxychlorine small molecule formulation that is
designed to treat a wide range of organisms that cause disease,
or pathogens, including viruses, fungi, spores and antibiotic
resistant strains of bacteria. The Company conducts its business
worldwide, with significant operating subsidiaries in Europe and
Mexico.
Delaware
Reincorporation
On December 15, 2006, the Company merged into OIS
Reincorporation Sub, Inc., a Delaware corporation (the Delaware
Company). Pursuant to the Merger Agreement, an amendment to the
certificate of incorporation was filed pursuant to which
(i) each four shares of outstanding Company common stock
were converted into one share of the Delaware Companys
common stock ($0.0001 par value), (ii) each four
shares of the Companys outstanding Series A
convertible preferred stock were converted into one share of the
Delaware Companys Series A convertible preferred
stock ($0.0001 par value), (iii) each four shares of
the Companys outstanding Series B convertible
preferred stock were converted into one share of the Delaware
Companys Series B convertible preferred stock
($0.0001 par value), and (iv) each four shares of the
California Companys outstanding Series C convertible
preferred stock were converted into one share of the Delaware
Companys Series C convertible preferred stock
($0.0001 par value). In addition, all options, warrants or
rights to purchase shares of Company common stock or Company
convertible preferred stock outstanding immediately prior to the
Reincorporation were converted into options, warrants or rights
to purchase an equivalent number of shares of the Delaware
Companys common stock or convertible preferred stock, as
the case may be, and those securities will continue to vest upon
the same terms and conditions as existed immediately prior to
the Reincorporation.
Incorporation
of Oculus Japan
In October 2006, the Company incorporated Oculus Innovative
Sciences K.K., (Oculus Japan) a wholly owned
subsidiary. The Japanese subsidiary will primarily conduct
research and development activities. Oculus Japan is
insignificant with respect to the Companys consolidated
operating results for the year ended March 31, 2007.
Reverse
Stock Split
On December 15, 2006, the Company effected a
1-for-4
reverse split of its common stock and convertible preferred
stock. All common and convertible preferred shares and per share
amounts have been retroactively restated in the accompanying
consolidated financial statements and notes for all periods
presented.
|
|
NOTE 2
|
Liquidity
and Financial Condition
|
The Company incurred net losses of $19,783,000, $23,099,000, and
$16,530,000 for the years ended March 31, 2007, 2006 and
2005, respectively. At March 31, 2007, the Companys
accumulated deficit amounted to $70,489,000.
Through March 31, 2007, the Company raised, net of offering
costs, an aggregate of approximately $85,752,000 in various
equity financing transactions that, together with the proceeds
of certain debt financing transactions, enabled it to sustain
operations while attempting to execute its business plan. The
Company had working capital of $13,834,000 as of March 31,
2007.
69
OCULUS
INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
In June 2006, the Company entered into a $5,000,000 credit
facility from which it drew $4,182,000, to fund its operations,
and invest in new equipment. In addition, on November 7,
2006, the Company entered into a $4,000,000 Bridge Loan
agreement which becomes due on November 7, 2007 with
Mr. Robert Burlingame, one of the Companys directors
(Note 10).
The Companys Board of Directors and stockholders approved
an amendment to the Articles of Incorporation (that became
effective on August 28, 2006) to authorize the
issuance of up to 875,000 shares of Series C
convertible preferred stock. On September 14, 2006 and
October 20, 2006 the Company sold an aggregate of
193,045 units, consisting of 193,045 shares of
Series C convertible preferred stock and warrants to
purchase 38,604 shares of the Companys common stock.
Net proceeds from the offering, after deducting commissions were
$2,903,000 (Note 13).
The Companys Registration Statement on
Form S-1,
Amendment No. 7, (File
No. 333-135584)
related to the Companys initial public offering was
declared effective by the SEC on January 24, 2007. A total
of 3,025,000 shares of the Companys common stock were
registered with the SEC. All of these shares were registered on
the Companys behalf. The offering commenced on
January 25, 2007 and 3,025,000 shares of common stock
offered were sold on January 30, 2007 for an aggregate
offering price of $24,200,000 through the managing underwriters:
Roth Capital Partners, Maxim LLC and Brookstreet Securities
Corporation.
On February 16, 2007 the underwriters of the Companys
initial public offering exercised a portion of their
over-allotment option and purchased 328,550 shares of the
Companys common stock in accordance with the terms of the
underwriting agreement for an aggregate offering price of
$2,628,000 through the managing underwriters: Roth Capital
Partners, Maxim LLC and Brookstreet Securities Corporation.
The Company paid to the underwriters underwriting discounts,
commissions and non-accountable expenses totaling $2,146,000 in
connection with the initial public offering and the underwriters
exercise of the over-allotment shares. In addition, the Company
incurred additional expenses of approximately $2,746,000 in
connection with the initial public offering, which when added to
the underwriting discounts, commissions and non-accountable
expenses paid by the Company amounts to total expenses of
$4,892,000. Thus the net offering proceeds to the Company (after
deducting underwriting discounts and commissions and offering
expenses) were approximately $21,936,000.
The Company currently intends to use the proceeds of the initial
public offering to fund its sales and marketing activities,
clinical trials and related research. The remaining proceeds are
to be used for general corporate purposes, including working
capital. The Company anticipates it will incur significant costs
in connection with Sarbanes-Oxley compliance and other costs
associated with reporting as a public entity.
The Company currently anticipates that its cash, cash
equivalents, and restricted cash balances, together with
revenues it expects to generate and interest it expects to earn
on invested funds will be sufficient to meet its anticipated
cash requirements through at least April 1, 2008. The
Company also expects to continue incurring losses for the
foreseeable future and must raise substantial additional capital
during the year ending March 31, 2008 to pursue its product
development initiatives, fund clinical trials and penetrate
markets for the sale of its products. The Company is currently
planning to commence Phase 3 clinical trials of its Microcyn
products. Management considers the execution and eventual
completion of these trials to be a critical milestone in the
development of the business. These clinical trials are likely to
be lengthy and expensive and cannot be commenced during the year
ending March 31, 2008 unless the Company raises additional
capital. These clinical trials must also be completed in order
for the Company to commercialize Microcyn as a drug product in
the United States.
Management believes that the Company has access to capital
resources through possible public or private equity offerings,
debt financings, corporate collaborations or other means;
however, the Company has not secured any commitment for new
financing at this time nor can it provide any assurance that new
financing will be available on commercially acceptable terms, if
at all. If the Company is unable to secure additional capital,
it will be required to curtail its research and
development initiatives, delay clinical trials and take
additional measures to reduce costs
70
OCULUS
INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
in order to conserve its cash. These measures could cause
significant delays in the Companys efforts to
commercialize its products in the United States, which is
critical to the realization of its business plan and the future
operations of the Company.
|
|
NOTE 3
|
Summary
of Significant Accounting Policies
|
Principles
of Consolidation
The accompanying consolidated financial statements include the
accounts of the Company and its wholly-owned subsidiaries,
Aquamed Technologies, Inc., Oculus Technologies of Mexico C.V.
(OTM), Oculus Innovative Sciences B.V. (OIS
Europe), and Oculus Innovative Sciences K.K. (OIS
Japan). All significant intercompany accounts and
transactions have been eliminated in consolidation.
The consolidated financial statements are presented in United
States Dollars in accordance with Statement of Financial
Accounting Standard (SFAS) No. 52,
Foreign Currency Translation
(SFAS 52). The Companys subsidiary OTM
uses the local currency (Mexican Pesos) as its functional
currency, OIS Europe uses the local currency (Euro) as its
functional currency and OIS Japan uses the local currency (Yen)
as its functional currency. Assets and liabilities are
translated at exchange rates in effect at the balance sheet date
and revenue and expense accounts are translated at average
exchange rates during the period. Resulting translation
adjustments are recorded directly to accumulated other
comprehensive (loss) income. Loans made to subsidiaries OTM and
OIS Europe will be paid back to the Company in the future when
subsidiaries begin to generate cash.
The Company, in determining whether it is required to
consolidate investee businesses, considers both the voting and
variable interest models of consolidation as required under
Financial Accounting Standards Board (FASB)
Interpretation No. 46(R) Consolidation of Variable
Interest Entities, (FIN 46(R)).
Accordingly the Company consolidates investee entities when it
owns less than 50% of the voting interests but, based on the
risks and rewards of its participation has established financial
control. As described in Note 18, the Companys
consolidated financial statements for the year ended
March 31, 2006 include the results of a variable interest
entity that is being presented as a discontinued operation in
accordance with SFAS No. 144 Accounting for the
Impairment and Disposal of Long Lived Assets,
(SFAS 144).
Use of
Estimates
The preparation of consolidated financial statements in
conformity with accounting principles generally accepted in the
United States of America requires management to make estimates
and assumptions that affect the reported amounts of assets and
liabilities and disclosures of contingent liabilities at the
dates of the consolidated financial statements and the reported
amounts of revenues and expenses during the reporting periods.
Actual results could differ from these estimates. Significant
estimates and assumptions include reserves and write-downs
related to receivables and inventories, the recoverability of
long-term assets, deferred taxes and related valuation
allowances and valuation of equity instruments.
Revenue
Recognition
The Company generates revenue from sales of its products to
hospitals, medical centers, doctors, pharmacies, and
distributors. The Company sells its products directly to third
parties and to distributors through various cancelable
distribution agreements. The Company has also entered into
agreements to license its technology.
The Company also provides regulatory compliance testing and
quality assurance services to medical device and pharmaceutical
companies.
The Company applies the revenue recognition principles set forth
in Securities and Exchange Commission Staff Accounting Bulletin
(SAB) 104 Revenue Recognition with
respect to all of its revenue. Accordingly, the
71
OCULUS
INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Company records revenue when (i) persuasive evidence of an
arrangement exists, (ii) delivery has occurred,
(iii) the fee is fixed or determinable, and
(iv) collectability of the sale is reasonably assured.
The Company requires all of its product sales to be supported by
evidence of a sale transaction that clearly indicates the
selling price to the customer, shipping terms and payment terms.
Evidence of an arrangement generally consists of a contract or
purchase order approved by the customer. The Company has ongoing
relationships with certain customers from which it customarily
accepts orders by telephone in lieu of a purchase order.
The Company recognizes revenue at the time in which it receives
a confirmation that the goods were either tendered at their
destination when shipped FOB destination, or
transferred to a shipping agent when shipped FOB shipping
point. Delivery to the customer is deemed to have occurred
when the customer takes title to the product. Generally, title
passes to the customer upon shipment, but could occur when the
customer receives the product based on the terms of the
agreement with the customer.
The selling prices of all goods that the Company sells are
fixed, and agreed to with the customer, prior to shipment.
Selling prices are generally based on established list prices.
The Company does not customarily permit its customers to return
any of its products for monetary refunds or credit against
completed or future sales. The Company, from time to time, may
replace expired goods on a discretionary basis. The Company
records these types of adjustments, when made, as a reduction of
revenue. Sales adjustments were insignificant during the years
ended March 31, 2007, 2006 and 2005.
The Company evaluates the creditworthiness of new customers and
monitors the creditworthiness of its existing customers to
determine whether events or changes in their financial
circumstances would raise doubt as to the collectability of a
sale at the time in which a sale is made. Payment terms on sales
made in the United States are generally 30 days and
internationally, generally range from 30 days to
180 days.
In the event a sale is made to a customer under circumstances in
which collectability is not reasonably assured, the Company
either requires the customer to remit payment prior to shipment
or defers recognition of the revenue until the time of
collection. The Company maintains a reserve for amounts which
may not be collectible due to risk of credit losses.
During the fiscal year ended March 31, 2005, approximately
$434,000 of sales in Mexico was recognized when cash was
collected since collection was not reasonably assured.
The Company has entered into distribution agreements in Europe.
Recognition of revenue and related cost of revenue from product
sales is deferred until the product is sold from the
distributors to their customers.
When the Company receives letters of credit and the terms of the
sale provide for no right of return except to replace defective
product, revenue is recognized when the letter of credit becomes
effective and the product is shipped.
Revenue from consulting contracts is recognized as services are
provided. Revenue from testing contracts is recognized as tests
are completed and a final report is sent to the customer.
Cash
and Cash Equivalents
The Company considers all highly liquid investments with an
original maturity of three months or less when purchased to be
cash equivalents. Cash equivalents may be invested in money
market funds, commercial paper, variable rate demand
instruments, and certificates of deposits. Cash equivalents are
carried at cost, which approximates fair value.
72
OCULUS
INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Restricted
Cash
On March 29, 2007, the Company entered into Amendment
No. 1 to the Bridge Loan with Mr. Robert Burlingame,
one of the Companys directors. Pursuant to the Amendment,
the Company deposited $2,000,000 into a segregated
interest-bearing account and is reported in current assets in
the accompanying consolidated balance sheet (Note 10).
In connection with certain operating lease agreements
(Note 12), the Company is required to maintain cash
deposits in a restricted account. Restricted cash held as
security under this arrangement amounted to $49,000 and $44,000
at March 31, 2007 and 2006, respectively and is reported in
non-current assets in the accompanying consolidated balance
sheets as restricted cash.
Concentration
of Credit Risk
Financial instruments that potentially subject the Company to
concentration of credit risk consist principally of cash, cash
equivalents and accounts receivable. Cash and cash equivalents
are maintained in financial institutions in the United States,
Mexico, The Netherlands and Japan. The Company is exposed to
credit risk in the event of default by these financial
institutions for amounts in excess of the Federal Deposit
Insurance Corporation insured limits. Management believes that
the financial institutions that hold the Companys deposits
are financially sound and have minimal credit risk. Cash and
cash equivalents held in foreign banks are intentionally kept at
minimal levels, and therefore have minimal credit risk
associated with them.
The Company grants credit to its business customers, which are
primarily located in Mexico, Europe and the United States.
Collateral is generally not required for trade receivables. The
Company maintains allowances for potential credit losses. One
customer represented 12% of the net accounts receivable balance
at March 31, 2007. In the years ended March 31, 2007
and March 31, 2005, one customer in each year represented
13% and 15% of sales in each of the years, respectively.
Accounts
Receivable
Trade accounts receivable are recorded net of allowances for
cash discounts for prompt payment, doubtful accounts, and sales
returns. Estimates for cash discounts, and sales returns are
based on contractual terms, historical trends and expectations
regarding the utilization rates for these programs. With respect
to government chargebacks, the Mexican Ministry of Healths
(MOH) policy is to levy penalties on its vendors for
product received after scheduled delivery times. The Company has
not incurred any such chargebacks to date; however such
penalties (if incurred) would be recorded as a reduction of
revenue and the related accounts receivable balance.
The Companys policy is to reserve for uncollectible
accounts based on its best estimate of the amount of probable
credit losses in its existing accounts receivable. The Company
periodically reviews its accounts receivable to determine
whether an allowance for doubtful accounts is necessary based on
an analysis of past due accounts and other factors that may
indicate that the realization of an account may be in doubt.
Other factors that the Company considers include its existing
contractual obligations, historical payment patterns of its
customers and individual customer circumstances, an analysis of
days sales outstanding by customer and geographic region, and a
review of the local economic environment and its potential
impact on government funding and reimbursement practices.
Account balances deemed to be uncollectible are charged to the
allowance after all means of collection have been exhausted and
the potential for recovery is considered remote. The Company had
a low occurrence of credit losses through the year ended
March 31, 2005 and therefore did not consider it necessary
to establish an allowance for doubtful accounts as of
March 31, 2005. The allowance for doubtful accounts at
March 31, 2007 and 2006 represents probable credit losses
in the amounts of $207,000 and $90,000, respectively.
73
OCULUS
INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Inventories
Inventories are stated at the lower of cost, cost being
determined on a standard cost basis (which approximates actual
cost on a
first-in,
first-out basis), or market.
Due to changing market conditions, estimated future
requirements, age of the inventories on hand and production of
new products, the Company regularly reviews inventory quantities
on hand and records a provision to write down excess and
obsolete inventory to its estimated net realizable value. The
Company recorded reserves to reduce the carrying amounts of
inventories to their net realizable value in the amounts of
$94,000 and $996,000 for the years ended March 31, 2007 and
2006, respectively. During the year ended March 31, 2007,
the Company disposed of inventory reserved in prior periods.
Property
and Equipment
Property and equipment are stated at cost less accumulated
depreciation and amortization. Depreciation of property and
equipment is computed using the straight-line method over the
estimated useful lives of the respective assets. Depreciation of
leasehold improvements is computed using the straight-line
method over the lesser of the estimated useful life of the
improvement or the remaining term of the lease. Estimated useful
asset life by classification is as follows:
|
|
|
|
|
|
|
Years
|
|
|
Office equipment
|
|
|
3
|
|
Manufacturing and lab equipment
|
|
|
5
|
|
Furniture and fixtures
|
|
|
7
|
|
Upon retirement or sale, the cost and related accumulated
depreciation are removed from the consolidated balance sheet and
the resulting gain or loss is reflected in operations.
Maintenance and repairs are charged to operations as incurred.
Impairment
of Long-Lived Assets
The Company periodically reviews the carrying values of its long
lived assets in accordance with SFAS 144 Long Lived
Assets when events or changes in circumstances would
indicate that it is more likely than not that their carrying
values may exceed their realizable values, and records
impairment charges when considered necessary. Specific potential
indicators of impairment include, but are not necessarily
limited to:
a significant decrease in the fair value of an asset;
a significant change in the extent or manner in which an asset
is used or a significant physical change in an asset;
a significant adverse change in legal factors or in the business
climate that affects the value of an asset;
an adverse action or assessment by the U.S. Food and Drug
Administration or another regulator;
an accumulation of costs significantly in excess of the amount
originally expected to acquire or construct an asset; and
operating or cash flow losses combined with a history of
operating or cash flow losses or a projection or forecast that
demonstrates continuing losses associated with an
income-producing asset.
When circumstances indicate that an impairment may have
occurred, the Company tests such assets for recoverability by
comparing the estimated undiscounted future cash flows expected
to result from the use of such assets and their eventual
disposition to their carrying amounts. In estimating these
future cash flows, assets and liabilities are grouped at the
lowest level for which there are identifiable cash flows that
are largely independent of the cash flows generated by other
such groups. If the undiscounted future cash flows are less than
the carrying amount of the asset, an impairment loss, measured
as the excess of the carrying value of the asset over its
estimated
74
OCULUS
INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
fair value, will be recognized. The cash flow estimates used in
such calculations are based on estimates and assumptions, using
all available information that management believes is reasonable.
Research
and Development
Research and development expense is charged to operations as
incurred and consists primarily of personnel expenses, clinical
and regulatory services and supplies. For the years ended
March 31, 2007, 2006 and 2005, research and development
expense amounted to $4,508,000, $2,600,000 and $1,654,000
respectively.
Advertising
Costs
Advertising costs are expensed as incurred. Advertising costs
amounted to $54,000, $126,000 and $122,000, for the years ended
March 31, 2007, 2006 and 2005, respectively. Advertising
costs are included in selling, general and administrative
expenses in the accompanying consolidated statements of
operations.
Shipping
and Handling Costs
The Company applies the guidelines enumerated in Emerging Issues
Task Force Issue (EITF)
00-10
Accounting for Shipping and Handling Fees and Costs
with respect to its shipping and handling costs. Accordingly,
the Company classifies amounts billed to customers related to
shipping and handling in sale transactions as revenue. Shipping
and handling costs incurred are recorded in cost of sales. To
date, shipping and handling costs billed to customers have been
insignificant.
Foreign
Currency Transactions
Foreign currency gains (losses) relate to working capital loans
that the Company has made to its foreign subsidiaries. The
Company recorded foreign currency gains (losses) for the years
ended March 31, 2007, 2006 and 2005 of $407,000, ($283,000)
and $134,000, respectively. The related gains (losses) were
recorded in other income (expense) in the accompanying
consolidated statements of operations.
Stock-Based
Compensation
Prior to April 1, 2006, the Company accounted for
stock-based employee compensation arrangements in accordance
with the provisions of APB No. 25, Accounting for
Stock Issued to Employees, and its related interpretations
and applied the disclosure requirements of
SFAS No. 148, Accounting for Stock-Based
Compensation-Transition and Disclosure, an amendment of FASB
Statement No. 123. The Company used the minimum value
method to measure the fair value of awards issued prior to
April 1, 2006 with respect to its application of the
disclosure requirements under SFAS No. 123.
Effective April 1, 2006, the Company adopted
SFAS No. 123(R) Share Based Payment
(SFAS 123(R)). This statement is a revision of
SFAS No. 123, and supersedes APB Opinion No. 25,
and its related implementation guidance. SFAS 123(R)
addresses all forms of share based payment (SBP)
awards including shares issued under employee stock purchase
plans, stock options, restricted stock and stock appreciation
rights. Under SFAS 123(R), SBP awards result in a cost that
will be measured at fair value on the awards grant date,
based on the estimated number of awards that are expected to
vest and will result in a charge to operations.
The Company had a choice of two attribution methods for
allocating compensation costs under SFAS 123(R): the
straight-line method, which allocates expense on a
straight-line basis over the requisite service period of the
last separately vesting portion of an award, or the graded
vesting attribution method, which allocates expense on a
straight-line basis over the requisite service period for each
separately vesting portion of the award as if the award was, in
substance, multiple awards. The Company chose the former method
and amortized the fair value of each option on a straight-line
basis over the requisite period of the last separately vesting
portion of each award.
75
OCULUS
INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Under SFAS 123(R), nonpublic entities, including those that
become public entities after June 15, 2005, that used the
minimum value method of measuring equity share options and
similar instruments for either recognition or pro forma
disclosure purposes under SFAS No. 123 are required to
apply SFAS 123(R)prospectively to new awards and to awards
modified, repurchased, or cancelled after the date of adoption.
In addition, SFAS 123(R), requires such entities to
continue accounting for any portion of awards outstanding at the
date of initial application using the accounting principles
originally applied to those awards. Accordingly, stock-based
compensation expense relating to awards granted prior to
April 1, 2006 that are expected to vest in periods ending
after April 1, 2006 are being recorded in accordance with
the provisions of APB 25 and its related interpretive guidance.
The Company has adopted the prospective method with respect to
accounting for its transition to SFAS 123(R). Accordingly,
the Company recognized in salaries and related expense in the
accompanying consolidated statements of operations $158,000 of
stock-based compensation expense during the year ended
March 31, 2007, which represents the intrinsic value
amortization of options granted prior to April 1, 2006 that
the Company is continuing to account for using the recognition
and measurement principles prescribed under APB 25. The Company
also recognized in salaries and related expense in the
accompanying consolidated statements of operations $815,000 of
stock-based compensation expense during the year ended
March 31, 2007 which represents the amortization of the
fair value of options granted subsequent to adoption of
SFAS 123(R). During the year ended March 31, 2007, the
Company reclassified certain components of its
stockholders equity to reflect the elimination of deferred
compensation arising from unvested share-based compensation
pursuant to the requirements of Staff Accounting
Bulletin No. 107, regarding SFAS. 123(R). This
deferred compensation was previously recorded as an increase to
additional paid-in capital with a corresponding reduction to
stockholders equity for such deferred compensation. This
reclassification had no effect on net loss or total
stockholders equity (deficit) as previously reported. The
Company will record an increase to additional paid-in capital as
the share-based payments vest.
Non-Employee
Stock-Based Compensation
The Company accounts for equity instruments issued to
non-employees in accordance with the provisions of
SFAS No. 123(R) and EITF Issue
No. 96-18,
Accounting for Equity Instruments That are Issued to Other
Than Employees for Acquiring, or in Conjunction with Selling,
Goods or Services,
(EITF 96-18)
which requires that such equity instruments are recorded at
their fair value on the measurement date. The measurement of
stock-based compensation is subject to periodic adjustment as
the underlying equity instrument vests. Non-employee stock-based
compensation charges are being amortized over the vesting period.
Income
Taxes
The Company accounts for income taxes in accordance with
SFAS No. 109, Accounting for Income Taxes
(SFAS No. 109). Under
SFAS No. 109, deferred tax assets and liabilities are
determined based on the differences between the financial
reporting and tax bases of assets and liabilities and net
operating loss and credit carryforwards using enacted tax rates
in effect for the year in which the differences are expected to
impact taxable income. Valuation allowances are established when
necessary to reduce deferred tax assets to the amounts expected
to be realized.
Comprehensive
Loss
Other comprehensive loss includes all changes in
stockholders equity (deficit) during a period from
non-owner sources and is reported in the consolidated statement
of stockholders equity (deficit). To date, other
comprehensive loss consists of changes in accumulated foreign
currency translation adjustments during the years.
76
OCULUS
INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Net
Loss Per Share
The Company computes net loss per share in accordance with
SFAS No. 128 Earnings Per Share and has
applied the guidance enumerated in Staff Accounting
Bulletin No. 98 (SAB Topic 4D) with
respect to evaluating its issuances of equity securities during
all periods presented.
Under SFAS No. 128, basic net loss per share is
computed by dividing net loss per share available to common
stockholders by the weighted average number of common shares
outstanding for the period and excludes the effects of any
potentially dilutive securities. Diluted earnings per share, if
presented, would include the dilution that would occur upon the
exercise or conversion of all potentially dilutive securities
into common stock using the treasury stock
and/or
if converted methods as applicable. The computation
of basic loss per share for the years ended March 31, 2007,
2006 and 2005, excludes potentially dilutive securities because
their inclusion would be anti-dilutive.
In addition to the above, the Securities and Exchange Commission
(SEC) (under SAB Topic 4D) requires new
registrants to retroactively include the dilutive effect of
common stock or potential common stock issued for nominal
consideration during all periods presented in its computation of
basic earnings (loss) per share and diluted earnings per share
as if they were, in substance, recapitalizations. The Company
evaluated all of its issuances of equity securities prior to the
completion of its IPO on January 30, 2007
(Note 13) and determined that it had no nominal
issuances of common stock or common stock equivalents to include
in its computation of loss per share for any of the years
presented.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
|
(In thousands)
|
|
|
Anti-dilutive securities
excluded from the computation of basic and diluted net loss per
share are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
Options to purchase common stock
|
|
|
2,020
|
|
|
|
1,969
|
|
|
|
1,340
|
|
Warrants to purchase common stock
|
|
|
1,369
|
|
|
|
858
|
|
|
|
464
|
|
Convertible preferred stock (as if
converted)
|
|
|
|
|
|
|
3,984
|
|
|
|
2,352
|
|
Warrants to purchase convertible
preferred stock (as if converted)
|
|
|
|
|
|
|
17
|
|
|
|
17
|
|
Convertible debt
|
|
|
|
|
|
|
|
|
|
|
10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,389
|
|
|
|
6,828
|
|
|
|
4,183
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
During the year ended March 31, 2007, the Company issued
common stock in connection with the conversion of its
convertible preferred stock to common stock at the close of its
initial public offering, sold common stock in its initial public
offering, sold common stock in connection with its
underwriters partial exercise of their over- allotment
option and issued common stock in connection with the exercise
of warrants (Note 13). These transactions resulted in
significant additional dilution.
Fair
Value of Financial Instruments
The carrying amounts reported in the balance sheet for cash and
cash equivalents, accounts receivable, accounts payable and
accrued expenses approximate fair value based on the short-term
maturity of these instruments. The carrying amounts of the
Companys line of credit obligation and other long term
obligations approximate fair value as such instruments feature
contractual interest rates that are consistent with current
market rates of interest or have effective yields that are
consistent with instruments of similar risk, when taken together
with equity instruments issued to the holder.
77
OCULUS
INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Preferred
Stock
The Company applies the guidance enumerated in
SFAS No. 150 Accounting for Certain Financial
Instruments with Characteristics of both Liabilities and
Equity and EITF Topic D-98 Classification and
Measurement of Redeemable Securities, when determining the
classification and measurement of its convertible preferred
shares. Preferred shares subject to mandatory redemption (if
any) are classified as liability instruments and are measured at
fair value in accordance with SFAS 150. All other issuances
of preferred stock are subject to the classification and
measurement principles of EITF Topic D-98. Accordingly the
Company classifies conditionally redeemable preferred shares (if
any), which includes preferred shares that feature redemption
rights that are either within the control of the holder or
subject to redemption upon the occurrence of uncertain events
not solely within the Companys control, as temporary
equity. At all other times, the Company classifies its preferred
shares in stockholders equity.
The Companys convertible preferred shares did not feature
any redemption rights within the holders control or
conditional redemption features not within the Companys
control as of March 31, 2006 and 2005. Accordingly all
issuances of convertible preferred stock are presented as a
component of stockholders equity (deficit). All shares of
convertible preferred stock automatically converted into to
common stock at the closing of the Companys initial public
offering on January 30, 2007.
Convertible
Instruments
The Company evaluates and accounts for conversion options
embedded in its convertible instruments in accordance with
SFAS No. 133 Accounting for Derivative
Instruments and Hedging Activities
(SFAS 133) and
EITF 00-19
Accounting for Derivative Financial Instruments Indexed
to, and Potentially Settled in, a Companys Own Stock
(EITF 00-19).
SFAS 133 generally provides three criteria that, if met,
require companies to bifurcate conversion options from their
host instruments and account for them as free standing
derivative financial instruments in accordance with
EITF 00-19.
These three criteria include circumstances in which (a) the
economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic
characteristics and risks of the host contract, (b) the
hybrid instrument that embodies both the embedded derivative
instrument and the host contract is not remeasured at fair value
under otherwise applicable generally accepted accounting
principles with changes in fair value reported in earnings as
they occur and (c) a separate instrument with the same
terms as the embedded derivative instrument would be considered
a derivative instrument subject to the requirements of
SFAS 133. SFAS 133 and
EITF 00-19
also provide an exception to this rule when the host instrument
is deemed to be conventional (as that term is described in the
implementation guidance to SFAS 133 and further clarified
in
EITF 05-2
The Meaning of Conventional Convertible Debt
Instrument in Issue
No. 00-19).
The Company accounts for convertible instruments (when it has
determined that the embedded conversion options should not be
bifurcated from their host instruments) in accordance with the
provisions of
EITF 98-5
Accounting for Convertible Securities with Beneficial
Conversion Features,
(EITF 98-5)
and
EITF 00-27
Application of
EITF 98-5
to Certain Convertible Instruments. Accordingly, the
Company records when necessary discounts to convertible notes
for the intrinsic value of conversion options embedded in debt
instruments based upon the differences between the fair value of
the underlying common stock at the commitment date of the note
transaction and the effective conversion price embedded in the
note. Debt discounts under these arrangements are amortized over
the term of the related debt to their earliest date of
redemption. The Company also records when necessary deemed
dividends for the intrinsic value of conversion options embedded
in preferred shares based upon the differences between the fair
value of the underlying common stock at the commitment date of
the note transaction and the effective conversion price embedded
in the note.
The Company evaluated the conversion option embedded in its
convertible instruments during each of the reporting periods
presented and has determined, in accordance with the provisions
of these statements, that it does
78
OCULUS
INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
not meet the criteria requiring bifurcation of these
instruments. Additionally, the Companys conversion
options, if free standing, would not be considered derivatives
subject to accounting guidelines prescribed under SFAS 133.
The characteristics of common stock that is issuable upon a
holders exercise of conversion options embedded in the
Companys preferred shares are deemed to be clearly and
closely related to the characteristics of the preferred shares
(as that term is clarified in paragraph 61 l of the
implementation guidance included in Appendix A of
SFAS 133). The Company did not record deemed dividends
during any of the periods presented because the effective
conversion price of the convertible preferred shares exceeded
the fair value of the Company common stock at the respective
dates of issuance.
Common
Stock Purchase Warrants and Other Derivative Financial
Instruments
The Company accounts for the issuance of common stock purchase
warrants issued and other free standing derivative financial
instruments in accordance with the provisions of
EITF 00-19.
Based on the provisions of
EITF 00-19,
the Company classifies as equity any contracts that
(i) require physical settlement or net-share settlement or
(ii) gives the Company a choice of net-cash settlement or
settlement in its own shares (physical settlement or net-share
settlement). The Company classifies as assets or liabilities any
contracts that (i) require net-cash settlement (including a
requirement to net cash settle the contract if an event occurs
and if that event is outside the control of the Company) or
(ii) gives the counterparty a choice of net-cash settlement
or settlement in shares (physical settlement or net-share
settlement). The Company assesses classification of its
freestanding derivatives at each reporting date to determine
whether a change in classification between assets and
liabilities is required. The Company determined that its
freestanding derivatives, which principally consists of warrants
to purchase common stock satisfied the criteria for
classification as equity instruments at March 31, 2007 and
2006.
Recent
Accounting Pronouncements
In March 2006, the FASB issued SFAS No. 156
Accounting for Servicing of Financial Assets
an amendment of FASB Statement No. 140
(SFAS 156). SFAS 156 is effective for the
first fiscal year beginning after September 15, 2006.
SFAS 156 changes the way entities account for servicing
assets and obligations associated with financial assets acquired
or disposed of. The Company has not yet completed its evaluation
of the impact of adopting SFAS 156 on its results of
consolidated operations or financial position, but does not
expect that the adoption of SFAS 156 will have a material
impact.
In June 2006, the Financial Accounting Standards Board issued
FASB Interpretation No. 48, Accounting for Uncertainty in
Income Taxes. This Interpretation prescribes a recognition
threshold and measurement attribute for the financial statement
recognition and measurement of a tax position taken or expected
to be taken in a tax return. This Interpretation also provides
guidance on derecognition, classification, interest and
penalties, accounting in interim periods, disclosure, and
transition. The Interpretation is effective for fiscal years
beginning after December 15, 2006. The Company has not yet
completed its analysis of the impact this Interpretation will
have on its financial condition, results of operations, cash
flows or disclosures.
In February 2007, the FASB issued SFAS 159, The Fair
Value Option for Financial Assets and Financial
Liabilities (SFAS 159). SFAS 159
provides companies with an option to report selected financial
assets and liabilities at fair value and establishes
presentation and disclosure requirements designed to facilitate
comparisons between companies that choose different measurement
attributes for similar types of assets and liabilities.
SFAS 159 is effective for fiscal years beginning after
November 15, 2007. The Company is in the process of
evaluating the impact of the adoption of this statement on the
Companys results of operations and financial condition.
In September 2006, the FASB issued SFAS No. 157,
Accounting for Fair Value Measurements
(SFAS 157). SFAS 157 defines fair value,
and establishes a framework for measuring fair value in
generally accepted accounting principles and expands disclosure
about fair value measurements. SFAS 157 is effective for
79
OCULUS
INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
financial statements issued subsequent to November 15,
2007. The Company does not expect that the adoption of this the
standard will have a material impact on its financial position,
results of operations or cash flows.
In September 2006, the SEC issued Staff Accounting
Bulletin 108, Considering the Effects on Prior Year
Misstatements when Quantifying Misstatements in Current Year
Financial Statements, (SAB 108). SAB 108
requires registrants to quantify errors using both the income
statement method (i.e. iron curtain method) and the rollover
method and requires adjustment if either method indicates a
material error. If a correction in the current year relating to
prior year errors is material to the current year, then the
prior year financial information needs to be corrected. A
correction to the prior year results that are not material to
those years, would not require a restatement process where prior
financials would be amended. SAB 108 is effective for
fiscal years ending after November 15, 2006. The
Companys adoption of SAB 108 did not have a material
effect on its financial position, results of operations or cash
flows.
In December 2006, the FASB issued FSP
EITF 00-19-2
Accounting for Registration Payment Arrangements
(FSP
EITF 00-19-2).
FSP
EITF 00-19-2
addresses an issuers accounting for registration payment
arrangements. This pronouncement specifies that the contingent
obligation to make future payments or otherwise transfer
consideration under a registration payment arrangement, whether
issued as a separate agreement or included as a provision of a
financial instrument, should be separately recognized and
accounted for as a contingency in accordance with SFAS 5
Accounting for Contingencies. FSP
EITF 00-19-2
amended previous standards relating to rights agreements became
effective on December 21, 2006 with respect to arrangements
entered into or modified beginning on such date and for the
first fiscal year beginning after December 15, 2006 with
respect to those arrangements entered into prior to
December 21, 2006. The Company is in the process of
evaluating the impact of the adoption of this statement on the
Companys results of operations and financial condition.
Other accounting standards that have been issued or proposed by
the FASB or other standards-setting bodies that do not require
adoption until a future date are not expected to have a material
impact on the consolidated financial statements upon adoption.
|
|
NOTE 4
|
Accounts Receivable
|
Accounts receivable consists of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Accounts receivable
|
|
$
|
1,571
|
|
|
$
|
1,166
|
|
Less: allowance for doubtful
accounts
|
|
|
(207
|
)
|
|
|
(90
|
)
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,364
|
|
|
$
|
1,076
|
|
|
|
|
|
|
|
|
|
|
Allowance for doubtful accounts activities are as follows (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additions
|
|
|
|
|
|
|
Balance at
|
|
Charged to
|
|
|
|
|
|
|
Beginning
|
|
Costs and
|
|
Deductions
|
|
Balance at
|
Year Ended March 31,
|
|
of Period
|
|
Expenses
|
|
Write-offs
|
|
End of Period
|
|
2006
|
|
$
|
|
|
|
$
|
90
|
|
|
$
|
(
|
)
|
|
$
|
90
|
|
2007
|
|
$
|
90
|
|
|
$
|
284
|
|
|
$
|
(167
|
)
|
|
$
|
207
|
|
80
OCULUS
INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Inventories consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Raw materials
|
|
$
|
311
|
|
|
$
|
267
|
|
Finished goods
|
|
|
65
|
|
|
|
1,046
|
|
|
|
|
|
|
|
|
|
|
|
|
|
376
|
|
|
|
1,313
|
|
Less: inventory allowances
|
|
|
(94
|
)
|
|
|
(996
|
)
|
|
|
|
|
|
|
|
|
|
|
|
$
|
282
|
|
|
$
|
317
|
|
|
|
|
|
|
|
|
|
|
Reserve for obsolete inventories activities are as follows (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additions
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
Charged to
|
|
|
|
|
|
|
|
|
|
Beginning
|
|
|
Costs and
|
|
|
Deductions
|
|
|
Balance at
|
|
Year Ended March 31,
|
|
of Period
|
|
|
Expenses
|
|
|
Write-offs
|
|
|
End of Period
|
|
|
2006
|
|
$
|
221
|
|
|
$
|
1,074
|
|
|
$
|
(298
|
)
|
|
$
|
996
|
|
2007
|
|
$
|
996
|
|
|
$
|
102
|
|
|
$
|
(1,004
|
)
|
|
$
|
94
|
|
|
|
NOTE 6
|
Prepaid
Expenses and Other Current Assets
|
Prepaid expenses and other current assets consist of the
following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Prepaid expenses
|
|
$
|
976
|
|
|
$
|
304
|
|
Value Added Tax receivable
|
|
|
125
|
|
|
|
722
|
|
Other current assets
|
|
|
71
|
|
|
|
360
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,172
|
|
|
$
|
1,386
|
|
|
|
|
|
|
|
|
|
|
|
|
NOTE 7
|
Debt
Issue Costs
|
Debt issue costs consists of the following (in thousands):
|
|
|
|
|
|
|
March 31,
|
|
|
|
2007
|
|
|
Fair value of common stock
purchase warrants issued to Western Technologies, Inc. in
connection with a Line of Credit (Note 10)
|
|
$
|
1,046
|
|
Fair value of common stock
purchase warrants issued to Brookstreet Securities Corporation
(Brookstreet) in connection with a Bridge Loan
(Note 10)
|
|
|
105
|
|
Cash paid for debt offering
expenses
|
|
|
77
|
|
|
|
|
|
|
|
|
|
1,228
|
|
Less: accumulated amortization
recorded as non-cash interest expense
|
|
|
(402
|
)
|
|
|
|
|
|
|
|
$
|
826
|
|
|
|
|
|
|
81
OCULUS
INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)